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General Introduction to the Thesis 
Chapter 1 
Four decades ago, a plant alkaloid was isolated from the Chinese tree 
Camptotheca acuminata (Nyssaceae family), which showed promising antitumor 
activity in vitro (1 ). At that moment, a relatively new class of anticancer agents was 
born. Unfortunately, during clinical trials, this alkaloid, called camptothecin (CPT), 
showed severe and unpredictable side effects (myelosuppression, diarrhea, and 
hemorrhagic cystitis), which were unmanageble during this early chemotherapeutic era 
(2-4). Later on, the drug's relative lack of hydrophility was found to be the main reason 
for these adverse events. 
Despite this ''false starf', renewed interest in this compound was found after the 
elucidation of its mechanism of action during the mid-1980s (i.e the inhibition of 
topoisomerase I; ref. 5-7). Topoisomerase I is an essential enzyme in DNA replication 
and RNA transcription and is present in all eukaryotic cells (8). In the physiologic state 
of the cell nucleus, DNA is double-stranded, super-coiled and fits tightly into a 
chromosome. To synthesize new DNA, this topological constrained DNA should 
unwind. To this end, topoisomerase I binds to the DNA, forms a covalent reversible 
adduct (which is called the cleavable complex), cleaves a phosphodiester bond and a 
single-strand break occurs (6). Next, the DNA molecule is able to rotate freely around 
its intact single strand, and relaxation of DNA takes place. After the religation of the 
cleavage, the enzyme dissociates from DNA. The cleavable complex usually binds for 
a short period, just to allow the single strand to unwind (9, 1 0). CPT induces the 
stabilization of the cleavable complexes (11, 12), what will lead to a disruption of the 
DNA-strand when the replication fork meets the cleavable complex (7). This double-
strand break will lead to the activation of apoptosis pathways and ultimately result in 
cell-death (7). 
In subsequent years, various derivatives of CPT with improved water solubility 
have been developed, of which irinotecan (CPT-11) was considered to be among the 
most promising ones (13). It is a semisynthetic water-soluble prodrug, with minor 
intrinsic cy1otoxic activity. After administration, the drug is partially converted into the 
1 00- to 1 ,000-times more active metabolite SN-38 by the enzyme carboxyl esterase 
(14-17). In the liver, SN-38 is de-toxified by undine-diphosphate 
glucuronosyltransferase 1 A isoforms, whereby SN-38-glucuronide is formed (18). All 
these compounds can be secreted into the bile by specific transporters (19). In the 
intestines, several bacteria produce ~-glucuronidase, which enables re-activatation of 
the glucuronidated form of SN-38 (20). Relatively high concentrations of SN-38 will 
lead to damage of the bowel mucosa, which results in one of the drug's most 
prominent side effects: diarrhea (21). In addition, irinotecan can also be oxidated by 
cy1ochrome P450 isozymes (22, 23), which will lead to the formation of several inactive 
metabolites, including APC and NPC. 
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The pharmacokinetics of irinotecan become even more complex, as CPT analogs 
exists in two structurally different forms (24). In the lactone form, the pharmacologically 
active a-hydroxy-0-lactone ring is closed, while in the carboxylate form this ring is 
opened and the molecule looses its activity. Between both forms of irinotecan, a pH 
and protein-dependent equilibrium exists, with the carboxylate form predominating at 
equilibrium in human plasma. 
Although much is known about the way the drug behaves, patients still react very 
diverse to the therapy. The pharmacokinetics of irinotecan and SN-38 between 
patients may vary greatly (25). Also, some patients have little or no side effects, while 
in others these are very severe/ life-threatening (13). In addition, in some patients there 
is a clearly measurable antitumor effect, while in others therapy with irinotecan will be 
not effective at all. As irinotecan is currently one of the most important 
chemotherapeutic drugs in the first-line treatment of colorectal cancer, in combination 
with 5-fluorouracil and folinic acid (26), it is imperative to identify the causes of the 
interindividual variability of drug effects. To achieve this, individual patterns in 
pharmacokinetics and pharmacodynamics should be further investigated, and find the 
most prominent factors which influence the disposition of irinotecan. 
In this thesis, "lrinotecan: From Clinical Pharmacokinetics to PharmacogeneticS', 
we first provide an overview of the pharmacokinetics of irinotecan, then evaluate 
pharmacokinetic-pharmacodynamic relationships for this agent using different 
techniques, and finally focus on a variety of factors (including dosing strategies, effects 
of co-medication, and the influence of genetic constitution of the patient), which may 
have relevance for future use of irinotecan in clinical practise. 
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ABSTRACT 
CPT -11 belongs to the class of topoisomerase I inhibitors, and it acts as a 
prod rug of SN-38, which is approximately 100 to 1000-fold more cytotoxic than the 
parent drug. CPT-11 has shown a broad spectrum of antitumor activity in preclinical 
models as well as clinically, with responses observed in various disease types 
including colorectal, lung, cervical and ovarian cancer. The pharmacokinetics and 
metabolism of CPT -11 are extremely complex, and have been the subject of 
intensive investigation in recent years. Both CPT-11 and SN-38 are known in an 
active lactone form and an inactive carboxylate form, between which an equilibrium 
exists that depends on the pH and the presence of binding proteins. CPT-11 is 
subject to extensive metabolic conversion by various enzyme systems, including 
esterases to form SN-38, UGT1A1 mediating glucuronidation of SN-38, as well as 
CYP3A4 which forms several pharmacologically inactive oxidation products. 
Elimination routes of CPT-11 are also depending on the presence of drug-
transporting proteins, notably P-glycoprotein and cMOAT, present on the bile 
canalicular membrane. The various processes mediating drug elimination, either 
through metabolic breakdown or excretion, likely impact substantially on 
interindividual variability in drug handling. Strategies to individualize CPT -11 
administration schedules based on patient differences in enzyme or protein 
expression or by co-administration of specific agents modulating side effects are 
underway, and may ultimately lead to more selective chemotherapeutic use of this 
agent. 
INTRODUCTION 
Camptothecin, a plant alkaloid isolated from Camptotheca acuminata (family 
Nyssaceae), was first discovered in the early 1960s (1). Due to severe and 
unpredictable side effects of camptothecin in early clinical studies, the clinical 
development was halted in the 1970s (2-5). It was later revealed that the 
water-insolubility of camptothecin was an important factor mediating the unpredictable 
toxic effects (6). The elucidation of the mechanism of action of camptothecin, viz. 
inhibition of topoisomerase I, a nuclear enzyme which relaxes torsionally strained 
(super coiled) DNA (7-9), resulted in renewed interest in this agent, and subsequently, 
numerous derivatives have been synthesized and tested clinically (1 0-12). Some of 
these agents, including CPT-11 (13), topotecan (14), 9-aminocamptothecin and 
9-nitrocamptothecin (15-17), lurtotecan (GI147211, GG211) (18), and DX-89511 (19), 
have a broad spectrum of antitumor activity both in vitro and in vivo, and show more 
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predictable and clinically-manageable toxicities than the originally isolated structure. 
Two of these agents, topotecan and CPT-11, have recently been introduced into 
clinical practice for the treatment of ovarian and colorectal cancer, respectively. Of the 
currently available camptothecin analogs, CPT-11 has an extremely complex 
pharmacological profile, which is dependent on a host of enzymes involved in 
metabolic transformation and active transport proteins, regulating intestinal absorption 
and hepatobiliary secretion mechanisms (Fig. 1 ). 
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Figure 1. Metabolic pathways of CPT-11 showing carboxylesterase (CE)-mediated formation 
of the active metabolite SN-38, and its subsequent conversion to a glucuronide 
der1vative (SN-38G) by UGT1A1 and UGT1A7 isoforms, with deglucuronidation by 
intestinal B-glucuronidase (B-Giu). CPT-11 can also undergo CYP3A4-mediated 
oxidative metabolism to form APC and NPC, of which the latter can be hydrolyzed by 
CE to release SN-38. 
Furthermore, CPT-11 is chemically unique because of the presence of a bulky side 
chain on the core structure, the enzymatic cleavage of which is a requirement for 
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pharmacological activity. In addition, GPT-11 is known in two distinguishable forms, an 
active a-hydroxy-0-lactone ring form and an inactive carboxylate form, between which 
a pH-dependent equilibrium exists (12), which significantly impacts on the compound's 
kinetic profile. In recent years, a wealth of information has become available that has 
substantially aided in our understanding of the clinical actions of this agent. Here, we 
will review the clinical pharmacokinetic properties of GPT-11 and its metabolites that 
appear to be crucial for optimal anticancer chemotherapeutic use. 
PHARMACOKINETIC PROPERTIES 
Plasma Disposition 
The plasma pharmacokinetics of GPT-11 in humans has now been addressed in 
several studies, and taking into account that these data are from different laboratories, 
the results are fairly comparable. Most of the initial studies have been performed with 
the drug administered as a short i.v. infusion (0.5-1.5 h). Following such administration, 
peak plasma concentrations were reached at the end of infusion (20-36), with a rapid 
decrease thereafter as a result of multiple distribution and elimination pathways (32, 
36). A rebound peak in the concentration-curve has been noticed in some studies (22, 
26, 31, 36), and was initially ascribed to enterohepatic recirculation (22, 26). More 
recently, it has been suggested that this phenomenon is related to substantial uptake 
of GPT-11 lactone by erythrocy1es and its subsequent release followed by 
accumulation of the carlboxylate form in the plasma compartment (37). Equilibrium 
between the two drug forms is rapidly established and in contrary to GPT-11, the 
principal metabolite SN-38 predominates in its active lactone form (33, 34). The 
lactone form of SN-38 accounts for approximately 60-70% of total plasma SN-38 after 
the end of a GPT-11 infusion, declining to of 33-66% at equilibrium (23, 33). The mean 
lactone to total AUG ratio of SN-38 is high, being approximately 64%, albeit with large 
interpatient variability (23, 24, 33, 34, 38). This ratio remains constant for the whole 
dose range measured. Examples of concentration-time profiles for the lactone and 
carboxylate forms of GPT-11 and SN-38 are shown in Fig. 2. 
The peak concentration of GPT-11 appears to be dose-proportional in a large 
dose range (100-750 mg/m2), although substantial interpatient variability has been 
noted (21-23, 25, 26, 39, 40). This variability increases at later time-points (41). GPT-
11 systemic exposure or area under the plasma concentration-time curve (AUG) also 
increases in a dose-independent way at doses ranging from 33-180 mg/m2 (24-26, 39, 
40, 42), indicating linear pharmacokinetics. 
18 
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Figure 2. Plasma concentration-time profiles of the lactone (open ligures) and total drug (i.e., 
lactone plus carboxylate, closed figures) lonms of CPT-11 (triangles) and SN-38 
(circles) in a group of 17 patients receiving CPT-11 at 200 mg/m2 as a 90-min i.v. 
infusion. All pharmacokinetic curves were fit to a 3~exponential equation, using 
Siphar version 4.0 (lnnaPhase, Philadelphia, PA), assuming a three-
compartmental model for distribution and elimination of the compounds. Data are 
presented as mean values ± standard deviation. Data were obtained from 
Mathijssen eta/. (38). 
The ratio of the lactone to total AUC remains relatively constant over the entire 
dose range of CPT-11, with mean values ranging from 34±5% up to 44±4% (33, 34). 
The conversion of the lactone into the carboxylate fonm of CPT-11 is rapid, with a 
mean half-life of 9.5 min (34). The plasma profiles of the two forms of CPT-11 are 
comparable, and can best be fitted in a bi- or tri-exponential equation (22, 25, 43), with 
mean terminal half-life values of about 9.3-14.2 h (22, 25, 35). More recently, it has 
been suggested that the terminal disposition half-life of CPT-11 is much longer, which 
may be related to the fact that prolonged sampling schedules were applied in 
combination with a highly sensitive detection method (20, 43). 
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The volume of distribution at steady state of CPT-11 is large, suggesting 
extensive tissue distribution, and remained unchanged with an increase in dose (20, 
22, 24, 31). Similarly, the total plasma clearance of CPT-11 was found to be 
dose-independent, with a value of 13.5±3.5 Uh/m2 for the total drug (i.e., lactone 
plus carboxylate forms) and 45.6±10.8 Uh/m2 for the lactone form (35). The 
clearance is unaltered during repeated cycles, despite a mean interpatient variability 
of approximately 30% (21, 35), and an intra-patient variability of approximately 
13.5%. 
Plasma Protein Binding 
An important factor in the pharmacology of drugs is its binding to plasma 
proteins. In accordance with the hydrophilic nature of CPT-11, in blood, 80% of the 
drug is mainly bound to, and/or localized in erythrocytes, whereas SN-38 is bound for 
at least 99%, mainly to albumin and lymphocytes, but also to erythrocytes and 
neutrophils (44). Although binding to plasma proteins appears to be of subordinate 
importance for CPT-11, binding of the principal metabolite SN-38 to plasma proteins 
in adults and pediatric patients is thus substantial, and independent of (pre-therapy) 
serum albumin levels (-94to 96%) (44-46). In the presence of albumin, the lactone 
forms of CPT-11 and SN-38 are more stable (47), with higher percentages of the 
lactone forms available, compared with the situation without this protein. The protein 
binding is not significantly different for the lactone and carboxylate form of CPT-11. 
In contrast, SN-38 lactone binds significantly stronger to albumin than its 
corresponding carboxylate form, which could explain the better stability of SN-38 in 
vivo, compared with CPT-11 (47). This, in turn, may play a role in the differential 
terminal disposition half-lives and volumes of distribution between these molecules. 
In in vitro incubations in the presence of human serum albumin, the apparent half-life 
of the interconversion of CPT-11 is more than 3 times higher than that in patients 
(34). This suggests that there is an early preferential uptake and/or metabolism of 
the lactone form of CPT-11, thereby altering the ratio of CPT-11 lactone versus 
carboxylate (34). 
METABOLISM 
Several studies have shown that hepatic metabolism and biliary secretion are 
major pathways of CPT-11 elimination in both animals and humans, with major 
contributions from various classes of enzymes, including CEs, UGTs, CYP3As, and B-
glucuronidases. 
20 
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Esterases-Mediated Biotransformation 
The conversion of CPT-11 to SN-38 through cleavage of the ester-bond at C1 0 
by CEs has been studied extensively in recent years. Two human isozymes of liver 
CE, viz. hCE-1 and hCE-2, have been characterized that might catalyze this 
conversion (48, 49). No tumor reduction in SQ20b cells was seen after incubation of 
CPT-11 with hCE-1, compared with a 60% reduction for hCE-2 (49). Therefore, hCE-2 
probably plays the most important role in CPT-11 conversion by CEs in cancer 
patients. The plasma of several species, including mouse and horse, contains high 
levels of esterases other than CE and it converts CPT-11 much better into SN-38 than 
human plasma does. It has been suggested that butyrylcholinesterase, which has 
CPT-11 converting activity, might be responsible for this phenomenon (50, 51). 
SN-38 concentrations have been shown to increase with the CPT-11 dose over 
the dose range studied (1 00-750 mg/m2) (35). The terminal disposition half lives of SN-
38 lactone and total drug are significantly longer than those of CPT-11 (38, 43). In an 
in vitro study of human liver microsomes, twice as much SN-38 was formed when 
CPT-11 was present in its lactone form in comparison with CPT-11 in its carboxylate 
form (52). As CPT-11 lactone is converted easier, this phenomenon might contribute to 
the predominance of SN-38 in its lactone form in plasma (52). 
A clear relationship between CE levels and the chemosensitivity of proliferating 
tissues and cell lines in general has been suggested (53-55). CPT-11 was significantly 
more active in five human small-cell lung cancer cell lines than in four non-small cell 
lung cancer cell lines, and this was attributed to a higher CE activity in the former case 
(55). CPT-11-converting CE activity in human tumors has also been studied in vivo 
(56). A wide range of variability in enzyme activity in primary colorectal tumors was 
seen, with no significant difference between primary and secondary tumors. Relatively 
high CE activity in these tumors, as compared with normal liver tissue has been 
noticed, which might suggest a local activation of CPT-11 in tumor tissues (56). There 
were no significant differences between enzyme activity in human liver and colon 
tissues. 
Selective upgrading of CE levels in tumors, thereby producing tumor-specific 
activity may clearly have substantial clinical implications; it will maximize the exposure 
of tumors to SN-38 and limit systemic drug concentrations and therefore also limit 
adverse effects of CPT-11. This upgrading has been studied for several 
enzyme/prodrug combinations, using antibodies or viruses to attack tumor cells. For 
the CE/CPT-11 combination, a recombinant replication deficient adenovirus vector 
coding for human CE eDNA has been developed (57). This vector effectively 
suppressed A549 cell growth in vitro in the presence of CPT-11 by 7 to 17-fold. AsSN-
38 diffuses from the tumor cell in which it has been produced to its neighbor cells in 
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growth suppressive concentrations, only 1 0% of the A549 cells need to be infected for 
a cytotoxic effect in 48% of the cells (57). In CPT-11-resistant A549 cells, which had a 
6-fold resistance and 42% CE activity compared with normal A549 cells, functional CE 
expression could be accomplished by infection with this vector (57, 58), and these 
resistant cells could be suppressed efficiently in vitro and in vivo (58). This sensitivity 
has also been described for 2 other human tumor cell lines, although in another 8 
human cell lines only a minimal effect was seen (59). 
In various studies, the activity of CE isozymes from animal species has been 
compared with the human enzyme(s), and the latter show consistently lower activity 
than those of the other species investigated (60, 61). Although the active site amino 
acids of rabbit and human CE are almost identical, human CE converts CPT-11 1 00 to 
1 000-fold less efficiently (59). In Rh30 human rhabdomyosarcoma cells, expression of 
the rabbit enzyme was associated with more rapid tumor regression and a better 
prevention of tumor recurrence in vitro (59, 62). In addition, immune-deprived mice, 
carrying rabbit CE expressing Rh30 cells, were more sensitive to CPT-11 than human 
CE expressing cells or control cells. No recurrent tumors occurred in the rabbit-enzyme 
group, in contrast to 29% and 1 00% recurrence in the two other groups, respectively 
(59). The clinical utility of this approach is currently under further investigation. 
UGT-Mediated Biotransformation 
SN-38 itself is further metabolized in human liver by UGT1A1 to an inactive 
compound, SN-38G (63-65). The lactone functionality of SN-38G could also be 
hydrolyzed following a pH-dependent equilibrium (65). Mostly, the plasma 
concentrations of SN-38G are related to SN-38 plasma concentrations, with peak 
values at approximately 1.2 hours (range, 15 min to 4.5 hours) after the end of 
infusion (31, 43, 66). SN-38G concentrations increase linearly with the administered 
CPT-11 dose, suggesting that hepatic glucuronidation is not saturated in the dose 
ranges studied (up to 600 mg/m2) (36, 42). The AUC of SN-38G is about 7-fold 
higher than that of SN-38, suggesting extensive glucuronidation of SN-38 into 
SN-38G (32, 66), with high interpatient variability (41 ). 
Considerable variation in the conversion of SN-38 into SN-38G in human liver 
cells has also been noticed in vitro (63). This may be due to different enzyme activities 
of the various UGT isoforms. Two distinct gene families of UGT enzymes exist, UGT1 
and UGT2, which are both being sub-classified into several isoforms. Results obtained 
from transfection studies have shown that isoform UGT1 A 1 is primarily responsible for 
the SN-38 conversion (63), although it was shown more recently that isoform 1A7 is 
about 21-fold more efficient at physiological pH than UGT1 A 1 (67). 
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A genetic polymorphism has been reported in the TATA box sequences of 
UGT1 A 1 (68). Normally, the box contains (T A)6 T AA in its promotor region, and 
sometimes a box contains an extra TA repeat (68, 69). An extra TA repeat in the TATA 
box has been associated with Gilbert's syndrome (70). The metabolic ratio (SN-38/SN-
38G) for these patients is significantly higher compared with the common genotype, 
suggesting less SN-38 glucuronidation capacity (69). In addition, it has been reported 
that in patients with the Gngler-Naliar type I syndrome, UGT1 activity is totally lacking 
(63, 71, 72). As a result, SN-38 can not be inactivated adequately into SN-38G and 
therefore patients with these disorders are at increased risk for severe GPT-11-induced 
toxicity (63). Based on the relative importance of the systemic glucuronidation and the 
existence of genetic polymorphism, it has been proposed that UGT1A1 genotyping 
might be an approach to individualize GPT-11 treatment schedules (68, 73). 
A significant correlation was recently observed between SN-38 glucuronidation 
rates and bilirubin glucuronidation by human liver microsomes (63). Interestingly, 
UGT1 A 1 is the isozyme that also conjugates bilirubin (72). Also for bilirubin 
glucuronidation an inverse correlation between glucuronidation rate and number of TA 
repeats has been reported (68-70). It has been shown subsequently that baseline 
values of unconjugated bilirubin correlate significantly with both neutropenia and the 
AUGs of GPT-11 and SN-38, and this relationship might thus be useful in individual 
dose prescription or adaptation (72). No relationship has been observed between the 
glucuronidation of SN-38 and that of para-nitrophenol, which is glucuronidated by 
several UGTs, including UGT1A 1 (63). An intriguing observation has been that valproic 
acid, an inhibitor of glucuronidation, given 5 min before GPT-11 in rats, caused 99% 
inhibition in SN-38G formation (74), resulting in a mean increase in SN-38 AUG of 
270%. Pretreatment with phenobarbital, an inducer of UGT, resulted in a 72% 
enhancement in the AUG of SN-38G, with a concomitant reduction in the AUGs of 
GPT-11 and SN-38 of 31% and 59%, respectively (74). These findings are consistent 
with data indicating that a patient with Gilbert's syndrome could be treated successfully 
with simultaneous administration of GPT-11 and phenobarbital (31). GPT-11 and SN-
38 were formed in concentrations comparable to those achieved in nonmal patients, 
although the AUG of SN-38G appeared to be substantially altered (31 ). 
In human lung cancer cell lines, the role of SN-38 glucuronidation in cytotoxicity 
profiles has been studied extensively (75). PG-7/GPT cell lines showed an increased 
glucuronidation in comparison to nonmal PG-7 cells and when UGT activity was 
inhibited, the cells became more sensitive to SN-38. Thus, an up-regulation of the UGT 
activity may lead to SN-38 resistance in the tumor (75). BGRP or mitoxantrone-
resistance half-transporter (MXR) expression was also found to result in 400 to 1 000-
fold resistance to SN-38 as compared with parental cell lines (76). As MXR-cells were 
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highly capable to efflux drugs that are susceptible to glucuronidation, UGT activity in 
resistant and normal cell lines were compared. In resistant cells higher SN-38G levels 
were seen than in normal cells. Thus, in cancer cells glucuronidation might contribute 
to drug resistance, but the lack of high UGT levels in resistant MXR-cells suggests that 
BCRP alone is sufficient to induce drug resistance patterns (76). 
CYP3A-Mediated Biotransformation 
Recently, other quantitatively important metabolites of CPT-11 have been 
identified, the formation of which is dependent of CYP3A. Of these, APC is a major 
metabolite detectable in plasma, and is formed by a CYP3A-mediated oxidation of the 
distal piperidine group at C1 0 of CPT-11 (77-79). NPC is also formed through this 
pathway, by cleavage of the distal piperidine group of CPT-11 (77, 79-82). APC peaks 
at about 2 hours after the end of infusion, and AUC values increase linearly with 
increasing CPT-11 dose, despite important inter-patient variation (36). At equimolar 
concentrations (as compared to CPT-11), APC did not inhibit the conversion of CPT-11 
into SN-38 (83). 
Similar to CPT-11, APC shows little cytotoxic activity, although it has some 
inhibitory effect on acetylcholinesterase, an enzyme involved in the acute cholinergic 
syndrome observed directly following CPT-11 administration (83). Likely, APC does not 
contribute directly to the total activity and toxicity following CPT-11 administration in 
vivo, as it shows minor antitumor activity in vitro compared to SN-38 and less toxicity 
compared to CPT-11. NPC is also a poor inhibitor of cell growth and a poor inducer of 
topoisomerase-1-DNA cleavable complexes, with less antitumor activity in cell lines 
than CPT-11 (80, 84). In addition, formation of APC and NPC is unlikely to take place 
in human (colorectal) tumors where CYP3A levels are generally very low (85). It is of 
particular interest, though, that human liver microsomes and human liver CE are able 
to hydrolyze NPC into SN-38 though still to a lesser extent than CPT-11 (80, 84), 
whereas for APC this conversion has not been conclusively demonstrated (80, 86). 
Nevertheless, patients with high AUCs of SN-38, also had high AUCs of CPT-11 and 
APC, suggesting that some degree of correlation might be present (36). In addition, 
NPC can not be formed from APC, in contrast to a formerly suggested conversion (81, 
84). 
The recognition that CPT-11 is a CYP3A substrate is an important finding, since it 
makes this agent subject to a host of enzyme-mediated drug interactions, even with 
commonly prescribed co-medication (81, 87). For example, the prototypical CYP3A 
inhibitors, ketoconazole and troleandomycine, inhibit the conversion of CPT-11 into 
APC and NPC almost completely (77-79, 81). In addition, both loperamide and 
racecadotril inhibit APC and NPC formation by more than 50%, whereas ondansetron 
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inhibits these formations by 25% and 75% respectively (78, 81 ). APC and NPC 
formation correlated significantly with testosterone 6-B hydroxylation, which is also 
mediated by CYP3A (78, 81). It has been shown recently, that the subtype CYP3A4 is 
the main isozyme involved in formation of both APC and NPC (79, 82), although it was 
suggested previously that cytosolic aldehyde dehydrogenase might also be involved in 
APC formation (81 ). CYP3A5 also showed catalytic activity, but neither APC nor NPC 
were formed in its presence (79, 82). Instead a new (unidentified) metabolite was 
found (79, 82). As this enzyme is expressed in only 25 to 30% of adult livers, this might 
explain some of the inter-patient variability in CPT-11 metabolism (82). Preliminary 
evidence has also been generated indicating that SN-38 might be metabolized by 
CYP3A4, although the clinical implications of this finding have not yet been evaluated. 
8-g/ucuronidase-Mediated Biotransformation 
When SN-38G is excreted in bile and intestines, several bacteria including 
Escherichia coli, Bacteroides species and Clostridium perfringens can convert this 
compound back to the active metabolite SN-38, by producing the enzyme 
B-glucuronidase (88-90). Various studies have described (microflora-derived) B-
glucuronidase activity in non-human (91-94) and human intestines (95-97). In rats and 
athymic mice, within 1 hour after the end of infusion, acute diarrheal symptoms with 
impaired water absorption and increased PGE2 levels have been found (92, 93). 
Histopathological changes in the descending colon, cecum and ileum were observed 
after the daily administration of CPT-11 (91-93). Recently, these mucosal 
abnormalities were confirmed in human colon (97). A good correlation between this 
histological damage and B-glucuronidase activity in the intestinal lumen has been 
noticed, while a poor correlation was observed with CE activity (91 ). The lesser 
damage found in small intestines compared with damage in colon could be explained 
by a lower exposure of this tissue to SN-38. This may be due to a smaller amount of B-
glucuronidase in the lumen of small intestines (94). 
Because many drugs could affect the functioning of the intestinal bacteria, co-
medication may influence the chemotherapeutic treatment of patients with CPT-11 
(98). As bacteria producing B-glucuronidase activity will be killed by antibiotics, it is 
anticipated that this will lead to a reduction in acute and delayed diarrhea and cecal 
damage (91 ). It has been demonstrated that antibiotics had no effects on the plasma 
concentrations of CPT-11, SN-38 or SN-38G in mice (penicillin/streptomycin) (94), and 
in humans (neomycin) (99). This combined treatment also resulted in reduced SN-38 
concentrations in the intestinal contents with concomitantly increased SN-38G levels 
(94, 99). A potential approach for modulating CPT-11-induced intestinal toxicity may 
therefore be to reduce bacterial B-glucuronidase-mediated deconjugation of SN-38 and 
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subsequent mucosal destruction. A clinical trial to evaluate the toxicological 
consequences of pretreatment with neomycin before the administration of CPT-11 is in 
progress at our institute. 
EXCRETION 
Several studies have examined the excretion of CPT-11 in bile, feces and urine in 
animals and humans. In humans, only 52% of the given dose has been recovered 
using non-radiometric HPLC methods (32, 1 00), whereas in a recent radiometric study 
quantitative recovery (95.8±2.7% of radioactivity) was obtained (20). CPT-11 and its 3 
most common metabolites (SN-38, SN-38G and APC) were responsible for almost all 
(-93%) detected material (20). 
Urinary Elimination 
In urine, CPT-11, APC and SN-38G are the main compounds detected within 24 
hours following CPT-11 administration (20, 32), with CPT-11 accounting for about 10-
22% of the administered dose, and SN-38 contributing for only 0.18-0.43% (20, 22, 25, 
31, 66, 1 00). Consistent with the highly polar nature of the glucuronic-acid group and 
increased aqueous solubility, SN-38G may be excreted rapidly by the kidneys (32). 
The cumulative excretion of APC and NPC was very low, amounting to less than 1% of 
the dose (32). This suggests that the bulk of CPT-11 and its metabolites is excreted 
during the first 24 hours after infusion, while assessing urinary recovery of radiolabeled 
CPT-11 over 196 hours also showed that the excretion was almost complete within 48 
hours (Table 1) (20). Similar findings were obtained with daily administration schedules 
of CPT-11, indicating unchanged urinary excretion profiles (26, 29). 
Biliary Secretion 
In a few patients CPT-11 and SN-38 concentrations in bile have been measured 
(20, 24, 25, 100). CPT-11, SN-38 and SN-38G biliary secretion varies between 
approximately 3-22%, 0.1-0.9% and 0.6-1.1% respectively (100). NPC was also 
detected in bile at very low concentrations (80). In a female patient, carrying a biliary T-
tube and receiving radiolabeled CPT-11, 30.1% of the administered dose was 
recovered in bile as radioactive compounds (20). 
In rats, a cMOAT located on the bile canalicular membrane was shown to be 
responsible for the transport of CPT-11 carboxylate, SN-38 carboxylate and both SN-
38G carboxylate and lactone (101). For CPT-11 carboxylate, cMOAT appeared to be a 
low affinity transporter, whereas a high affinity transporter is still unknown (1 02). 
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Table 1. Cumulative urinary and fecal excretion of CPT-11 and metabolites. 
Compound Urine Feces Total 
CPT-11 22.4 ±5.50 32.3±4.47 54.7 
SN-38G 3.02 ± 0.77 0.27±0.17 3.29 
SN-38 0.43 ± 0.12 8.24±2.51 8.67 
APC 2.23 ± 1.53 8.29 ±2.95 10.5 
NPC 0.14 ± 0.08 1.36 ±0.94 1.50 
Total compounds 30.2± 6.60 62.0±7.60 92.2 
Not extracted 1.25±1.55 9.86±3.77 11.1 
Parent drug and metabolite abundance are expressed as percentage of administered dose and 
were determined by quantitative raiometric high-performance liquid chromatography. Data 
were obtained from Slatter et al. (20). 
For SN-38G lactone and carboxylate, cMOAT is the high affinity transporter, while 
most likely also a low affinity transporter exists, presumably P-glycoprotein. It has also 
been found that cMOAT transports SN-38G carboxylate more efficiently than its 
lactone form (102). In humans, the same transport mechanisms by cMOAT of CPT-11 
carboxylate, SN-38 carboxylate and SN-38G were found as in rats (see Fig. 3 for a 
schematic representation) (1 03). 
Cyclosporine, an inhibitor of the biliary secretion (1 04), and a known substrate 
and inhibitor of P-glycoprotein (1 05), significantly increased plasma concentrations of 
CPT-11, SN-38 and SN-38G in rats (104). At a cyclosporine dose of 60 mg/kg, the 
AUCs of CPT-11, SN-38 and SN-38G increased 2 to 4-fold. This is most likely the 
result of reduced renal and non-renal clearance, which simultaneously reduced by 55 
and 81%, respectively. Simultaneously, the terminal disposition half-lives of CPT-11 
and its metabolites were substantially prolonged. The conversion of CPT-11 into 
SN-38 was not altered, but the glucuronidation of SN-38 decreased in comparison to 
CPT-11 infusion without cyclosporine (1 04). In view of these results, it has been 
suggested that P-glycoprotein is one of the high affinity transporters of CPT-11 
carboxylate (1 06). However, like P-glycoprotein, also cMOAT function may be inhibited 
by cyclosporin A, or other substrates and modulators (1 06). Therefore, inhibition has 
been studied at various concentrations of CPT-11. As the high affinity component is 
most active at substrate concentrations of 5 j.lM, and cMOAT is most active at 250 j.lM, 
inhibitors of P-gp and cMOAT were compared at these concentrations. It appeared that 
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Figure 3. Primary active transport systems for CPT-11 and its metabolites in the bile 
canalicular membrane of humans indicating the hypothesis for the mechanism of 
toxicity caused by i.v. administration of CPT-11 [modified from Sugiyama et a/. 
(1 05)]. 
Abbreviations: 1, carboxylesterase mediated conversion; 2, CYP3A-mediated 
conversion; 3, UGT1 A-mediated conversion; 4, B-glucuronidase-mediated 
conversion. 
P-gp substrates or modulators like verapamil, PSC-833 (valspodar) or cyclosporine, 
inhibited the uptake of CPT-11 carboxylate most at concentrations of 5 11M. This 
suggests that P-gp might be the high affinity component in CPT-11 carboxylate 
transport (1 06). 
As an adverse effect, cyclosporine also inhibits bilirubin excretion and this may 
lead to hyperbilirubinemia (1 04). In the human Dubin-Johnson syndrome, chronic 
hyperbilirubinemia is seen as a result of a mutation in the cMOAT gene (107), and 
variability in the expression of this protein might play a role in the variability in 
experienced toxicity during CPT-11 treatment (1 03). 
Fecal Excretion 
In a mass balance study using radio labeled CPT-11, fecal excretion was the 
major route of drug elimination, with 63.7% of the administered drug recovered (20). 
28 
Review 
The unexpectedly high SN-38 concentrations and relatively low SN-38G 
concentrations in fecal specimens are suggestive for substantial B-glucuronidase 
activity in human intestinal contents, and consequently, the SN-38/SN-38G ratio was 
relatively high in all patients (20, 32). SN-38, APC and NPC are mainly excreted in 
feces; 2.5% and 1.7% for SN-38 and NPC, respectively (32). 
CONSIDERATIONS OF SCHEDULE AND ROUTE OF ADMINISTRATION 
Despite all kinds of dosing schedules, the total CPT-11 dose that can be tolerated 
in any time period is the same (23-25). Prolonged infusion times might theoretically 
improve the efficacy of CPT-11, as cytotoxicity of topoisomerase-1 inhibitors isS-phase 
specific (1 0), although the relevance of this principle for CPT-11, given the prolonged 
terminal disposition half-life of SN-38, is unclear. From xenograft models it was known 
that low-dose protracted schedules of CPT-11 administration were more effective and 
less toxic than the usual higher dosed short infusion periods (108, 109). Chronic low-
dose exposure of CPT-11 in patients has been studied recently (29, 39, 45, 110, 111 ), 
and revealed that the AUC ratios of lactone to total drug for CPT-11 and SN-38 were in 
the same range as for the shorter infusion periods (29). The maximal and 
recommended tolerated doses in these studies, 10 to 30 mg/m2/day, are much lower 
for the prolonged infusions than for the shorter durations. Surprisingly, the SN-38 AUC 
levels reach similar values as compared to those of the shorter infusion periods, 
presumably reflecting saturation of enzymatic biotransformation with the latter 
schedules (29, 39, 45, 11 0). 
Oral Administration 
Clearly, the availability of a suitable oral formulation of CPT-11 would allow more 
convenient use of prolonged dosing schedules. When human liver and intestine S9 
fractions were incubated with CPT-11, the agent was mostly hydrolyzed into SN-38 by 
liver, duodenal, jejunal and ileal fractions and less by colona! and rectal fractions (91, 
112). Since it has been discovered that CEsare widely expressed in the human liver 
and gastro-intestinal tract, it may be possible to effectively administer CPT-11 orally 
(112, 113), with the knowledge that substantial presystemic metabolism could take 
place. The low pH-value of the stomach may be favorable for the retention of CPT-11 
in its lactone form (113). 
Oral administration of CPT-11 in mice resulted in peak concentrations of CPT-11 
and SN-38 in plasma within 1 hOur after administration (114, 115), and the 
bioavailability of CPT-11 increased with increasing dose and amounted to 10 to 20% 
(115). In contrast, and of concern, the SN-38 AUC after oral administration did not 
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correlate linearly with the dose, and in fact even decreased with increasing CPT-11 
dose. It has been suggested that saturation of CE might cause this non-linear 
correlation (115), but the high levels of CE expressed in human intestinal tissues do 
not render this suggestion very likely (113). The higher SN-38 total to CPT-11 total 
ratios, compared with i.v. administration, suggest a presystemic CPT-11 conversion 
(116). Lactone versus carboxylate CPT-11 ratio was comparable with i.v. infusions, but 
the SN-38 ratio was much higher (113), suggesting a longer persistence of SN-38 
lactone when it is given orally. When CPT-11 was given orally to nude mice bearing 
human tumor xenografts, the agent retained its cytotoxic properties (53). Furthermore, 
in early clinical trials initial antitumor activity has been observed (113), suggesting that 
oral CPT-11 might be an attractive therapeutic option for the treatment of several 
human malignancies. 
The uptake rates of [' 4C]CPT-11 and [' 4C]SN-38 from hamster intestinal epithelial 
cells and human colon carcinoma HT29 cells were recently published, providing 
important insight into the absorption characteristics of these agents (117). The lactone 
forms of CPT-11 and SN-38 were transported mainly by a passive diffusion, while the 
carboxylate forms were absorbed as a result of an active transport mechanism. Both 
compounds were transported significantly more in their lactone form, and the uptake 
rates showed a clear pH-dependency, as the uptake decreased to 68% when the pH-
values were higher than 6.8. Lower SN-38 uptake rates also correlated with lower 
cytotoxicity (117). It was suggested that raising pH-values in human intestines might 
decrease the re-absorption of the drug and as a result it will lower the intestinal side 
effects (117). The clinical utility of this concept is currently under further investigation. 
Clearly, demonstration of unaltered pharmacokinetics of SN-38 in the presence of 
intestinal alkalization is of crucial importance. Thus, although these investigators have 
shown that this concept can reduce CPT-11-induced intestinal toxicity, this may be a 
pyrrhic victory if a simultaneously altered metabolic clearance (by way of a decreased 
enterohepatic recirculation of SN-38) results in reduced antitumor activity. 
Intraperitoneal Administration 
Intraperitoneal (i.p.) administration of CPT-11 has also been studied recently and 
may have some potential advantages over the i.v. route. It appeared that the therapy 
was more effective and less toxic in mice bearing C26 colon cancers (118). In mice 
bearing P388 leukemia ascites, substantially elevated peritoneal AUCs of CPT-11 and 
SN-38 were found, while the achieved plasma levels were comparable to those after 
i.v. dosing (118). If the i.p. administration of CPT-11 does not prove to have major local 
toxicities, this administration pathway might be an asset for the adjuvant therapy of 
colorectal cancer. 
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PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS 
Relationships between pharmacokinetic parameters and CPT-11-induced side 
effects have been studied extensively. For abdominal cramps, nausea, vomiting and 
anorexia no correlation with any parameter has been found (23). For 
myelosuppression and diarrhea in relation to the AUCs of CPT-11 and SN-38 
respectively, the findings are highly variable and final conclusions can not yet be drawn 
(Table 2; ref. 21, 29, 45). 
The product of the plasma AUC ratio of SN-38 to SN-38G and the plasma CPT-
11 AUC (viz., the biliary index) may be an important kinetic variable as it is thought to 
be correlated with SN-38 bile concentrations (66). Patients with high biliary indices, 
suggestive of high SN-38 biliary concentrations, in some studies experienced more 
severe diarrhea (graded 3 and 4 on the National Cancer Institute-Common Toxicity 
Criteria scale) than those with low biliary indices (31, 66), but this could not be 
confirmed in other studies (21, 119, 120). It has been hypothesized that consideration 
of interindividual differences in fecal B-glucuronidase activity would likely assist in a 
more accurate prediction of CPT-11-induced intestinal side effects, and may provide a 
basis to modulate the experienced toxicity (32). 
Table 2. Correlation between toxicities and the AUCs of CPT-11 and SN-38. 
Observed toxicity CPT-11 AUC SN-38AUC Refs. 
Neutropenia No No 26,29,40,45 
No Yes 23,39 
Yes Yes 21,22,25,27 
Diarrhea No No 21,23,29,45 
No Yes 40 
Yes No 26,39 
Yes Yes 22,25,27 
EVALUATION OF DRUG INTERACTIONS 
Drug interactions may arise as a result of altered pharmacodynamics or 
pharmacokinetics of the drugs involved. In the case of pharmacokinetic interactions, 
this is usually due to modification of tissue disposition and metabolism of the drugs. 
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These phenomena are of particular importance in cancer chemotherapy when 
cytotoxic agents are used, because of the increased risks of severe toxicity. Most of 
the data currently available to evaluate potential drug interactions with CPT-11 come 
from clinical trials of CPT-11 given in combination with one or more other anticancer 
agent(s) (Table 3). Although in several cases only limited infonmation is available, 
some (preliminary) conclusions can be drawn. 
Table 3. Evaluation of pharmacokinetic interactions between CPT-11 and anticancer agents. 
Combination drug(s) Dose (CPT-11) Kinetic alterations Refs. 
(mg/m2) 
Carboplatin 5" (60) AUCcPT-11 .J.; AUCsN-38 .J. 127, 128 
Cisplatin 80 (260) none 32,119,120, 
124, 125 
CisplatinNindesine 100/3.0 (37.5) none 121, 122 
Cisplatin!lfosfamide 70/1.5 (60) none 123 
Docetaxel 75 (200) none 135 
70 (250) none 149 
50 (60) none 150 
Etoposide 80 (80) none 30 
5-Fiuorouracil 500(125) AUCcPT-11 I; AUCsN-38 .J. 130 
5-Fiuorouracil/ 
Leucovorin 2600 (80) none 131' 132, 134 
Oxaliplatin 85 (200) none 148 
Paclitaxel 175 (150) AUCcPT-11 I; AUCsN-38 I 136, 137 
75 (50) none 139 
Raltitrexed 3.0 (350) none 151 
a Target AUC in mg.min/mL 
Pharmacokinetic interaction studies have been performed with cisplatin either 
given alone or in combination with vindesine (121, 122) or ifosfamide (123), and 
indicated unaltered disposition profiles of both CPT-11 and its metabolites at any dose 
level or sequence tested (124-126). Likewise, the pharmacokinetics of carboplatin 
were not influenced by CPT-11, although in one study, the AUC of both CPT-11 and 
SN-38 was lower than expected, suggesting increased clearance of CPT-11 when 
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given together with carboplatin (127, 128). The basis for this apparent change in 
pharmacokinetic behavior is unknown, although an effect on CYP3A expression due to 
prior exposure to carboplatin can not be excluded (129). 
In a Japanese study, altered pharmacokinetics were also found when 5-
fluorouracil was administered immediately after CPT-11 infusion (130). Compared with 
an earlier CPT-11 monotherapy study conducted by the same group, the AUG of CPT-
11 substantially increased while the AUG of SN-38 decreased. An inhibition of CE by 
5-FU was suggested to explain these unexpected results (130). Other studies did not 
find altered pharmacokinetics for this combination therapy or eventually with the further 
addition of leucovorin (folinic acid) (131-134). The conclusion from the Japanese study 
has been criticized in view of the large interpatient variation and non-comparable 
patient populations (134). 
Although no comparative pharmacokinetic data are available it has also been 
suggested that an interaction or sequence-dependent effect is present for the 
combination of CPT-11 and docetaxel. As both drugs are metabolized by CYP3A, 
competition might occur when these drugs are given sequentially, and as a result, the 
clearance of docetaxel might be decreased (135). A significant pharmacokinetic 
interaction has been observed between CPT-11 and paclrraxel, which is characterized 
by increased plasma levels of both CPT-11 and SN-38 (136). Similar reactions have 
also been reported in rats (137), and Cremophor EL, the vehicle used for paclitaxel 
formulation seems to play a mayor role (1 04). This type of interaction appears to be 
related to micellar encapsulation of certain agents in this vehicle, and has also been 
demonstrated to occur with paclitaxel itself and anthracyclines (138). In any event, 
because this interaction occurs during the terminal disposition phase of CPT-11, in 
currently applied dosing schedules the interaction is likely of only minor importance. 
The combination of weekly administration of CPT-11 with a fixed dose of paclitaxel (75 
mg/m2) indicated that the sequence of drug administration did not affect elimination of 
CPT-11 (139). There was also no sequence-dependent chemotherapy-related toxicity. 
To date, no other cytotoxic drug has been shown to affect the pharmacokinetics of 
CPT -11 or was affected itself by CPT -11. 
Anticonvulsants, phenytoin and phenobarbital in particular, are known to induce 
several metabolic pathways relevant to xenobiotics. CYP3A4, in particular, has 
increased expression when patients are treated with these compounds. Indeed, a 
recent study in patients with recurrent or progressive malignant glioma receiving CPT-
11 and phenytoin indicated that AUCs of CPT-11, SN-38 and SN-38G were 
approximately 40%, 25% and 25%, respectively, of those determined previously in 
patients with metastatic colorectal cancer not receiving antiepileptics (140). Similarly, 
enzyme-inducing anticonvulsants significantly lowered systemic exposure to CPT-11 
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importance since it suggests that anticonvulsants thereby largely reduce the potential 
antitumor effects of CPT-11. In addition to modulation of CYP3A4, another possible 
explanation for the interaction is the induction of membrane transporters that enhance 
drug excretion (142). 
CONCLUSIONS AND PERSPECTIVES 
CPT-11, because of its broad spectrum of antitumor activity, is clearly one of the 
most important new anticancer drugs developed in the last few decades. The clinical 
pharmacokinetic behavior of CPT-11 has been explored extensively in recent years, and 
the generated information has been of fundamental importance in our understanding of 
the clinical effects of this agent (Table 4). 
Table 4. Factors contributing to variability in response to CPT-11. 
Parameter Source of variability 
Dose selection Patient's condition 
Host sensitivity 
Systemic exposure Concomitant drugs 
Pharmacogenetics 
Altered organ functions 
Example(s) 
Performance status 
Previa us treatments 
Cyclosporin A (P-glycoprotein 
inhibitor) 
Valproic acid (UGT1A1 inhibitor) 
Phenobarbital (UGT1A1 inducer) 
Phenytoin (CYP3A4 inducer) 
Ketoconazole (CYP3A4 inhibitor) 
Gilbert's syndrome 
(UGT1A1 mutation) 
Crigler-Na]ar type 1 syndrome 
(UGT1 A 1 deficiency) 
Dubin-Johnson syndrome 
(cMOAT mutation) 
Hepatic dysfunction 
Active site levels Resistance mechanisms P-glycoprotein 
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Topoisomerase I mutations 
CYP3A4 and/or UGT1A1 
Overexpression 
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In addition, a wealth of information has become available that has yielded valuable 
insight into the mechanism of action, the mechanisms of tumor resistance, toxicities, 
and considerations of dosage and schedule and route of drug administration. Many of 
these studies have been made possible by the development of selective analytical 
methodologies to specifically monitor the parent drug and individual metabolites, with 
sufficient sensitivity to detect the compounds at levels achieved after therapeutic 
dosing. However, only through further investigations that may allow better definition of 
the biochemistry and phanmacokinetics of CPT-11 can the rational optimization of 
therapy involving this agent be achieved. This need has become even more important 
in light of the current clinical use of CPT-11 in combination with other antineoplastic 
drugs or agents specifically administered to modify CPT-11-induced toxicity profiles 
(143). In this respect, the use of mathematical models to predict systemic exposure 
measures for CPT-11 and its metabolites by application of limited-sampling strategies 
(38, 41, 144-147), coupled with continued investigations into the role of individual 
enzyme-expression levels and detection of enzyme polymorphisms, will allow more 
rational and selective chemotherapy with this agent. 
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ABSTRACT 
The clinical pharmacokinetics of the antineoplastic agent irinotecan (CPT-11) are 
associated with substantial interpatient variability. The degree to which this variability in 
CPT-11 exposure impacts upon the response and toxicity of the drug has not yet been 
properly determined. In general, the area under the plasma concentration-time curve 
(AUC) is an appropriate indicator of exposure, but requires collection of up to 17 timed 
blood samples. This presents difficulties if large-scale population samplings are 
required. The present study involved the development and validation of a strategy to 
estimate the AUCs of the lactone and total (i.e. lactone plus carboxylate) forms of 
CPT-11 and its active metabolite SN-38 from a limited number of blood samples in 
patients co-treated with cisplatin. Using data from 24 patients, univariate and 
multivariate regression analyses were employed to generate the models. The best 
predictive models for simultaneous estimation of CPT-11 and SN-38 AUCs were 
obtained with three time points at 0.5, 1.67 and 5.50 h after start of the 90-min i.v. 
infusion of CPT-11. The models were tested separately in another group of 24 patients 
receiving the same combination treatment. This validation set demonstrated that CPT-
11 and SN-38 AUCs after standard dose administration could be predicted sufficiently 
unbiased and precise with three timed samples to warrant clinical application. 
INTRODUCTION 
The antineoplastic agent irinotecan (CPT-11; 7-ethyl-1 0-[4-(1-piperidino)-1-
piperidino] carbonyloxycamptothecin) is a promising water soluble semisynthetic 
derivative of camptothecine, a plant alkaloid from the Chinese tree Camptotheca 
acuminata (1, 2). The drug displays potent antitumor activity against a variety of 
tumors, and has recently been approved for the treatment of refractory colorectal and 
ovarian carcinomas in several countries (3). The mechanism of action of CPT-11 and 
its structurally related analogues is thought to be related to inhibition of the intranuclear 
enzyme topoisomerase-1, thereby indirectly impeding DNA-replication and RNA-
transcription (4). 
CPT-11 and its active metabolite SN-38 (7-ethyl-1 0-hydroxycamptothecin; Figure 
1) are both subject to a rapid, reversible, pH-dependent hydrolysis of a lactone ring 
moiety in the molecule, generating an open-ring carboxylate (5). At neutral or 
physiologic pH, e.g. in blood, the equilibrium between the two drug species favors the 
pharmacologically less active carboxylate for most camptothecines (6). However, the 
relative importance of the lactone-carboxylate interconversion of CPT-11 and SN-38 
with respect to pharmacodynamic outcome is still not completely understood. 
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Furthennore, the clinical pharmacokinetic behavior of GPT-11 is associated with a 
substantial degree of interindividual variability. Thus, careful measurement of both drug 
fonns is clearly warranted in order to fully characterize the clinical phannacology of 
these agents. 
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Figure 1. Chemical structures of the lactone (A) and carboxylate (B) forms of CPT-11, its 
active metabolite SN-38, and the related compound camptothecin. 
The major dose-limiting toxicities encountered with single agent GPT-11 therapy 
were neutropenia and diarrhea (7). Relationships for GPT-11 and SN-38 between 
clinical pharmacokinetics and pharmacodynamic outcome are extremely complex and 
not thoroughly discerned (reviewed in Takimoto and Arbuck; Ref. 8). Based on the 
knowledge of camptothecine pharmacology, GPT-11 induced myelosuppression 
probably occurs due to the inhibition of topoisomerase-1 by SN-38 lactone in bone 
marrow cells. In contrast, acute GPT-11 mediated diarrhea is most likely caused by the 
anticholinesterase activity of the parent compound. Supporting this theory are reports 
that the area under the plasma concentration-time curve (AUG) of SN-38 correlated 
with myelosuppression and the AUG of GPT-11 correlated with diarrhea (8, 9). 
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However, some studies have not found such associations, indicating that additional 
studies applying selective analytical methods are essential to help clarify these 
contrasting results. Such studies will likely involve large numbers of patients and 
generally require the collection of up to 17 timed blood samples after i.v. drug 
administration (1 0). Thus, the objective of the current study was to develop a model for 
prediction of the AUCs of CPT-11 and SN-38 from a limited blood sampling schedule 
in patients with advanced solid cancer receiving the drug in combination with cisplatin. 
MATERIALS AND METHODS 
Patients and Treatment 
The pharmacokinetic models were developed and validated in 48 patients with 
proven malignant solid tumors, participating in a phase I and pharmacokinetic study of 
combined chemotherapy with CPT-11 and cisplatin (9). Detailed clinical and 
toxicological profiles will be reported separately. Inclusion criteria included the 
following: (a) no more than one prior combination chemotherapy regimen or two single 
agent regimens; (b) off previous anticancer therapy for at least 4 weeks (6 weeks if 
nitrosoureas, mitomycin or radiotherapy); (c) no prior treatment with topoisomerase-1 
inhibitors or platinum derivatives; (d) age between 18 and 70 years; (e) WHO 
performance status o>2; (~ life expectancy greater than 12 weeks; (g) adequate bone-
marrow, liver and renal functions and symptomatic peripheral neurotoxicity graded 1 or 
less (according to National Cancer Institute Common Toxicity Criteria). Written 
informed consent was obtained from all patients prior to treatment in accordance with 
the guidelines of the institutional review board. 
CPT-11 was provided by Aventis Pharma (Antony, France) as an aqueous 
formulation containing d-sorbitol, lactic acid and sodium hydroxide with a final pH-value 
of 3.5. The drug was administered at dose levels ranging from 175 to 300 mg/m2 as a 
90-min i.v. infusion. Cisplatin was given as a 3-h intravenous infusion directly after the 
end of the CPT-11 infusion. 
Pharmacokinetic Analysis 
For CPT-11 and SN-38 pharmacokinetic analysis heparinized blood samples 
were drawn from an indwelling cannula at 0.5, 1.5, 1.67, 1.83, 2.0, 2.5, 3.5, 4.5, 5.0, 
5.5, 6.5, 8.0, 12.0, 25.5, 32.0, 49.5 and 56.0 h after the start of the infusion. The 
plasma fraction was obtained by centrifugation and analyzed for CPT-11 and SN-38 
using a validated reversed-phase high-performance liquid chromatography system with 
fluorescence detection (11). The lower limits of quantitation were 0.5 ng/mL for the 
lactone forms (1-mL samples) and 2.0 ng/mL for the total forms (0.25-mL samples), 
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respectively. The percentage deviation from the nominal value and the between-run 
and within-run precision were always less than 15.0%. 
GPT-11 and SN-38 (lactone and total) concentration-time data of all patients 
were fitted to a tri-exponential equation. using Siphar version 4.0 (lnnaPhase. 
Philadelphia, PA), based on discriminating tests described elsewhere (12). All 
compartmental analyses were obtained by inverse square weighting of the obseNed 
concentration. The terminal drug disposition half-life [t,!2(y)] and the AUG from time 
zero to infinity were determined on the basis of the best fitted cuNes, whereas the 
peak plasma concentration (Gmax) was determined graphically from semi-logarithmic 
concentration-time plots. 
Model Development and Validation 
Limited sampling models were constructed on a training data set that contained 
24 patients, randomly assigned from each separate dose level to avoid bias in the 
predictive values of one set to another. The models were constructed by assuming that 
concentration(s) at a fixed time could predict the AUG of each of the compounds of 
interest simultaneously. Simple linear correlations were initially determined between 
the concentrations at each time point (independent variables) and the corresponding 
AUG (dependent variable) by a univariate linear-regression analysis, to find the optimal 
single-sample time point for each substance measured. Next, forward stepwise 
multivariate-regression analyses was undertaken to develop the best linear equation 
describing the association between concentrations at more than one time point and 
AUG, to increase the precision of the method. The optimal model was eventually 
identified on the basis of Pearson's correlation coefficient (t), and root mean square 
residual values as determined from the regression (13). 
The pharmacokinetic data from the remaining 24 patients was used to validate 
the applicability of the constructed models. This was achieved by comparing actual 
AUGs from the tri-exponential computer fit with estimated AUGs using the best single 
or multiple time-point models developed from the training set. The predictive 
performance of the developed models was evaluated using calculations of bias (or 
percentage mean predictive error; %MPE) and precision (or percentage root mean 
square error; %RMSE). Due to missing concentrations in this data set at the relevant 
time points, 3 patients were excluded from validation. Pearson's correlation coefficient 
was used to rank the concordance between measured and predicted AUGs. 
Differences in patient demographics and pharmacokinetics between training and 
validation set patients were evaluated by using Student's t-test. All statistical 
calculations were performed with the Number Gruncher Statistical System software 
version S.X (Dr JL Hintze, East Kaysville, UT, 1992). 
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RESULTS 
Pharmacokinetic studies were completed in 48 patients with various types of solid 
tumors, treated with a 90-min i.v. infusion of CPT-11, directly followed by a 3-h infusion 
of cisplatin. The total group of patients was composed of 31 males and 17 females, 
with a mean age 53 years and a median Eastern Cooperative Oncology Group 
performance status of 0 (Table 1 ). Patients were randomly divided in two groups, a 
training set and a validation set, both containing 24 patients. No significant differences 
were observed between both groups in patient characteristics (Table 1 ). 
Table 1. Patient demographics. 
Characteristic 
No. of patients 
Age (years/range) 
Sex (male/female) 
ECOG performance status (0/1/2) 
Primary tumor site 
colo rectal 
lung 
pancreas 
mesothelioma 
tonsil 
unknown 
other 
'Results expressed as mean value (range). 
Training set 
24 
53 (42-69) 
16:8 
17:7:0 
12 
3 
2 
2 
2 
2 
Validation set 
24 
52 (36-68}" 
15:9 
14:9:1 
9 
3 
0 
0 
1 
4 
7 
The mean plasma concentration-time curves for the lactone and total forms of 
CPT-11 and SN-38 in all patients treated at a dose level ol200 mg/m2 of CPT-11 are 
shown in Fig. 2. During the drug infusion, the plasma concentrations of the lactone and 
total forms of CPT-11 and SN-38 increased steadily, after which a decrease was 
observed with a decay best described by a tri-exponential equation. Relatively large 
amounts of CPT-11 and SN-38 were continually present in the lactone forms of these 
substances, as described for these compounds previously (14). The terminal 
elimination phases of CPT-11 lactone and total were more rapid than those of the SN-
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38 forms, which resulted in prolonged biological half-lives for the active metabolite 
relative to CPT-11. A summary of the main pharmacokinetic parameters, including 
AUC, Cm"' and t,l2(y) of CPT-11 and SN-38 between the two patient groups is 
presented in Tables 2 and 3, respectively. 
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Figure 2. Plasma concentration-time curves of CPT-11 (triangles) lactone and total and of SN-
38 (circles) lactone and total in 17 patients given CPT-11 at 200 mg/m' as a 90 min 
i.v. infusion. The open symbols represent the lactone forms and the closed symbols 
represent the total forms of CPT-11 and SN-38. All pharmacokinetic curves were 
fitted to a tri-exponential equation, using Siphar version 4.0 (lnnaPhase), assuming a 
three-compartment model for distribution and elimination of the compounds. Data 
are presented as mean values (symbols)± SO (error bars). 
There were no significant differences in any pharmacokinetic parameter between the 
two groups as shown by an unpaired two-sided Student's t-test (Tables 2 and 3). 
lnterpatient variability in the concentrations of CPT-11 and SN-38 in the training and 
validation sets at each of the 17 sample-time points was large (coefficient of variation 
ranged from 64% (0.5 h) to 96% (1.67 h). The interpatient variability in corresponding 
AUCs of CPT-11 and SN-38 was slightly dependent on the dose level and ranged from 
46%to 64%. 
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Table 2. Summary of the plasma pharmacokinetic parameters of CPT-11 total and lactone 
after a 90-min i.v. infusion of CPT-11 in the training (A) and validation (B) sets. 
Data represent mean values± SD. 
Dose level Set n AUCo-total AU Co- lactone Cmax total 
(mg/m2) (~g.h/ml) (~g.h/ml) (!lg/ml) 
175 A 1 6.53 2.03 1.37 
B 2 7.77, 15.9 2.36, 4.78 2.39, 3.16 
200 A 9 11.5±3.75 3.79±0.98 2.49±0.35 
B 7 12.8±3.01 3.66±0.78 2.51±0.41 
230 A 3 13.1±2.65 4.32±1.43 2.98±0.72 
B 4 17.7±2.05 5.02±1.11 3.32±0.30 
260 A 6 13.5±4.65 4.01±1.07 2.61±0.65 
B 6 13.6±5.88 4.86±2.19 2.70±0.72 
300 A 5 22.3±13.3* 6.20±2.96 4.04±1.45* 
B 5 21.2±5.92 7.27±2.61 4.17±1.22 
Dose level Set n Cmax lactone t112(y) total t112(Y) lactone 
(mg/m2) (~g/ml) (h) (h) 
175 A 1 0.60 12.14 12.80 
B 2 1.07, 1.80 8.48, 11.1 5.43, 7.94 
200 A 9 1.04±0.22 14.2±7.80 17.3±10.4 
B 7 1.12±0.22 13.6±5.82 12.2±5.65 
230 A 3 1.50±0.68 9.21±2.20 13.4±3.72 
B 4 1.39±0.29 11.5±2.22 9.62±2.61 
260 A 6 1.31±0.30 12.6±5.86 12.8±4.21 
B 6 1.38±0.43 11.4±1.81 11.2±2.41 
300 A 5 1.71±0.59 11.5±2.97* 12.9±3.67 
B 5 1.97±0.59 12.5±1.72 12.0±2.64 
All parameters were obtained from a nonlinear three-compartment computer-fitted model with 
1/(concentration)2 weighting. Results are shown as mean ±SO. Abbreviations: n, number of 
data sets; AUC, area under the plasma-concentration time curve; Cmax. maximum plasma 
concentration; t1!2(y), terminal elimination half-life. 
*n=4. 
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Table3. Summary of the plasma pharmacokinetic parameters of SN-38 total and lactone 
after a 90-min i.v. infusion of CPT-11 in the training (A) and validation (B) sets. 
Data represent mean values± SD. 
Dose level Set n AUCo- total AU Co- lactone Cmax total 
(mg/m2) (Jlg.h/ml) (Jlg.hlml) (ng/ml) 
175 A 1 0.13 0.07 11.43 
B 2 0.29, 0.35 0.16, 0.17 44.6, 47.4 
200 A 9 0.43±0.20 0.21±0.08 36.7±10.9 
B 7 0.30±0.08 0.16±0.05 29.2±7.25 
230 A 3 0.39±0.16 0.16±0.04 27.4±3.50 
B 4 0.79±0.46 0.27±0.08 57.9±25.8 
260 A 6 0.34±0.18 0.22±0.07 40.3±15.8 
B 6 0.51±0.22 0.31±0.13 44.4±14.5 
300 A 5 0.43±0.25 0.33±0.21 47.9±27.6 
B 5 0.51±0.22 0.35±0.14 51.2±18.5 
Dose level Set n Cmax lactone t112(y) total t, 12(y) lactone 
(mg/m2) (ng/mL) (h) (h) 
175 A 1 6.52 7.72 6.76 
B 2 27.5, 27.7 16.87, 10.3 13.9, 13.2 
200 A 9 25.1±7.33 30.4±15.1 24.8±7.61 
B 7 20.8±7.35 20.3±7.64 19.3±5.09 
230 A 3 18.4±5.43 42.0±35.2 18.3±7.99 
B 4 42.8±26.5 29.9±14.5 23.4±6.83 
260 A 6 25.7±11.3 23.1±10.6 29.8±15.5 
B 6 31.5±8.00 26.9±10.9 23.0±5.80 
300 A 5 36.7±27.2 29.9±18.0 39.9±19.3 
B 5 38.4±12.5 29.8±14.6 30.8±11.7 
All parameters were obtained from a nonlinear three-compartment computer-fitted model with 
1/(concentration)2 weighting. Results are shown as mean ±SO. Abbreviations: n, number of 
data sets; AUC, area under the plasma-concentration time curve; Cmax. maximum plasma 
concentration; t112(y), terminal elimination half-life. 
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Table4. Univariate correlation of CPT-11 and SN-38 (lactone and total) concentrations at 
each sample-time point with the corresponding AUC in the training-data set. 
Time point CPT-11 lactone CPT-11 total SN-38 lactone SN-38total 
(h) n r n r n r n r 
0.5 23 0.633 23 0.611 17 0.362 24 0.097 
1.5 22 0.607 22 0.790 22 0.478 23 0.332 
1.67 21 0.422 23 0.841 19 0.823 23 0.523 
1.83 22 0.676 23 0.923 22 0.505 24 0.611 
2.0 24 0.473 23 0.929 24 0.691 24 0.651 
2.5 23 0.766 23 0.942 22 0.477 24 0.686 
3.5 22 0.883 23 0.954 20 0.690 24 0.637 
4.5 23 0.857 23 0.959 24 0.686 24 0.712 
5.0 23 0.886 23 0.968 23 0.742 24 0.636 
5.5 23 0.920 23 0.965 24 0.598 23 0.743 
6.5 23 0.873 22 0.950 22 0.486 23 0.661 
8.0 21 0.938 21 0.946 20 0.621 22 0.586 
12.0 21 0.619 21 0.873 20 0.419 20 0.621 
25.5 23 0.842 23 0.898 23 0.426 15 0.480 
32.0 20 0.756 22 0.894 19 0.477 12 0.528 
49.5 23 0.481 22 0.723 20 0.378 8 0.223 
56.0 23 0.396 23 0.712 18 0.377 8 0.126 
Abbreviations: n, number of data sets at that specific time point; r, Pearson's correlation 
coefficient. 
CPT-11 and SN-38 (both lactone and total) concentrations at each sample-time 
point were correlated with their AUC by using univariate-regression analysis for the 
training-data set (Table 4). The correlation coefficient ranged from 0.396 to 0.938 for 
CPT-11 lactone, from 0.611 to 0.968 for CPT-11 total, from 0.362 to 0.823 for SN-38 
lactone and from 0.097 to 0.743 for SN-38 total (Table 4). The best correlation was 
found at the sample-time point of 5.50 h, taken all substances into account 
simultaneously. Following this univariate-regression, multivariate-regression with a 
restriction to models with no more than two additional time points was evaluated. In the 
trivariate models, sample-time point combinations with the highest correlation and 
precision (lowest %RMSE), were found at different sample-time points for CPT-11 
total, CPT-11 lactone, SN-38 total and SN-38 lactone (data not shown). Assuming the 
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lactone forms being most predictive for toxicities of the given drug, the best sample-
time points for the combination of CPT-11 lactone and SN-38 lactone were used for 
further model development. 
The most predictive sample-time points were found at 0.5, 1.67 and 5.5 h after 
the start of infusion. In the training-data set, the models of all substances 
demonstrated little bias, with values for the %MPE ranging from 0.22 to 0.85 (Table 5). 
In this set, the correlation coefficient of SN-38 total was estimated at 0.764 with a 
%RMSE of 21.1 %, suggesting less correlation and lower accuracy than found for the 
other compounds (correlation coefficients ranging from 0.903 for SN-38 lactone to 
0.982 for CPT-11 total and %RMSE ranging from 6.83 for CPT-11 total to 7.94 for SN-
38 lactone). 
TableS. Limited-sampling models for the prediction of the AUCs of CPT-11 lactone and 
total and of SN-38 lactone and total. 
Models: 
Model 
A 
B 
c 
D 
A 
B 
c 
D 
r 
AUCcPT-11 lactooe (~g.h/mL) = 1.11*Co.s + 0.0531*C1.67 + 16.53*Cs.s + 
0.439 
AUCcPT-11 total (~g.h/mL) = 1.84*Co.s + 1.19*C1.67 + 11.5*Cs.s + 0.215 
AUCsN-38 lactooe ~g.h/ml) = 2.46*Co.s + 2.36*C1.67 + 9.66*Cs.s + 0.0521 
AUCsN-3Btotal (~g.h/mL) = -6.27*Co.s + 3.72*C1.67 + 20.2*Cs.s + 0.121 
Training set Validation set 
%MPE %RMSE r %MPE %RMSE 
0.953 0.34 7.88 0.936 0.36 11.3 
0.982 0.22 6.83 0.966 0.10 3.31 
0.903 0.52 7.94 0.443 1.06 31.7 
0.764 0.85 21.1 0.869 1.08 29.8 
Abbreviations: r, Pearson's correlation coefficient; %MPE, percentage mean predictive error; 
%RMSE, percentage root mean-squared predictive error; AUC, area under the plasma-
concentration time curve; C0.5, C1.67 and Cs.s are the plasma concentrations in f.tg/ml at 0.5, 
1.67 and 5.5 h after start of infusion. 
Next, we used the validation-data set, containing the remaining 24 patients to 
evaluate the predictive performance of the developed models. For CPT-11 lactone and 
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total, correlation coefficients were 0.936 and 0.966 respectively, with the %MPE (0.36 
and 0.10 respectively) and the %RMSE (11.30 and 3.31 respectively) were low, 
indicating minor bias and excellent precision (Table 5 and Fig. 3). 
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Figure 3. Observed correlations between the measured AUC using a linear three-
compartment computer-fitted model with 1/(concentration)2 weighting and the 
predicted AUC from the limited sampling models (Table 5) for CPT-11lactone (A), 
CPT-11 total (B), SN-38 lactone (C) and SN-38 total (D). In all models plasma 
samples were taken at sample-time points of 0.5, 1.67 and 5.5 h after the start of 
infusion. Closed symbols represent data from the training set and open symbols 
data from the validation set. Pearson's correlation coefficients in the training and 
validation sets were 0.953 and 0.936 for CPT-11 lactone, 0.982 and 0.966 for 
CPT-11 total, 0.903 and 0.443 for SN-38 lactone, and 0.764 and 0.869 for SN-38 
total, respectively. The solid lines represent the lines of identity. 
For SN-38 total, similar acceptable data could be obtained using the same model. 
However, in the validation data-set SN-38 lactone data showed poor results for the 
correlation coefficient, %MPE and %RMSE, due to a poor correlation between AUG 
and concentrations at the higher dose levels of CPT-11 (230 to 300 mg/m2). Hence, 
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the limited-sampling model was not suitable for prediction of SN-38 lactone AUCs in 
patients treated at dose levels of CPT-11 higher than 230 mg/m2. 
We also performed an additional analysis to evaluate the use of CPT-11 and SN· 
38 total concentrations for prediction of the AUCs of the respective lactone drug forms. 
In general, the best models demonstrated deteriorated correlations and poor accuracy, 
with values for the %RMSE of up to 42% (data not shown). 
DISCUSSION 
In recent years, various statistical models have been developed for antineoplastic 
agents to predict pharmacokinetic parameters from a limited blood sample schedule 
(15). Previous studies have indicated that such strategies are also feasible for the 
estimation of CPT-11 and SN-38 pharmacokinetics with the drug given by i.v. infusion, 
although no differentiation has been made solar between the lactone and carboxylate 
forms of the compounds (16·19). In view of the discrepant data published on 
relationships between drug levels and the observed toxicity, further investigations of 
CPT -11 kinetics including separate quanfltation of the lactone and the total forms of 
CPT-11 and SN-38 are clearly needed. Previously described limited-sampling models 
differed considerably in administered dose and infusion duration and are only valid for 
CPT-11 given as a single agent. In our current study, the follow-up period for sample 
collection after infusion was much longer as compared to the other studies, resulting in 
more reliable pharmacokinetic data. Moreover, our limited-sampling models are the 
first applicable for CPT-11 given in combination with another drug, in this case 
cisplatin. 
To achieve high predictive values for the developed models, i.e. high correlation 
coefficients and precision with low bias (12), at least three sample-time points were 
required in all models. Although inclusion of additional samples might have upgraded 
the predictive performance of the models, fewer samples are more cost-effective and 
convenient for the patients. In addition, sampling over shorter periods enables 
pharmacokinetic-pharmacodynamic studies during day-time treatment in an outpatient 
setting, even in multi-institutional clinical trials. 
The pharmacokinetic behavior of SN-38, the principal (active) metabolite of CPT-
11, is markedly different from that of the parent drug. The objective of our approach 
was to accurately predict the AUCs of CPT-11 and SN-38 simultaneously in both 
lactone and total drug forms, from only three sample-time points. The best compro-
mise for the concurrent determination of the AUCs was found at the sample-time 
points at 0.5, 1.67 and 5.5 hours after the start of infusion. In selecting these sample-
time points, clinical constraints also were taken into consideration. For example, the 
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samples have to be taken as early as possible after infusion, in view of the potential 
future usage of CPT-11 in clinical practice with drug-level monitoring for adaptive 
controlled dosing. In addition, a late sample-time point is not clinically convenient as it 
makes outpatient treatment difficult or even impossible. For all four limited-sampling 
models developed, the first sample-time point (at 0.5 h) is critical, for it is part of the 
ascending part of the concentration-time cuNes. The second point (at 1.67 h) lies just 
after the end-of-infusion time-point, and is indicative for near-maximum plasma 
concentrations of CPT-11 and SN-38. The third sample point (at 5.5 h) is also 
important for it is part of the descending part of the concentration-time cuNes. 
Theoretically, limited-sampling strategies employing other sample-time points which 
are also predictive, could have been constructed, but would probably lack the above 
mentioned advantages. 
The CPT-11 total AUC is an important pharmacologic parameter, essential for 
the calculation of the total body clearance and for the calculation of individual 
metabolic ratios. The active lactone fonms, especially that of SN-38, are important as 
they are assumed to be the real cytotoxic species and responsible for the toxic effects 
of CPT-11 therapy (8). The proposed models for estimation of the AUCs of CPT-11 
lactone and total and SN-38 total were shown to be valid, with excellent predictive 
utility in a large group of patients given CPT-11 at different dose levels in combination 
with cisplatin. In case of SN-38 lactone, however, the AUG estimates were slightly 
biased and less predictable especially at dose levels of >230 mg/m2• In combination 
therapy studies, for instance with cisplatin, these high dose levels of CPT-11 may be 
less relevant for clinical practice, and therefore this model can still be considered 
useful in a normal clinical setting. Other studies confirmed the variable and less 
predictive behavior of SN-38 in limited-sampling model development, probably due to 
the complex phanmacokinetics of this metabolite (20-22). 
In future clinical studies, our limited-sampling models will enable prediction of the 
systemic exposure to CPT-11 and SN-38. Studies to examine the relationships 
between CPT-11 and SN-38 pharmacokinetics and pharmacodynamics could be 
explored conveniently using our model and sampling strategy. In our continued 
investigations, we will be examining these relationships in a future clinical phase II trial 
with combined CPT-11 and cisplatin chemotherapy. 
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ABSTRACT 
Puroose: To build population pharmacokinetic (PK) models for irinotecan (CPT-11) and 
its currently identified metabolites. 
Patients and Methods: Seventy cancer patients (24 women and 46 men) received 90-
minute intravenous infusions of CPT-11 in the dose range of 175 to 300 mg/m2• The 
PK models were developed to describe plasma concentration profiles of the lactone 
and carboxylate forms of CPT-11 and 7-ethyl-10-hydroxy-camptothecin (SN-38) and 
the total forms of SN-38 glucuronide (SN-38G), 7-ethyi-10-[4-N-(5-aminopentanoic 
acid)-1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-1 0-[4-amino-1-
piperidino]-carbonyloxycamptothecin (NPC) by using NONMEM. 
Results: The interconversion between the lactone and carboxylate forms of CPT-11 
was relatively rapid, with an equilibration half-life of 14 minutes in the central 
compartment and hydrolysis occurring at a rate live times laster than lactonization. The 
same interconversion also occured in peripheral compartments. CPT-11 lactone had 
extensive tissue distribution (steady-state volume of distribution [V,], 445 L) compared 
with the carboxylate form (Vss, 78 L, excluding peripherally formed CPT-11 
carboxylate). Clearance (CL) was higher lor the lactone form (74.3 Uh), compared with 
the carboxylate form (12.3 Uh). During metabolite data modeling, goodness of fit 
indicated a preference of SN-38 and NPC to be formed out of the lactone form of CPT-
11, whereas APC could be modeled best by presuming formation from CPT-11 
carboxylate. The interconversion between SN-38 lactone and carboxylate was slower 
than that of CPT-11, with the lactone form dominating at equilibrium. The Cls for SN-
38 lactone and carboxylate were similar, but the lactone form had more extensive 
tissue distribution. 
Conclusion: Plasma data of CPT-11 and metabolites could be adequately described 
by this compartmental model, which may be useful in predicting the time courses, 
including interindividual variability, of all characterized substances after intravenous 
administration of CPT-11. 
INTRODUCTION 
lrinotecan (CPT-11), an inhibitor of DNA topoisomerase I, is widely used in the 
treatment of several types of tumors, including colo rectal cancer (1 ). CPT-11 is 
extensively metabolized in the liver to various metabolites. It is cleaved enzymatically 
by carboxylesterases to form 7-ethyl-10-hydroxycamptothecin (SN-38), which has 
cytotoxic activity that is 100 to 1,000 times greater than that of the parent drug (2). SN-
38 is further conjugated to an inactive glucuronide (SN-38G) by uridine diphosphate 
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glucuronosyltranslerases (3, 4). Other CPT-11 metabolites identified are the major 
plasma metabolite 7-ethyl-1 0-[4-N-(5-aminopentanoic acid)-1-piperidino]-
carbonyloxycamptothecin (APC) and 7 -ethyl-1 0-[4-amino-1-piperidino]-
carbonyloxycamptothecin (NPC), resulting from a ring-opening oxidation of the terminal 
piperidine ring of CPT-11 mediated by cytochrome P450 3A4 enzymes (5, 6). 
CPT-11 and its metabolites contain a a-hydroxy-8-lactone ring, which is 
chemically unstable and undergoes pH-dependent reversible hydrolysis to a hydroxyl-
carboxylate form. An intact lactone group is essential for interaction with the DNA-
enzyme complex (7). Therefore, the pharmacokinetics (PK) of CPT-11 lactone and SN-
38 lactone are of particular interest. Individual plasma concentrations of CPT-11 and 
its lour currently identified metabolites can be described by three-compartment models 
(8). Others report that two- or three-compartment models may be used to lit CPT-11 
and SN-38 concentration profiles with non-compartmental or compartment approaches 
(9-12). Ma et a/. (13) have analyzed individual concentration data of total forms of 
CPT-11, SN-38, and APC simultaneously by using a four-compartmental model with 
the assumption of an identical volume of distribution lor these substances. The PK of 
the lactone and carboxylate forms of CPT-11 and SN-38 were investigated previously 
(9-11, 14), but parameters other then the area under the curve (AUC) of SN-38 were 
not estimated. The clinical PK, metabolism, and pharmacodynamics of CPT-11 have 
been widely studied to dale (see reviews 9-11 ). However, for the metabolites, most 
publications limit the PK analysis to reporting on the AUC ratio of metabolite to parent 
drug. 
In this study, we used nonlinear mixed-effect modeling to analyze data from all 
patients simultaneously and considered the influence of covariates on the PK 
parameters. The purposes of this study were to build suitable PK models for CPT-11 
and four of its metabolites, including lactone and carboxylate forms, to more clearly 
understand the PK interrelations between the parent drug and metabolites, and to 
provide potentially useful information for clinical treatment of CPT-11. 
PATIENTS AND METHODS 
Patients and study design 
Patients with a histologically or cytologically proven malignant solid tumor were 
treated with CPT-11 intravenously between May 1996 and October 1999 at the 
Erasmus MC (Rotterdam, the Netherlands). Criteria for eligibility included the following: 
(a) age younger than 75 years; (b) an Eastern Cooperative Oncology Group 
performance status ~; (c) adequate hematologic function (WBC ;, 3.0 x 1 09/L, 
absolute neutrophil count ;, 2.0 x 1 09/L, and platelet count ;, 100 x 109/L), hepatic 
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function (total serum bilirubin :0 1.25 times the upper limit of normal and AST and AL T 
levels :0 3.0 times the upper limit of normal), and renal function (serum creatinine :0 135 
~ or creatinine clearance" 60 mUmin); (d) no previous anticancer treatment for at 
least 4 weeks, or 6 weeks in case of nitrosoureas or mitomycin; and (e) no previous 
therapy with other topoisomerase I inhibitors. The clinical protocol was approved by the 
Erasmus MC Ethical Board, and all patients gave written, informed consent before 
study entry. 
CPT-11 lactone was administered in a 3-weekly regimen as a 90-minute 
intravenous infusion in the dose range of 175 to 300 mg/m2, after dilution of the 
pharmaceutical preparation in 250 ml of isotonic sodium chloride. In all patients, 
premedication consisted of ondansetron (8 mg intravenously) combined with 
dexamethasone (1 0 mg intravenously), both administered 30 minutes before the start 
of CPT-11 infusion. Delayed-type diarrhea was treated with loperamide (4 mg), 
followed by 2 mg every 2 hours for a 12-hour time period after the last liquid stool. 
Frequent sampling was performed before dosing and at approximately 0, 0.5, 1.5, 
1.67, 1.83, 2, 2.5, 3.5, 4.5, 5, 5.5, 6.5, 8, 12, 25.5, 49, and 56 hours. Venous blood 
was drawn from the arm opposite the one used lor infusion, and plasma was 
separated by centrifugation (3,000 x g for 5 minutes at 4°C). Plasma samples were 
stored at -80°C and analyzed lor the lactone and total drug forms of CPT-11 and SN-
38 and for the total drug forms only of APC, NPC, and SN-38G by using reversed-
phase high-performance liquid chromatography with fluorescence detection, as 
described previously (15). Because of limited sample supply, concentrations could not 
be determined lor all metabolites in all samples. 
PKmodeling 
The PK models for CPT-11 and four of its metabolites were sequentially built, and 
the PK analysis was based on multicompartmental models (up to three compartments 
for each substance). CPT-11 lactone concentrations were first analyzed neglecting any 
interconversion with the carboxylate form (step 0). This analysis was performed to 
allow some direct comparison between this analysis and previous analyses that did not 
consider the pH-dependent lactone-carboxylate interconversion. Thereafter, both 
lactone and total forms of CPT-11 data were simultaneously analyzed allowing for 
interconversion and assuming that total CPT-11 was the sum of lactone and 
carboxylate concentrations (step 1 ). Models were parameterized in terms of clearances 
(CLs) and volumes of distribution, whereas rate constants were used lor quantifying 
the interconversion between lactone and carboxylate forms. 
For all metabolites except SN-38G, we tested whether the concentration-time 
data were best described by formation from CPT-11 lactone, CPT-11 carboxylate or a 
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combination of these two. For SN-38G, models with formation from SN-38 lactone, SN-
38 carboxylate, or both were tested. For each model, we tested whether the formation 
of metabolites was proportional to the dose, which is likely to be the case for a major 
metabolite, or whether it was proportional to the AUC of CPT-11, which is more likely 
to be the case for a minor metabolite. For the former, metabolite disposition 
parameters were expressed as ratios with the fraction of the dose metabolized to the 
particular metabolite. For the latter, metabolite parameters were expressed as ratios 
with the CL associated with formation of the metabolite in question (CL1). The individual 
CPT-11 lactone or carboxylate concentration-time profile, or both, from step 1 was 
used as the input for metabolite formation. Models based on lactone and carboxylate 
interconversion were simultaneously developed for SN-38 lactone and total 
concentrations (step 2), and then a model for SN-38G was developed, with individual 
parameters of SN-38 lactone and carboxylate from the final model of step 2 being fixed 
(step 3). As for CPT-11, the total concentrations of SN-38 were assumed to be the 
sum of lactone and carboxylate concentrations. Models containing an enterohepatic-
cycle component were tested to describe SN-38 and SN-38G data. One strategy to do 
this was by presuming an extra biliary compartment to store part of the eliminated SN-
38G; after a certain (estimated) time period stored SN-38G would be released to 
another extra compartment (intestine) to be deconjugated to SN-38. Another model, 
assuming that an oral dose was given to generate rebound concentrations of SN-38, 
was tested for improvement of the description of the data. Finally, models for APC 
(step 4) and NPC (step 5) were developed. 
Candidate covariate relations for covariate models were built on the basis of 
individual parameters from the basic model by using generalized additive models (16). 
The covariates that resulted in a significant decrease in the Akaike information criterion 
were introduced into the model and tested. The covariates considered were age 
(median, 54 years; range, 36 to 71 years), sex (24 women and 46 men), and body-
surface area (BSA; median, 1.86 m2; range, 1.35 to 2.5 m2). 
The models were fitted to the data from all individuals simultaneously using 
NONMEM VI (University of Califomia, San Francisco, CA) with first-order conditional 
estimation with interaction (17). The parameter for a specific subject (P;) can be 
described by equation 1: 
(eq.1) 
where Ppop is the parameter for a typical individual and 7J; is a symmetrically distributed 
zero-mean variable with SO {(). Several factors may cause interindividual correlations 
between all disposition parameters of a metabolite, but a major cause for such 
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correlations may be interindividual variability in the fraction of the dose forming the 
metabolite. We chose to parameterize the models so that any such correlation was 
expressed as variability in the fraction of dose forming the metabolite, because this 
may aid interpretation and simplify and have no detrimental effects on the fit of the 
models to the data. 
In mixed-effect models, the residual error is the difference between the observed 
concentration (Cobs) and the predicted value ( Cp,oo) by P1• The residual error model was 
characterized by both additive and proportional components: 
where E1 and E2 are zero-mean normally distributed variables with SDs cr1 and cr2, 
respectively. 
The model selection was guided by the decrease in the objection function value 
(OFV; -2*1og likelihood), as well as by using graphical goodness-of-fit analysis with 
Xpose 3.0 (Uppsala University, Uppsala, Sweden; ref 18). To statistically distinguish 
between hierarchical models, the difference in the OFV was used because the 
difference is approximately ·l distributed. A significance level of P < .001 was used; 
this corresponded to a difference in OFV of 10.8 for 1 df. Parameter uncertainty was 
expressed as RSE%, which is the estimate of SE obtained as part of the standard 
NONMEM output, divided by the parameter value. 
RESULTS 
Forty-six male and 24 female cancer patients received CPT-11 as a 90-minute 
intravenous infusion (range, 1.3 to 1.9 h) at doses ranging from 175 to 300 mg/m2• The 
predominant tumor types were colorectal cancer (n = 38), adenocarcinoma of unknown 
primary origin (n = 8), head and neck cancer (n = 5), and non-small-cell lung cancer (n 
= 4). Sixteen patients were also sampled during a second course, and the median time 
interval between two doses was 23 days (range, 11 to 38 days). 
The observed concentration-time profiles of CPT-11 and its four metabolites are 
shown in Fig 1, and all concentration units are nanograms per milliliter. The principal 
components of the model that resulted from the analysis are presented in Fig 2. 
Overall, CPT-11 carboxylate concentrations were higher than those of CPT-11 lactone, 
whereas concentrations of SN-38 carboxylate were lower than those of the lactone 
form. Both SN-38G and APC plasma concentrations were relatively high, whereas 
those of NPC were low. 
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Figure 1. Logarithmic observed concentration-time profiles of (A) CPT-11 lactone, (B) CPT-11 
total, (C) SN-38 lactone, (D) SN-38 total, (E) SN-38G, (F) APC, and (G) NPC. All 
concentration units are ng/ml. 
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Figure 2. The compartmental phanmacokinetic models for CPT-11 lactone (L) and carboxylate 
(C), SN-38 Land C, SN-38G, APC, and NPC. 
The best model to describe CPT-11 lactone data alone was a three-compartment 
model with CL estimated to be 107 Uh (57.5 Uh/m2; step 0). In the joint model for 
CPT-11 lactone and carboxylate forms (step 1), disposition could be characterized with 
a three- and two-compartment model for CPT-11 lactone and carboxylate, respectively 
(Fig 3). The model with interconversion between lactone and carboxylate in the central 
compartments, as well as in the peripheral compartments, provides the best model for 
both lactone and total forms of CPT-11. The intercompartmental CL and volume of 
distribution of the peripheral compartment for CPT-11 carboxylate were estimated to 
be small (0.0009 Uh and 0.01 L, respectively), but the OFV decreased by more than 
1,000 compared with a one-compartment model for CPT-11 carboxylate. A re-
parametrization, using rate constants between the central and peripheral compartment 
of the carboxylate, was applied for the CPT-11 model. The rate constant from central 
to peripheral of CPT-11 carboxylate was close to 0, according to the estimates of CL 
and volume of distribution, so this rate constant was fixed at 0, and the volume of 
distribution in the peripheral compartment was (arbitrarily) fixed to the corresponding 
value for the lactone in the final model with re-parameterization to the rate constant. 
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Such a model predicted that CPT-11 carboxylate would not have multicompartmental 
characteristics were it not fonned peripherally from the lactone fonn. However, 
because the mass flow of carboxylate is unidirectional from the peripheral 
compartment to the central, there is no information (or effect on the predictions) on the 
size of the peripheral carboxylate compartment. The population CL (12.3 Uh) and the 
steady-state volume of distribution (78 L, excluding peripherally formed carboxylate) of 
the carboxylate form were six-fold smaller than those of the lactone form (Table 1 ). 
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Figure 3. Logarithm of population predictions (logPRED) and individual predictions 
(logiPRE) versus the logarithm of observations (logDV; DV, dependent variable) 
of CPT-11 lactone and CPT-11 total. All concentration units are ng/mL. 
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Table 1. Population PK parameter of estimates and associated interindividual variability of 
CPT-11 lactone and carboxylate (step 1). 
Parameter 
Lactone 
CLL (Uh/m2) 
QL2 (Uh/m2) 
QL3 (Uh/m2) 
VL1 (Um2) 
VL2 (Um2) 
VL3 (Um2) 
kL1C1 (h'1) 
kL2C2 (h'1) 
Carboxylate 
Clc (Uh/m2) 
kc,, (h'') 
Vc1 (Um2) 
V02 (Um2) 
kc1L1 (h.1) 
kc2L2 (h.1) 
Estimate (RSE%) 
39.9 (27) 
94.1 (22) 
7.3 (15) 
20.7 (7.4) 
47.4 (11) 
171 (8.2) 
3 (14) 
0.465 (8.2) 
6.6 (54) 
0.0936 (20) 
41.8(15) 
47.4 (11)* 
0.64 (14) 
0.0921 (22) 
IIV%(RSE%) 
38 (50) 
95 (43) 
41 (40) 
NE 
40 (41) 
41 (40) 
31 (47) 
NE 
19 (62) 
NE 
22 (37) 
40(41)* 
19 (62) 
NE 
Abbreviations: RSE%, estimate of SE, divided by parameter value; IIV, interindividual 
variability; CL,, clearance of CPT-11 lactone; Cl.c. clearance of CPT-11 carboxylate; Q, 
intercompartment clearance; V, volume of distribution; kLc. interconversion rate constant from 
lactone to carboxylate; kcL. interconversion rate constant from carboxylate to lactone; 1, 2, and 
3, denoted to compartment!, 2, and 3; NE not estimated. 
*Value is arbitrary set to the same value as for lactone. 
The interindividual variability for parameters of CPT-11 lactone was generally 
high, with post hoc estimates of CL ranging from 24.8 to 149.9 Uh for the lactone form 
and 6.6 to 19.5 Uh for the carboxylate form. BSA was the only significant covariate 
included in the model and had a decrease in OFV of 26.99 compared with the basic 
model. For a typical individual with a BSA of 1.86 m2, the CL and steady-state volume 
of distribution of CPT-11 lactone were 39.9 Uh!m2 and 239 Um2, respectively. 
SN-38 concentrations were best described by a two-compartment model lor the 
lactone form and a one-compartmental model for the cariboxylate form, where the 
formation occurred from CPT-11 lactone in the central compartment to SN-38 lactone 
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in the central compartment (Fig 4). In the model, SN-38 lactone formation was better 
described as proportional to the dose of GPT-11, rather than proportional to the AUG 
of GPT-11 lactone. Unlike GPT-11, SN-38 lactone and carboxylate forms had similar 
GL values, whereas, as for CPT-11, the lactone form had more extensive tissue 
distribution (Table 2). A one-compartment model, with formation from SN-38 lactone, 
adequately described the SN-38G data (Fig 5). SN-38G formation was better 
described as proportional to the dose of CPT-11 than to the AUG of SN-38 lactone. 
Both SN-38 and SN-38G had substantial formation variability. In the most successful 
model, SN-38G was formed out of SN-38 lactone (Fig 2 and Table 2). 
SN-38 Lactone 
logDV logDV 
SN-38 Total 
logDV logDV 
Figure 4. Logarithm of population predictions (logPRED) and individual predictions 
(log I PRE) versus the logarithm of observations (logDV; DV, dependent variable) 
of SN-38 lactone and SN-38 total. All concentration units are ng/mL. 
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SN~38G Total 
logDV IogDV 
Figure 5. Logarithm of population predictions (logPRED) and individual predictions 
(logiPRE) versus the logarithm of observations (logDV; DV, dependent variable) 
of SN-38G total. All concentration units are ng/ml. 
Table 2. Population PK parameter of estimates and associated interindividual variability of 
SN-38 lactone and carboxylate and total SN-38G. 
Parameter Estimate (RSE%) IIV% (RSE%) 
SN-38 lactone 
CUFm,SNL (Uh) 2,220 (20) 40 (82) 
0/Fm,SNL (Uh) 5,480 (7.9) 40 (22) 
V/Fm.SNL1 (L) 10,700 (12) 40 (23) 
V/Fm,SNl2 (L) 66,300 (7.8) 22 (85) 
kl1C1 (h"1) 0.319 (27) NE 
Formation variability 40 (23) 
SN-38 carboxylate 
CUFm,SNC (Uh) 2,030 (40) 29 (11 0) 
V/Fm,SNC (l) 4,720 (19) 46 (46) 
kc1L1 (h-1) 0.835 (23) 29 (11 0) 
SN-38G 
CUFm,SNG (Uh) 115 (9.8) 34 (26) 
V/Fm,SNG (l) 150 (7.9) 23 (1 00) 
Fonmation variability 54 (16) 
Abbreviations: Fm, formation fraction; SNL, SN-381actone; SNC, SN-38 carboxylate. 
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A relatively high interindividual variability was found for the disposition parameters and 
formation variability of SN-38 lactone and carboxylate and SN-38G (Table 2). Rebound 
concentrations of SN-38 and SN-38G were observed in some subjects, but the models 
with an enterohepatic recycling component were unsuccessful, possibly because of a 
lack of information of the recycling process. No significant covariate relations were 
idenfrfied for SN-38 or SN-38G. 
A 2-compartment model best described the total concentration data of APC with 
formation from CPT-11 carboxylate (Fig 6). Formation was better described as 
proportional to the AUC of CPT-11 carboxylate rather than the CPT-11 dose. Age was 
found to be a statistically significant covariate for the CL of APC. The typical CL ratio 
(CUCL1) was 2.62 at an age of 55 years (Table 3), with a change of 1.4% per year. 
The only interindividual variability component was in the fraction forming APC, which 
was estimated to be 48%. 
APCTotal 
logDV logOV 
Figure 6. Logarithm of population predictions (logPRED) and individual predictions (logiPRE) 
versus the logarithm of observations (logDV; DV, dependent variables) of APC total. 
All concentration units are ng/ml. 
A two-compartment model with formation from CPT-11 lactone best described the 
concentration-time profiles of NPC (Fig 7). Fonmation was better described as being 
proportional to the AUC of CPT-11 lactone rather than the CPT-11 dose. The 
interindividual variability in CL was 11 0%; this might be due to one individual's having 
much higher NPC concentrations as compared with other individuals (2.2 to 11.7 times 
higher). In an analysis without that individual, the variability decreased to 43%. 
Considering the large effect of this individual on the variability component, final 
parameters of NPC are listed without this patient (Table 3). No statistically significant 
covariate relations were found for NPC. 
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Table 3. Population PK parameter of estimates and associated interindividual variability of total 
APCand NPC. 
Parameter Estimate (RSE%) I IV% (RSE%) 
APC 
CLAedCL, • 2.62 (8) NE 
OAedCL, 1.68 (12) NE 
VAPC1/Clt (h) 2.66 (9.7) NE 
V APC2/Clt (h) 5.91 (11) NE 
Factor for age -0.0142 (55) 
Formation variability(%) 48 (22) 
NPc•• 
CLNedCL, 8.85 (16) 43 (62) 
ONedCLt 1.77 (24) 120 (28) 
VNPC1/Clt (h) 5.41 (8.1) 43 (62) 
v NPC2/CL, (h) 197 (6) NE 
• CL included age, expressed as: CL= 91[1+9z•(age-55)Yexp(TJ,) . 
...... One individual was excluded from the data set. 
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Figure 7. logarithm of population predictions (logPRED) and individual predictions (logiPRE) 
versus the logarithm of observations (logDV) of NPC total. All concentration units are 
ng/ml. 
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Finally, the typical values of parameters for CPT-11, SN-38, SN-38G, APC or 
NPC {Tables 1 to 3) were used in a simulation for a typical individual with a BSA of 
1.86 m2, receiving a 1-hour infusion at a standard dose of 350 mg/m2• The simulated 
concentration-time profiles are presented in Fig 8. The terminal half-lives based on this 
simulation were 18.3, 18.1, 24.2, 24.2, 24.2, 18.3, and 33.3 hours for CPT-11 lactone, 
CPT-11 total, SN-38 lactone, SN-38 total, SN-38G, APC, and NPC, respectively. Of 
the dose administered, 74% was eliminated as CPT-11 lactone and 26% as CPT-11 
carboxylate. 
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Figure 8. Simulated concentration-time profiles: CPT-11 lactone and total, SN-38 lactone and 
total, SN-38G, APC and NPC for a typical individual with a BSA of 1.86 m2, receiving 
CPT-11 lactone infusion for 1 hour at a dose of 350 mg/m2• based on population 
estimates of corresponding compounds. 
DISCUSSION 
The clinical PK of CPT-11 has been extensively reported on in the literature (9, 
10, 14). The current investigation may add to that knowledge because (i) it is the first 
model-based analysis that takes into account the interconversion between lactone and 
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carboxylate forms, (ii) it reports more extensively on the PK of CPT-11 metabolites, 
and (iii) the database is substant;ally larger than the ones used in previous reports. In 
addition, we introduce parameterizations of population PK models that allow additional 
information compared with standard models to be extracted from metabolite data. 
The CL estimate of 107 Uh (57.5 Uh/m2) in the analysis of the lactone form of 
CPT-11 that ignores the carboxylate interconversion (step 0) is in good agreement with 
previously reported values from similar analyses (39 to 75.1 Uhlm2; ref. 8, 12, 19). 
Similarly, the steady-state volume of distribution estimate of 722 L (388 Um2) is in 
good agreement with previously reported values (8) of 601 to 871 L but is somewhat 
larger than a reported value (12) of 263 Um2• Also, the full model, including conversion 
between lactone and carboxylate, predicts similar value of CL (1 00 Uh; see Appendix). 
As mentioned previously, CPT-11 and its metabolites contain a lactone ring, 
which undergoes a pH-dependent equilibrium with the carboxylate form (20). At 
physiologic pH, the carboxylate form of CPT-11 dominates in plasma. However, only 
the lactone form has antitumor activity (7). Therefore, it is of interest to differentiate the 
PK of the lactone form from the total drug form (i.e., lactone plus carboxylate) of CPT-
11. From the model that considers the lactone-carboxylate interconversion, a relatively 
rapid interconversion of CPT-11 lactone to carboxylate was found with a half-life of 14 
minutes, which is close to the previously published value of 9.4 minutes (12). 
Population estimates of CL and steady-state volume of distribution of CPT-11 lactone 
were 39.9 Uh/m2 and 239 Um2 . The CL of CPT-11 lactone was six times higher than 
that of the carboxylate form. Published CL values of CPT-11 total are in the range of 
12 to 24 Uh/m2 during short time infusions (30 to 90 minutes; ref. 8, 9, 21). Our model 
predicts a CL of 18 Uh/m2 for total CPT-11 (see Appendix). The difference between 
lactone and total forms in CL may partly be explained by a lower distribution of the 
carboxylate form into the liver. The analysis also suggests a different metabolic 
pathway for CPT-11 carboxylate, with formation of APC while SN-38 and NPC are 
formed from CPT-11 lactone. CPT-11 lactone displayed extensive tissue distribution, 
and it was found that rate constants between the central and peripheral compartments 
of CPT-11 carboxylate were much smaller than the interconversion rate constants from 
lactone to carboxylate between peripheral compartments, implying local conversion of 
CPT-11. 
CPT-11 is extensively metabolized to its active metabolite SN-38 by the 
carboxylesterase enzyme system (14, 22), and the anticancer efficacy of SN-38 is far 
greater than the parent drug in vitro (23). Therefore, it is important to understand the 
PK of SN-38, especially for its active lactone form. During the model building for SN-
38, the model with hydrolysis from CPT-11 lactone and carboxylate forms to the 
corresponding forms of SN-38 was tested, and it seemed that the model with only 
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transformation between lactone forms performed best (final model). When the values 
of parameters were compared, the interconversion rate constant from SN-38 lactone to 
carboxylate (0.319/h; Table 2) was larger than the elimination rate constant of CPT-11 
carboxylate (0.158/h, calculated from CL of CPT-11 carboxylate and the volume of 
distribution of CPT-11 carboxylate in compartment one, Table 1). This lends further 
support to the supposition that SN-38 carboxylate is formed by hydrolysis (lactone to 
carboxylate) and not through carboxylesterase-mediated metabolism from CPT-11 
carboxylate. It has been reported that in vitro the steady-state formation rates of SN-38 
by CPT-11 lactone are two times higher than those through CPT-11 carboxylate (24). 
Similarly, the parameter estimates from this modeling analysis indicated that the 
interconversion rate constant for lactonization (carboxylate to lactone) was 2.6-fold 
higher than that of hydrolysis (Table 2). The reason might be that SN-38 lactone is 
more tightly bound to human serum albumin than the carboxylate form, so the dynamic 
equilibrium is preferential towards the lactone form (25). This could explain the in vivo 
observations that the lactone form of SN-38 was the dominant form in patient plasma 
in our study and the earlier investigation by Rivory et a!. (12). From modeling, it was 
found that SN-38 formation was proportional to the dose of CPT-11, suggesting that 
SN-38 is a major metabolite. The fact that SN-38 disposition parameters were 
relatively high may suggest otherwise, but these high values could also be a 
consequence of a sequential metabolism of SN-38 to SN-38G in the liver. 
SN-38 can be further converted into SN-38G by hepatic uridine diphosphate 
glucuronyltransferase (3, 4), and the plasma concentrations of this glucuronide 
compound were relatively high. It has been shown that the AUG ratio of SN-38G to SN-
38 ranges from 4.5 to 32 (8). SN-38G had the highest plasma concentrations of all 
metabolites. Evidence that SN-38G is the result of a major pathway of CPT-11 
elimination was also indicated by the fact that the model assuming SN-38 and SN-38G 
was best related to dose. 
Large interindividual variability for parameters of CPT-11 lactone and SN-38 
lactone was found in this study. This probably indicates that a large variability in 
carboxylesterase expression and activity exists between individuals and also indicates 
that variability in interconversion between lactone and carboxylate forms may partly 
contribute to the overall interindividual variability of these parameters (14, 26). 
During the modeling, no significant covariates were found, except for BSA in the 
case of CPT-11 and age in the case of APC. This is consistent with previous 
observations from phase I and II clinical trials indicating that the CL of CPT -11 or 1he 
formation ratio of SN-38 and SN-38G is not significantly correlated with age, sex, 
serum creatinine level, transaminase level, alkaline phosphatase level, or the presence 
of liver metastases (27). 
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Both APC and NPC total concentration-time profiles could be best described by 
two-compartment models. The model predicted that the metabolic pathway of CPT-11 
to APC was through the carboxylate form. The interindividual variability in exposure to 
APC suggests that the differences in metabolism and formation between patients are 
the main source of variability for APC PK. Unlike APC, NPC was predicted to be mainly 
formed from CPT-11 lactone, and no formation variability was needed. It has been 
found in vivo (8) that NPC is a minor plasma metabolite of the parent drug, which 
contrasts with in vitro results in which NPC was a major metabolite (6). An explanation 
for this apparent contradiction could be the fact that NPC is subject to conversion to 
SN-38 by plasma carboxylesterases (6, 14, 28). This alternative metabolic pathway 
might partly explain the high interindividual variability in NPC PK. 
In summary, we built population PK models to adequately describe plasma data 
of CPT-11 and its currently known metabolites, including the lactone-carboxylate 
interconversion. These data not only increase our knowledge to better understand 
the clinical PK of this drug but also may prove useful in predicting the PK of all 
characterized metabolites and interconversion products after various administration 
regimens of CPT-11. 
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APPENDIX 
Compartments are numbered from 1 to 5 in the following order with regards to CPT-11: lactone 
central; lactone peripheral 1; carboxylate central; carboxylate peripheral; and lactone peripheral 2. 
Deriving the equation to calculate CPT-11 lactone clearance (CLL) considering interconversion 
between lactone and carboxylate forms. The relationship between these two forms is present in Fig 2. 
The amount (A) of change in each compartment is described by equations 1 to 5: 
dA(,fdt = Ro +k21 ... Ac2J+k3, ... AcJJ+ks, ... Acw(k,o+k,2+k,J+k,s)* Ac1J 
dfo;,/dt = k,,' fo;,,+k,,'fo;,,-(k,+k,.)'~, 
dfo;,Ydt = k,0fo;,,+k,"fo;,,-(kao+k,)' fo;3l 
dfo;,fdt = kz4 A,,-(k.z+k.s)' fo;,, 
dfo;sfdt = k,s" A,,- k, • A,s) 
(eq. 1) 
(eq. 2) 
(eq. 3) 
(eq. 4) 
(eq. 5) 
where, Ro is the infusion rate and k is the rate constant. The Arabic numbers represent the 
compartmental numbers. At steady-state (ss), the amount in each compartment is derived according 
to equations 6-10: 
(eq. 6) 
(eq. 7) 
(eq. 8) 
kl" * .kz4 Ac.n"~ = - *Act)"' 
bt * (k4~+ k43) + b *k43 
(eq. 9) 
A.<sl~s = kts * A.<l)ss 
ksr 
(eq.10) 
If equations 6, 7, 8, 9, and 10 are rearranged, lactone concentration at steady-state can be expressed 
as 
Ro (eq.11) 
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The CLL is expressed as the ratio of Ro and C(,lss· Therefore, CLL (taking into consideration the 
equilibrium with the carboxylate form) can be calculated by using equation 12, where v, is the volume 
of distribution in the central compartment of the lactone form (compartment 1): 
k.Jz * b1 *(lao+ b1) * (k+2+ k4J) + kl::: *kt3 *1:24 *kn] 
(bo+ Jo,) *(b *(k>o+ b3) + b *k") (eq. 12) 
Deriving the equation to estimate the clearance of CPT-11 total forms (CLT), considering the 
interconversions between lactone and carboxylate forms. The steady-state plasma concentration of 
CPT-11 total (G-r.ss) is the sum of lactone (C(,)ss) and carboxylate (C(3Jss) forms. Combined with 
equation 8, CT.ss can be expressed as 
(eq. 13) 
where V3 is the volume of distribution in the central compartment of the carboxylate form (compartment 
3). The total clearance of CPT·11 lactone is the ratio of infusion rate and C,.,ss· Therefore, CLT can be 
derived from equations 12 and 13: 
CLL*V:. (eq. 14) 
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ABSTRACT 
Objectives: Our objective was to build population pharmacokinetic models that 
describe plasma concentrations of irinotecan (CPT-11) and its metabolites SN-38 and 
SN-38 glucuronide (SN-38G) and to investigate pharmacokinetic-pharmacodynamic 
relationships between drug exposure and diarrhea, the major dose-limiting toxicity. 
Methods: Data were obtained from 109 patients (65 men and 44 women) who 
received 1.5-hour (range, 0.75· to 2.25-hour) intravenous infusions of irinotecan at 
doses that ranged from 100 to 350 mg/m2; 44 patients had a second course. The 
population pharmacokinetic models were developed to describe plasma 
concentration-time profiles. The area under the concentration-time curve from time 
zero to 60 hours [AUC0.6oh] was used as a measure of drug exposure to model the 
probabilities of diarrhea with use of a logistic regression model. 
Results: A 3-compartment pharmacokinetic model best described the disposition of 
irinotecan, whereas SN-38 and SN-38G showed 2-compartmental characteristics. 
The population estimate of clearance for irinotecan was 31.6 Uh, and the volume of 
distribution at steady-state (V ,) was 263 L. The clearance devided by formation 
fraction (Fm) was 712 Uh and 66.8 Uh for SN-38 and SN-38G, respectively. The 
V,/Fm was 72,000 L for SN-38 and 85.4 L lor SN-38G. The frequencies of diarrhea 
scores in this study were 46% (grade 0), 28% (grade 1 ), 20% (grade 2), 4% (grade 
3), and 2% (grade 4). Significant correlations between AUCo.soh and diarrhea scores 
were found for irinotecan (P <.05) and SN-38G (P <.01) but not for SN-38 or the 
biliary index. 
Conclusions: In this population analysis, irinotecan and SN-38G AUG values were 
appropriate predictors of the risk for diarrhea, and SN-38G AUG showed the stronger 
relationship of the two. The developed population models may be useful in further 
clinical development of this agent. 
INTRODUCTION 
The anticancer agent irinotecan (CPT-11) has proven activity in a wide range of 
tumors and is registered for treatment of colo rectal cancer (1 ). It is extensively 
metabolized, and it is reported that cytotoxic activity of one of its metabolites, SN-38 
(7-ethyl-10-hydroxycamptothecin), is 100 to 1000 times greater than that of 
irinotecan itself (2). SN-38 is further conjugated to an inactive glucuronic acid 
conjugate (SN-38G) by UDP glucuronosyltransferase 1A1 (3, 4). Pharmacokinetic 
parameters of irinotecan and its metabolites reported are mostly based on individual 
analyses. Individual plasma concentrations of irinotecan and its metabolites have 
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been described previously by use of 2- or 3-compartment models (5-9). For 
population pharmacokinetic analysis purposes, Yamamoto et a/. (1 0) used a 2-
compartment model to characterize concentration profiles of irinotecan. 
The major dose-limiting nonhematologic toxicity of irinotecan is diarrhea (11 ). 
Although the pharmacokinetic-pharmacodynamic relationship between exposure and 
toxicity has been widely studied, the results have been discrepant because of its 
complex and incompletely understood relationship and because of different study 
designs (12). Although most investigations have reported that area under the 
concentration-time curve (AUC) values for both irinotecan and SN-38 significantly 
correlated with the severity of diarrhea (6, 7, 13), others have detected that 
correlation only for irinotecan AUC (14). Similarly, although several studies have 
suggested that there is a correlation between the biliary index and diarrhea (15, 16), 
other studies could not confirm that correlation (17, 18). Finally, some trials failed to 
find any relationship between diarrhea and any of the studied pharmacokinetic 
parameters (5, 18-20). All of these previous pharmacodynamic analyses have been 
based on statistical analysis, such as analysis of variance (ANOVA), correlation 
analysis, or t-tests. 
The purpose of this study was to create appropriate population pharmacokinetic 
models to describe plasma concentrations of irinotecan, SN-38, and SN-38G. In 
addition, we wanted to build pharmacokinetic-pharmacodynamic models for any 
potential relationship between drug or metabolite exposure (AUC) and diarrhea, the 
major dose-limiting toxicity. 
PATIENTS AND METHODS 
Patients and treatment 
Patients with a histologically or cytologically proven malignant solid tumor that 
stipulated an irinotecan-based chemotherapeutic regimen were eligible for the trials 
that formed the basis of the present study. All patients were treated between May 1996 
and February 2001 at the Erasmus MC (Rotterdam, the Netherlands). Additional 
criteria for eligibility included the following: (a) age between 18 and 75 years, (b) an 
Eastern Cooperative Oncology Group performance status s; 2, (c) adequate 
hematopoietic (absolute neutrophil count <: 1.5x1 09 per liter and platelet count ;;: 
100x109 per liter), liver and kidney function at the time of study entry, (d) no previous 
anticancer treatment for at least 4 weeks, and (e) no previous therapy wtth irinotecan 
or other topoisomerase I inhibitors. Written informed consent was obtained from each 
patient before study entry in accordance with federal and institutional guidelines. 
lrinotecan was provided by Aventis Pharma (Hoevelaken, the Netherlands) as 
85 
Chapter 5 
the hydrochloride trihydrate salt in 40- or 1 00-ml vials that contained 20 mg/ml 
irinotecan in sorbitol and a lactic acid-sodium hydroxide buffer system (pH 3.5- 4.5). 
The drug was administered once every 21 days as a 1.5-hour (range, 0.75- 2.25 
hour) intravenous infusion at doses ranging from 100 to 350 mg/m2 • Intestinal toxicity 
was graded as a diarrhea score measured on a point scale from 0 to 4 in accordance 
with the National Cancer Institute Common Toxicity Criteria. 
For the pharmacodynamic evaluation. the grade assigned to a patient was the 
worst grade of diarrhea experienced during the 3-week period alter drug 
administration. The strategy for treatment of diarrhea was the same for all patients. 
For delayed diarrhea the patient received 4 mg oral loperamide, followed by a dose 
of 2 mg loperamide administered every 2 hours for up to 12 hours alter the last liquid 
stool, without exceeding 48 hours of treatment. If diarrhea persisted for more than 24 
hours, the patient received a 7-day prophylactic oral antibiotic course with 
ciprofloxacin. This treatment was considered to be adequate for all patients, and no 
problems were encountered with the antidiarrheal medication (e.g. vomiting) in this 
group of patients. 
Sampling and analysis 
Serial blood samples were obtained from each patient before drug administration 
and at approximately 0.5, 1.5, 1.67, 1.83, 2, 2.5, 3.5, 4.5, 5, 5.5, 6.5, 8, 12, 25.5, 49, 
and 56 hours alter administration. The samples (approximately 7 ml) were drawn from 
a vein in the patient's arm that was opposite to the one used for infusion, and the 
plasma was immediately separated by centrifugation {3000 x g for 5 minutes at 4°C) 
and then stored frozen until analysis. Plasma samples were analyzed lor the presence 
of irinotecan and metabolites by use of a validated reversed-phase high-performance 
liquid chromatography system with fluorescence detection as described previously (5). 
It has previously been shown that the total drug levels (i.e., the total of lactone and 
carboxylate forms) of irinotecan, SN-38 and SN-38G provide a consistent and accurate 
reflection of the respective lactone concentrations with little variability (12). We 
therefore monitored total drug concentrations for all analytes in this study because it 
serves as an appropriate surrogate of the lactone forms. In brief, the sample pre-
treatment procedure involved a protein-precipitation step of 250-J.ll aliquots with a 
mixture of methanol and 5% (wt/vol) of aqueous perchloric acid (1 :1, vol/vol). 
Separation of the various analytes and endogenous compounds was achieved on a 
analytical column packed with Hypersil octadecylsilane material (internal diameter, 100 
x 4.6 mm; particle size, 5-J.lm; LC Service, Emmen, the Netherlands), and isocratic 
elution was accomplished with a mixture of methanol and 0.1 M ammonium acetate 
that contained 1 0 mM tetrabutylammonium sulphate (30:70, vol/vol), with the pH 
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adjusted to 5.3 (hydrochloric acid). The column effluent was monitored at excitation 
and emission wavelengths of 355 and 515 nm, respectively. The lower limit of 
quantitation of this method is 2.0 ng/ml for each of the analytes of interest. Because of 
the limited sample supply, concentrations could not be determined for all metabolites in 
all samples. 
Pharmacokinetic analysis 
Pharmacokinetic analysis was based on multi-compartmental models (up to 3 
compartments), and the pharmacokinetic models were built sequentially for irinotecan, 
SN-38, and SN-38G. lrinotecan concentrations were analyzed first, and then individual 
(post hoc) parameters for irinotecan were fixed in the further analysis of SN-38 and 
SN-38G. Similarly, individual parameter estimates of SN-38 were fixed in the analysis 
of SN-38G. It was assumed that SN-38 was formed from irinotecan according to a first-
order process and that SN-38G was formed from SN-38 by means of a first-order 
process. 
Covariate models were built on the basis of generalized additive models (21, 
22). The covariate that resulted in the largest decrease in the Akaike information 
criterion was introduced into the model and tested. The covariates considered were 
age, sex, body surface area and concomitant medication with cisplatin or tipifamib 
(R115777). 
The area under the concentration-time curve from time zero to 60 hours (AUCo. 
6oh) values for irinotecan, SN-38, and SN-38G were estimated according to their 
concentrations and the estimates of parameters from the final models. The models 
were fitted to the data for all individuals simultaneously by use of NONMEM (version 
VI) with a first-order conditional estimation method with interaction (23). 
lnterindividual variability in exponential expression was included in the 
pharmacokinetic parameters. The residual error model was characterized by both 
additive and proportional components. If one of the terms was estimated to be 
negligible, it was excluded from the model. Model selection was guided by the 
decrease in the objection function value ( -21og likelihood) and by graphical 
goodness-of-fit analyses with Xpose 3.0 (22). To differentiate between hierarchic 
models, P < .05 was chosen for an additional parameter or covariate, corresponding 
to a difference in the objective function value (OFV) of 3.84, with the OFV 
approximately x2 distributed. 
Pharmacokinetic-pharmacodynamic analysis 
The pharmacokinetic-pharmacodynamic relationship between exposure and 
toxicity (diarrhea) was established with AUCo-soh, which was obtained from the 
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pharmacokinetic analysis. Because nonhematologic toxicity of diarrhea score is a 
categoric variable (taking integer values of 0 to 4), the probability (P) of each 
diarrhea score was modeled with logistic regression, similar as used for dry mouth 
score (24). If Y, = (Y0 , Y1 , ••• ) is the vector of the diarrhea scores for individual 
patients, the probability for Y, larger than or equal to the score m (m = 0, 1, 2, 3, and 
4) can be expressed as follows: 
g{P(Y, <om)}= logit(p) = lnt+fo 
in which: 
logit(p) = Log[p/(1-p)] 
and: 
p = exp(lnt+ f0)/[1 + exp(lnt+ f0)] 
Int= i::~ 
!.=0 
f0 = Slop ' AUCo-soh 
in which g is the logit function of a probability (p is the short notation for P(Y, <om)), 
~u <: 0 specifies the baseline probabilities of diarrhea scores which are summed to 
lnt, and 10 is representing the drug or metabolite effect introduced in the model as a 
function of the AUCo.soh values of irinotecan, SN-38 or SN-38G and the parameter 
Slop. The biliary index (14), calculated as the product of the AUC0•6oh ratio of SN-38 
to SN-38G and irinotecan AUC0•60h, was tested in the model in a manner similar to 
that of the other exposure measures. Note that P(Y" <: 0) = 1, so that in the model it 
was necessary only to estimate the cumulative probabilities for the diarrhea scores 1 
to 4. The probability for each individual score could thereafter be calculated from the 
estimated cumulative probabilities. 
For each treatment course, the individual course-specific exposure was used. 
Some patients received 2 courses, which was taken into account through 2 different 
approaches (separately and in combination) as follows: (i) We investigated whether 
there was a different relation between exposure and diarrhea at the second visit; (ii) 
we included a random effect, which indicated interindividual variability in the 
exposure-diarrhea score relation. The effects of covariates (concomitant medication 
(cisplatin or R115777), and tumor type) on diarrhea were tested for incorporation into 
the pharmacokinetic-pharmacodynamic model. As in the pharmacokinetic analysis, 
the significance criteria (P <.05) with a difference in OFV of more than 3.84 was used 
to assess drug effect on the diarrhea score probability, and the model was analyzed 
with the NONMEM program. 
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RESULTS 
Patients 
Sixty-live male and 44 female patients between 34 and 75 years old were 
enrolled in this study (Table 1). The predominant tumor type in this group of patients 
was colorectal cancer (n=69). Eighty-two patients were treated in combination with 
other chemotherapy (i.e. 56 patients also received cisplatin, and 26 patients also 
received R115777) (5, 25). Forty-lour of the 1 09 patients were also evaluated during a 
second treatment course. Plasma samples were analyzed lor the presence of 
irinotecan and SN-38 in all 109 patients, whereas data lor SN-38G were available from 
56 patients. One hundred and four of 1 09 patients having irinotecan and SN-38 
concentrations had diarrhea scores, and 51 of 56 patients had both diarrhea scores 
and SN-38G concentrations. 
Table 1. Patient demographics. 
Characteristic 
No. of patients studied 
No. of evaluable courses 
Sex (man/ women) 
Age (y) 
Length (m) 
Weight {kg) 
Body-surface area (m2) 
Infusion duration (h) 
lrinotecan dose {mg/m2) 
Combination therapy: 
Tumor type: 
None 
Cisplatin 
R115777 
(A)CUP 
109 
153 
65/44 
54a {34-75) 
1.73a {1.51-1.92) 
74a {38-115) 
1.87' {1.29-2.40) 
1.5o• (O. 75-2.25) 
300' (1 00-350) 
27 
56 
26 
12 
Colorectal 69 
Miscellaneous 28' 
a mean values with range in parenthesis; b median values with range in parenthesis; 
'gastro-intestinal (nine), lung (six), head or neck (six), pancreatic (three), penile (one), 
kidney (one), bladder (one), thorax (one). 
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Pharmacokinetic analysis 
The observed total plasma concentration-time profiles of irinotecan, SN-38 and 
SN-38G are presented in Figure 1, and all concentrations are given in nanograms per 
milliliter. A 3-compartment model, including body-surface area as a covariate for all 
pharmacokinetic parameters (direct proportionality), best described the plasma 
concentration-time profiles of irinotecan (Fig. 2) which, compared to the basic model 
without body-surface area, resulted in a decrease in OFV of 81.3. Coadministration 
with cisplatin was found to have no significant effect on irinotecan pharmacokinetics, 
and the influence of R115777 on irinotecan clearance was less than 15%. Plasma 
concentrations of the SN-38 and SN-38G metabolites could be adequately described 
by 2-compartment models (Fig. 2). The population estimate of total body clearance 
(CL) for irinotecan was 31.6 Uh, and the volume of distribution at steady-state 0fss) 
was 263 L (Table 2). Pharmacokinetic parameters for SN-38 and SN-38G were 
estimated and expressed as parameter divided by formation fraction (Fm). Values for 
CUFm and VssfFm of SN-38 were much larger than those of irinotecan and SN-38G, 
and SN-38G had the smallest steady-state volume (Table 2). AUCo-soh values for all 
individuals were estimated from the models using individual-specific parameters. The 
mean(± SD) estimated AUCa-soh was 17,226 ± 8,016 ng/ml'h (range, 4,043-46,164 
ng/ml'h) for irinotecan, 403 ± 214 ng/ml'h (range, 126-1,229 ng/ml'h) for SN-38, and 
4,416 ± 3,816 ng/ml'h (range, 197- 22,734 ng/ml'h) for SN-38G. Sex and age were 
not significantly correlated to any pharmacokinetic parameter. 
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···.45-
00 
Fi'gure 1. ObseJVed total plasma concentration-time profiles of irinotecan (previous page), 
SN-38 (top panel), and SN-38G (bottom panel) after intravenous infusion of 
irinotecan. All concentrations are mentioned in ng/mL, and time is mentioned in 
hours. The dotted lines indicate connected ind-Ividual data points. 
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Figure 2. Population predicted (logPRED; left panels) and individual predicted (logiPRE; 
right panels) versus observed plasma concentrations (logDV) for irinotecan (top 
panels), SN-38 (middle panels) and SN-38G (bottom panels). Concentration is 
given in nanograms/milliliter. The dotted lines indicate connected individual data 
points, and the solid lines indicate the lines of identity. 
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Table 2. Summary of population pharmacokinetic estimates for irinotecan and metabolites. 
CPT-11 SN-38 SN-38G 
Parameters Estim. RSE (%) Estim. RSE (%) Estim. RSE(%) 
CL, Uh/m2 16.9 3.5 
CUFm, Uh 712 11 66.8 10 
02, Uh/m2 61.0 58 
02/Fm, Uh 1530 7.8 23.9 18 
03, Uh/m2 4.75 17 
V1, Um2 36.7 12 
V,/Fm, L 408 9.9 37 10 
V2, Um2 35.9 9.9 
V2/Fm, L 7160016 48.4 14 
V3, Um2 67.9 13 
V,., Um2 140.4 -
V,./Fm, L 72008- 85.4 
IIV (CL),% 32 19 
IIV (CUFm), % 58 64 80 17 
IIV (02),% 74 39 
IIV (02/Fm), % 56 35 97 49 
IIV (03),% 47 71 
IIV (V1),% 26 13 
IIV (V,!Fm), % 89 29 75 43 
IIV 0/2),% 27 21 
IIV (V2/Fm), % 59 31 59 42 
IIV (V3),% 45 16 
e1, ng/mL 1.3 40 0.56 26 34.5 12 
e2,% 16.7 4.2 26.8 4.5 
Abbreviations: Estim., Estimation; RSE, relative standard error; V1, V2, and V3, the volume of 
distribution in the central and peripheral compartments; Vss, volume of distribution at steady-
state; Oz and Q3, inter-compartment clearances; Fm, formation fraction for metabolite; !IV, 
inter-individual variability; £, and ~2. SO of additive and CV of proportional residual errors. 
Pharmacokinetic-pharmacodynamic analysis 
The probabilities of diarrhea scores from 0 to 4 for all patients were 46% for 
grade 0, 28% for grade 1, 20% for grade 2, 4% for grade 3 and 2% for grade 4. The 
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frequencies of scores in the SN-38G data set were 46% for grade 0, 24% for grade 1, 
20% for grade 2, 5% for grade 3 and 5% for grade 4. No correlation between diarrhea 
scores and tumor types was found. Coadministeration with cisplatin or R115777 did 
not show any influence in the effect of irinotecan or SN-38G on diarrhea. For 
irinotecan, SN-38 and SN-38G separately, models with and without a relationship 
between diarrhea score and exposure (AUC0-6oh) were tested to assess drug effect 
(Table 3). 
Table 3. Difference in objective function value (t.OFV). 
Drug 
lrinotecan 
SN-38 
SN-38G 
Biliary Index 
'P= .04, "P= .0038. 
t.OFV for full data set 
(n=1 04) 
-4.29' 
-2.468 
t>OFV lor reduced data set 
(n=51) 
-3.514 
-1.672 
-8.43" 
-0.522 
The model that included irinotecan AUC0•6oh was significantly better than the model 
that excluded AUC0-6oh, with a t>OFV of 4.29 (P <.05). Although SN-38 AUC0-6oh did not 
show any significant effect (P >.1), SN-38G AUC0•6oh was correlated with the diarrhea 
scores (P <.005). No significant improvement was observed in any of the models when 
the linear relation (on a logit scale) was replaced by a maximum effect (Emax) model 
(not shown). No significant improvements were observed when a component for 
interindividual variability in the exposure-diarrhea score relation or a difference 
between the first and second course were incorporated into the model. Figure 3 shows 
the goodness of fit of the final models, and Figure 4 shows predictions of probabilities 
of different diarrhea scores versus their corresponding AUC0-6oh values for irinotecan 
and SN-38G, respectively. The population estimates of these parameters are listed in 
Table 4. The biliary index showed no correlation with diarrhea score. 
For about half of all subjects, the SN-38G plasma concentrations were not 
available because of a limiting sample supply; therefore a reduced data set that 
contained data only from the subjects with observations lor irinotecan, SN-38, and 
SN-38G was also used to compare the effect of irinotecan, SN-38 and SN-38G in the 
same situation. The correlations between either irinotecan or SN-38 AUCo-eoh and 
diarrhea were not significant in this reduced data set (Tables 3 and 4). 
94 
3 
2 
0 2 0 
"' 
0 
4 
3 
0 
CPT-11 PK versus Diarrhea 
' 0 
0 0 
0 0 0 
0 
0 0 
0'0~ 0 <illl' 0 0 0 0 • 0 0 
oo:;., sooo:, cos ~0<::1 oW> o _______ ----- ----o 0 
-------·-
-
0~~ 08g~o 'Soooo£ <8OS~ cfJ 0 0 0 0 8 0 0 
10000 20000 30000 40000 
0 
0 0 
0 
O,?o 
// 
0 
5000 
0 
0 
CPT-11 AUC (ng/ml~h) 
0 
0 
0 
0 
10000 15000 20000 
SN·38G AUC (ng/ml•h) 
Figure 3. Diarrhea scores versus the AUCo.<;oh (ng/ml"h) for irinotecan (top panel) and SN-
38G (bottom panel). The solid lines are the smoothed lines for observed scores; 
the broken lines are the smoothed Jines for the predicted scores, which are 
simulated from the fina! pharmacokinetic-pharmacodynamic models. 
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AUC,.60h (ng/ml*h; bottom panel). 
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Table 4. Summary of population pharmacodynamic estimates. 
Parameter lrinotecan (n=1 04) SN-38 (n=1 04) SN-38G (n=51) 
Estimate SE Estimate SE Estimate SE 
Intercept, m=1 -0.55 0.42 -0.31 0.35 -0.62 0.37 
Intercept, m=2 -1.23 0.19 -1.22 0.19 -1.10 0.26 
Intercept, m=3 -1.69 0.31 -1.68 0.31 -1.58 0.39 
Intercept, m=4 -1.16 0.49 -1.15 0.49 -0.90 0.53 
Slope *10.5 4.26 2.0 120 79 18.7 6.0 
*Slope for linear drug effect on the log it scale. 
DISCUSSION 
Population pharmacokinetic models were established for irinotecan, SN-38, and 
SN-38G, in which pharmacokinetic parameters for all 3 substances were well 
estimated with a low relative standard error, except for one intercompartmental 
clearance of irinotecan. The total body clearance of irinotecan was estimated to be 
31.6 Uh, which is close to previously published results (18, 26). The V,. of irinotecan 
was 263 L, indicating extensive distribution into the peripheral compartments. We 
found no significant effect of coadministration with cisplatin on irinotecan 
pharmacokinetics, and the influence of the famesyltransferase inhibitor R115777 on 
irinotecan systemic clearance was less than 15% and was not considered to be 
clinical significant. Pharmacokinetic parameters for SN-38 and SN-38G were 
estimated as the true parameter value divided by the metabolite formation fraction 
(Fm). The estimated CUFm and Vss/Fm for SN-38 were 712 Uh and 72,000 L, 
respectively, which may suggest that SN-38 is excreted or metabolized quickly or is 
distributed extensively into tissues, but it could also reflect a low value of Fm for SN-
38. We found that SN-38G CUFm had a large variability compared with irinotecan 
and SN-38, probably reflecting a large interindividual variability in glucuronidation 
rate. 
The pharmacokinetic-pharmacodynamic analysis showed that the diarrhea 
score had the strongest correlation with SN-38G AUCO-Goh, whereas it failed to 
identify a relationship with SN-38 exposure. Although SN-38 is the active metabolite 
of irinotecan and SN-38G is inactive, these results may not be so surprising. It can 
be hypothesized that diarrhea was related mainly to local intestinal concentrations of 
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SN-38 formed from intestinal SN-38G by bacterial glucuronidases. If that were the 
case, intestinal SN-38G concentrations might have been closely related to plasma 
concentrations of SN-38G, whereas high plasma concentrations of SN-38 might 
have been (partly) a consequence of poor glucuronidation capacity and therefore 
associated with low local intestinal levels of SN-38G. Support for this hypothesis 
comes from a recently presented trial in which pretreatment of patients with 
neomycin (27), which presumably killed the bacteria in question, was shown to result 
in a markedly lower frequency and severity of irinotecan-induced diarrhea. 
Certain genetic polymorphisms in the promotor area and exons of the UDP 
glucuronosyltransferase UGT1A 1 gene have a dramatic effect on the functionality of 
the enzyme, leading to an altered glucuronidation of drugs (12). It has recently been 
shown that a mutation named UGT1 A 1 *28 is correlated with the main toxicities of 
irinotecan (i.e. leukopenia and diarrhea) (28, 29). In addition, a correlation with the 
irinotecan pharmacokinetics in American white patients and in Japanese patients has 
been detected (29, 30), although those data could not be confirmed in a large group 
of European patients (31). Pharmacogenetic screening may be attractive as a means 
to determine pharmacodynamic and therapeutic outcome in the (near) future. 
A relation was also found between diarrhea and exposure of irinotecan, 
although it was weaker than that for SN-38G and no statistically significant relation 
was found for the reduced data set, which was used to derive the SN-38G 
relationship. This difference in significance for irinotecan can be explained by the 
different sample sizes as already with the larger data set, the irinotecan relation was 
of borderline significance. 
The same significant results were obtained when diarrhea scores of 3 and 4 
were merged (data not shown). If diarrhea scores were treated as dichotomous 
outcome ("diarrhea" or "no diarrhea"), no significant correlations were observed 
between irinotecan AUCo-soh or SN-38G AUCo-soh and the diarrhea score. This 
analysis of relations between exposure and diarrhea therefore has two main 
advantages over previous reports. First, it is based on a larger number of patients 
and it uses a graded diarrhea score, not just characterization of the toxicity as 
present or absent. The latter is important because bivariate outcome variables lack 
the information provided by graded scales. The relation between the diarrhea score 
and SN-38G exposure supports clinical strategies to reduce diarrhea frequency that 
are based on a reduction in the amount of SN-38G formed. In addition, it gives a 
mechanistic support for treatment that limits intestinal glucoronidase activity to 
decrease the probability of diarrhea (12). Although no difference in the relation 
between exposure and diarrhea was found between the first and second courses, 
our analysis was limited because data after more than 2 courses of treatment were 
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not available. 
To investigate the influence of sample size on pharmacokinetic-
pharmacodynamic output, the reduced data sets for irinotecan and SN-38 {which 
included the same patients as SN-38G) were analyzed. A significant correlation 
between irinotecan AUG0•60h and severity of diarrhea score could not be established 
for that data set (Table 3). This suggests that the relationship between irinotecan 
exposure and diarrhea can be established only in a relatively large sample size and 
that it is not as strong an indicator as SN-38G. This could also partly explain the 
conflicting published results for these correlations, as mentioned earlier. For 
example, the biliary index (the product of the AUG ratio of SN-38/SN-38G and 
irinotecan AUG) has previously been reported to be an important pharmacokinetic 
parameter correlated with diarrhea (15, 16), but we did not find that relationship in 
this study. Various factors, including the study design, the particular patient 
population being studied, the number of subjects, or the differences in sampling 
times, are crucial for accurate determination of pharmacokinetic-pharmacodynamic 
relationships. 
In conclusion, we have developed population pharmacokinetic models for 
irinotecan, its pharmacologically active metabolite SN-38, and its glucuronic acid 
conjugate SN-38G. We used those models to establish a positive pharmacokinetic-
pharmacodynamic relationship between SN-38G AUG and the severity of diarrhea. 
The population modeling we have described continues to refine our knowledge of 
this clinically important drug and, where appropriate, will lead to more easily 
exportable and optimized dosing strategies. We are currently involved in the 
development of a population pharmacokinetic model to correlate irinotecan 
disposition with drug-induced hematologic toxicity. 
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SUMMARY 
We have shown previously that the terminal disposition half-life of SN-38, the 
active metabolite of CPT-11, is much longer than earlier thought (Kehrer eta/., Clin. 
Cancer Res., 6: 3451-3458, 2000). Currently, it is not known whether this prolonged 
exposure has any relevance toward SN-38-induced toxicity. Here, we found that SN-
38 concentrations present in human plasma for up to 3 weeks after a single CPT-11 
infusion induce significant cytotoxicity in vitro. Using pharmacokinetic data from 26 
patients, with sampling up to 500 hours, relationships were evaluated between 
systemic exposure (AUG) to SN-38 and the per cent decrease in absolute neutrophil 
count (ANC) at nadir, or by taking the entire time course of ANC into account (AOC). 
The time course of SN-38 concentrations (AUCsooh) was significantly related to this 
AOC (P < .001 ). Based on this findings, a new limited-sampling model (LSM) was 
developed for SN-38 AUCsooh using only 2 timed samples: AUCsooh = (6.588 x G.e.sh) + 
(146.4 x C49.sh) + 15.53, where C2.sh and C4s.sh are plasma concentrations at 2.5 and 
49.5 hours after start of infusion, respectively. The use of this LSM may open up 
historic databases to retrospectively obtain information about SN-38-induced toxicity 
in patients treated with CPT-11. 
INTRODUCTION 
lrinotecan (CPT-11) belongs to the family of camptothecins, and is a member of 
the class of topoisomerase I inhibitors. A broad spectrum of anti-tumor activity was 
seen in preclinical models as well as in patients, with responses observed in various 
disease types, including colorectal, lung, cervical, and ovarian cancers (1, 2). CPT-
11 is a prod rug that requires activation to the active metabolite, 7-ethyl-1 0-
hydroxycamptothecin (SN-38), which is approximately 1 00 to 1 000-fold more active 
than the parent drug (3). A host of enzymes, including carboxylesterases to form SN-
38 (4), UDP glucuronosyltransferases mediating SN-38 glucuronidation to form the 
J3-glucuronic acid conjugate, SN-38G, (5), intestinal and endogenous J3-
glucuronidases causing deconjugation of SN-38G (6, 7), as well as cytochrome P-
450 isoforms (8, 9) to form APC and NPC are involved in CPT-11 metabolism. In 
addition, several drug-transporting proteins, notably a canalicular multispecific 
organic anion transporter (cMOAT) located on the bile canalicular membrane (10), 
and P-glycoprotein (11), can influence CPT-11 elimination through hepatobiliary 
secretion and intestinal (re-) absorption. 
As a result of these (and probably also other presently unknown) mechanisms, 
CPT-11 and its metabolites are subject to large interindividual kinetic variability (12), 
and show relatively long disposition half-lives. We have recently shown that by 
104 
SN-38 Pharmacokinetics-Pharmacodynamics 
applying an extended sampling-time period of 500 hours, the circulation time of SN-
38 in cancer patients was found to be substantially longer than held previously (13). 
We hypothesized that, because of the poorly defined relationships between 
pharmacokinetic parameters and pharmacodynamic outcome of CPT-11 treatment 
(2), the prolonged terminal-disposition phase of SN-38 should be taken into 
consideration in future studies to identify kinetic correlates that would assist in 
prediction of the dose-limiting myelosuppression. Here, we examined the impact of 
this prolonged SN-38 exposure using an in vitro approach with a panel of human 
cancer cell lines, and re-examined exposure-toxicity relationships in a group of 26 
cancer patients treated with CPT-11 administered as a 90-minute intravenous 
infusion in a 3-weekly regimen at a dose of 350 mg/m2. 
MATERIALS AND METHODS 
Growth-inhibition studies 
Exponentially growing cells obtained from the IGROV (ovarian cancer), Caco-2 
(colon cancer) and H226 (lung cancer) cell lines were cultured in 4 ml of RPMI-1640 
medium, and plated in 25 cm2 T-flasks (Corning Costar), at a density of 10,000 
cells/flask. Hereafter, plates were incubated in a controlled environment at 37°C and 
95% air/5% C02, and 24 hours after the start of incubation, the mediurn was replaced 
by medium containing SN-38 at final concentrations of 1 00 pM (39.2 pg/ml), 1.00 nM 
(392 pg/ml), or 1 0.0 nM (3,920 pg/ml). These concentrations were chosen because 
they adequately simulated the median SN-38 plasma concentrations circulating in 
patients after 3 weeks, 10 days, and 2 days, respectively, after infusion of the standard 
dose of CPT-11 (350 mg/m2, given as a 90-minute infusion once every three weeks; 
see Figure 1 ). As a control, flasks containing cells in the absence of SN-38 were used. 
At 48-hour inte!Vals, and for a maximum period of about 3 weeks (i.e., 500 hours), the 
culture medium was replaced with fresh medium to minimize possibly confounding 
effects caused by chemical instability of SN-38. At the same inte!Vals, culture flasks 
were treated with trypsin for 30 minutes, and subsequently the cell suspension was 
centrifuged for 2 minutes at 500 x g (4°C). Next, the supernatant was discarded, and 
the cells were re-suspended in 50 J.ll of buffer and counted in a Burker-cell chamber. 
Each experiment was repeated twice, with each counting performed in quadruplicate. 
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Figure 1. Plasma concentration-time profiles of SN-38 in patients treated with a 90-min i.v. 
infusion of CPT-11 (dose level350 mg/m'}. 
Patients and treatment 
We retrospectively studied records from patients participating to various 
prospective clinical trials of CPT-11 in which pharmacokinetic monitoring was 
involved; the full clinical profiles are documented elsewhere {13-15). All patients had 
a histologically or cytologically confirmed malignant solid tumor for which CPT-11 
was considered to be a treatment option. An adequate haematopoietic {white blood 
cell count {WBC) <: 3.0 x 109/liter; absolute neutrophil count {ANC) <: 1.5 x 10%ter; 
and platelet count {PL T) <: 100 x 1 09/liter), hepatic and renal function at the time of 
study entry was required. Eligibility criteria also included a World Health Organization 
performance status of 0 or 1, and age between 18 and 70 years. Before study entry, 
written informed consent was obtained from all patients. 
CPT-11 was provided by Aventis Pharma (Antony Cedex, France) as a 
hydrochloride trihydrate salt in vials containing 40 or 100 mg, dissolved in d-sorbitol 
and a lactic acid-sodium hydroxide buffer system (pH 3.5-4.5) at a concentration of 
20 mg/mL. This solution was further diluted in 250 mL of sterile, isotonic sodium 
chloride, prior to dosing. The drug was administered as a 90-minute continuous 
intravenous infusion at a dose of 350 mg/m2 , and each patient received prophylactic 
antiemetics including ondansetron (8 mg) or granisetron (1 mg) and dexamethasone 
(1 0 mg). In the first course of treatment, patients did not receive any other 
medication known to interfere with CPT-11 pharmacokinetics. 
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Pharmacokinetic analysis 
Blood samples for pharmacokinetic analysis were drawn from an indwelling 
cannula from the arm opposite to that used for drug infusion. These samples were 
collected in glass tubes containing lithium heparin prior to infusion, at 0.5, and 1.5 
hours (end of infusion) during infusion, and at 10, 20, and 30 minutes, and 1, 1.5, 2, 
4, 5, 8.5, 24, 32, 48, 56, 190, 360, and 500 hours after the end of infusion. Blood 
samples were immediately centrifuged at 3000 x g for 10 minutes after collection to 
separate the blood cells and the plasma fraction was stored at -80'C until analysis. 
Concentrations of CPT-11 and it metabolite SN-38 were determined by reversed-
phase high-performance liquid chromatography with fluorescence detection, as 
described in detail elsewhere (16). To determine SN-38 at low femtomole levels, a 
more specific analytical method was used (17). Earlier pharmacokinetic findings 
showed that total drug levels (i.e., the total of lactone and carboxylate forms) of CPT-
11 and SN-38 provided a consistent and accurate reflection of the pharmacologically 
active lactone concentration of both compounds with little variability (18). Therefore, it 
was concluded that total drug monitoring of CPT-11 and SN-38 could serve as an 
appropriate surrogate of the respective lactone forms. For practical reasons, we only 
used total drug forms for further analysis. Plasma concentration-time data of CPT-11 
and SN-38 were fitted to a tri-exponential equation using the software package Siphar 
v4.0 (lnnaPhase, Philadelphia, PA), based on previously described considerations for 
model discrimination (6). Calculation of the area under the plasma concentration-time 
curve (AUC) was based on integration from the tri-exponential curve with extrapolation 
to infinity. Extrapolated AUC values of SN-38 were either based on a 56-hour (AUC56") 
or a 500-hour sampling-time period (AUCsoohl· 
Exposure-toxicity relationships 
Hematological parameters of interest (i.e., those derived from ANC, WBC and 
PL T) were determined before CPT-11 infusion and on a twice weekly basis during the 
entire pharmacokinetic sampling-time period, to enable a pharmacokinetic/ 
pharmacodynamic (PK/PD) evaluation. The pharmacodynamic endpoint for 
establishment of the PK/PD relationships was determined in 2 different ways. First, 
prior to the PKIPD analysis, individual toxicity data expressed as blood cell counts 
were plotted for each patient in a concentration versus time profile. The estimated area 
over these curves (AOC,,x), as well as the area under the curves (AUC,,x), was 
calculated by the linear-trapezoid method (Figure 2). 
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Figure 2. Example of an ANC-time pattern. The triangle represents the nadir count The 
horizontal line represents the baseline value of ANC. 
The ratio AOCtoJ(AOCtox+AUCto,J, referred to as AOC, in which the denominator 
represents the area described by the pre-therapy toxicity value times the maximum 
pharmacokinetic sampling time, was hypothesized to be a simple and accurate 
function of drug-related hematological toxicity (19). Second, drug-related hematological 
toxicities were evaluated by using the nadir count, which was measured to detennine 
the percent decrease in hematopoietic cells as: 
Percent decrease= (pre-therapy value- nadir count) I (pre-therapy value) x 100 
To avoid confounding bias due to changes in hematological data unrelated to 
treatment, patients showing extreme pre-infusion hematological numbers (i.e., with 
ANC > 13.0x1 o%ter) were excluded in these calculations. Each of these two relative 
hematological-toxicity functions were fitted to the AUG of SN-38 using a sigmoidal 
maximum effect (Emax) model, based on a modified Hill equation, as follows: 
E =Eo+ Emax x [(AUCsN-sal) I (AUCsN-381 + CEso')] 
In this equation, Eo is the minimum reduction possible, Emax is the maximum response, 
CE50 is the AUG value of SN-38 predicted to result in 50% of the maximum response, 
and y is the Hill constant, which describes the sigmoidicity of the curve (20). 
Phannacokinetic-phannacodynamic analysis was perfonned using the software 
package Siphar version 4.0, and weighted and extended least squares techniques 
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were used to estimate model parameters. Model selection was guided by the decrease 
in the objective function value (-2xlog likelihood). The criteria to assess the goodness 
of fit of the models was based on (i) computation of the coefficient of variation, defined 
as the ratio of the standard deviation computed using the variance-covariance matrix 
and the parameter value, (ii) the Akaike information criterion, and (iii) the correlation 
coefficient and P-value of the relationship. 
Statistical considerations 
All statistical calculations were performed using the Number Cruncher Statistical 
System package version 5.X (J.L. Hintze, East Kaysville, UT, 1992) and/or the Siphar 
package. The level of significance was set at P < .05. 
Limited sampling models (LSMs) 
Patients were randomly entered in 2 groups, a training-data set and a 
validation-data set containing up to 20 samples for each individual patient, as has 
been described before (21 ). A restricted block randomisation was performed as 
described elsewhere (22) to keep the number of patients close for both groups, and 
only one course of each patient was taken to avoid bias as a result of potential 
cumulative effects and to keep the observations independent. 
Our goal was to predict the AUG of SN-38 adequately with a minimum number 
of samples (1 to 3). Moreover, these samples should be taken at the most 
convenient time-points for practical reasons. The first step in the model development 
consisted of univariate linear-regression analysis to determine the best single-sample 
time points from the training data set. Next, we performed a stepwise (forward) 
multivariate linear-regression analysis using the optimal single sampling-time points 
to describe the association between SN-38 concentrations at multiple time points 
and its corresponding AUG. The Pearson's coefficient (t), root mean-square error 
(RMSE), and mean-predictive error (MPE), which describe correlation, precision and 
bias, respectively, were calculated to determine the best LSMs. The usefulness of 
the models was evaluated in the training data set, by comparing AUG values 
determined using the full data with AUG values predicted by the LSMs. 
RESULTS 
In vitro analysis of SN-38-induced cytotoxicity 
The growth-inhibitory potential of low SN-38 concentrations was evaluated in vitro 
against several cell lines using a 3-week continuous-exposure period. Clear 
109 
Chapter 6 
manifestation of growth-inhibiting effects were seen at SN-38 concentrations of 1 00 
pM, 1.00 nM and 10.0 nM in the IGROV cell lines, with the number of remaining viable 
cells being reduced by 46 ± 8.7%, 77 ± 1 0.4%, and > 99.9%, respectively, as 
compared to untreated controls (Figure 3). At these concentrations, 34 ± 5.9%, 73 ± 
4.0% and 98 ± 0.2% growth inhibition, respectively, was seen in the H226 cells, relative 
to their controls. As the doubling time of the Caco-2 was shorter than that of the 
IGROV cells, data could not be obtained for the entire 3-week period in the Caco-2 cell 
line. Nonetheless, the data suggest overall that the low circulating concentrations of 
SN-38 determined previously in patients receiving CPT-11 at a dose of 350 mg/m2 
induce substantial inhibition of cancer cell growth, in spite of evident concerns in 
extrapolating data from in vitro experiments to the clinical situation. 
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Figure 3. Cell-growth versus time curves for the IGROV (A), Caco-2 (B), and H226 (C) cell 
lines, incubated with medium containing 100 pM (A), 1.00 nM ('I') or 10.0 nM (Ill) of 
SN-38 or medium without SN-38 (Ill) (reference) for a 500-hour incubation time 
period. Data indicate mean values (symbol) with SD (error bars), which are shown 
when larger than symbol. 
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Patient population 
A total of 26 patients, predominantly suffering from colorectal cancer, were 
entered onto the current trial (Table 1). All patients received a single-agent regimen 
with CPT-11 in the first treatment course at a dose of 350 mg/m2. One course was 
excluded because of extreme pre-treatment values lor hematological parameters (i.e., 
ANC value greater than 13.0x109/liter), making a total of 25 courses assessable lor 
PK!PD analysis. 
Table 1. Patient characteristics for PK/PD evaluation. 
Characteristic 
Total number of patients 
Total number of courses 
Assessable courses 
Age [years (range)] 
Sex (male/ female)b 
Primary tumour siteb: 
Colo rectal 
Cervix 
Unknown primary site 
26 
38 
25 
54a (37-71) 
12/14 
24 
a Results expressed as median value; b Results expressed as number of patients 
Pharmacokinetics and pharmacodynamics 
The two groups of SN-38 AUCs based on short (56 hours) and prolonged 
sampling (500 hours), respectively, were highly correlated (r = 0.79). However, as 
shown in Figure 4, all AUG values calculated using the short sampling-time period 
substantially underestimated the true AUC, albeit with huge variation (7 up to 81 %). 
The mean dose over AUC ratio for SN-38 based on prolonged sampling was 860 ± 
410 Uh in this group of patients, and was 1400 ± 890 Uh when based on short 
sampling. 
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Figure 4. Relationship between calculated SN-38 AUCs, based on 500-h sampling and 56-h 
sampling respectively. (n--38). The solid line represents the line of identity (y=x). 
The parameter estimates for the different pharmacodynamic models, using data 
from 25 patients, are shown in Figure 5. Preliminary results demonstrated that 
separate estimation of the observed maximum effect did improve the fits, and that 
optimal results were obtained with a model fitted to the data using weighted least 
squares (weighting factor, 11y) and the Powell minimization algorithm. Data sets based 
on short and prolonged sampling were both plotted separately against individual values 
of ANC, WBC and PL T applying the ratio AOCtox I (AOCtox + AUG,,) and the percent 
decrease in blood cell counts, using the Emax·model (23, 24). The kinetic parameters 
predicted to result in half of the maximum response showed a substantial degree of 
interindividual variability, and were poorly estimated in some models, presumably 
because of the small number of patients. The exposure-neutropenia relationship was 
best described with the model based on the 500-hour sampling-time period and the 
ratio AOC,0,!(AOC,ox+AUC,0,) (Figure 58), although no significant improvement of the fit 
was obtained as compared to the relationship based on the short sampling time period 
(Figure SA). In the optimal model, the following model parameters were observed: 
CE50 = 460 ± 82.9 ng.hlml, y= 2.22 ± 1.55, P= .0001 and r= 0.77. With the use of the 
percent decrease in ANC at nadir as phanmacodynamic measure, the fits were worse 
than those based on AOC. The disparity in the data of ratio AOCANC I (AOCANc + 
AUCANc) and percent decrease in ANC suggests that PD analysis based on percent 
decrease in ANC is not sufficiently accurate to be used as a measure for prediction of 
hematological toxicity. In contrast to ANC, no correlations with PK were observed for 
WBCand PLT. 
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Figure 5. Relationship between ratio AOGANd(AOGANc+AUGANc) and SN-38 AUG based on a 
56-h sampling time period (A), or SN-88 AUG based on a 500-h sampling time 
period (B). Relationship between percent decrease in ANG at nadir versus SN-38 
AUG based on a 56-h sampling time period (C), or SN-38 AUG based on a 500-h 
sampling time period (D). (11=25). Open symbols represent excluded data as a result 
of a baseline ANG > 13.0x1 09~iter. 
Limited-sampling models 
We developed a new limited-sampling model (LSM) for detenmination of SN-38 
AUCsooh using one to three samples taken after drug administration, taking into 
account feasibility and usefulness in a routine clinical setting. There were no significant 
differences in patient characteristics between the training and validation data set. The 
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same 26 patients were included in this analysis, and in both groups 13 patients were 
entered (6females and 7 males in both cases). The median age in the training set was 
53 years (range, 37 to 71 years), versus 54 years (range, 42 to 71 years) in the 
validation set. Results of a univariate linear-regression analysis of SN-38 
concentrations at each sample time points and the corresponding AUC showed 
correlation coefficients ranging from 0.08 to 0.82 in the training set (Table 2). 
Table 2. Univariate correlation between SN~38 total concentrations at each sampled time 
point (after the start of infusion) and its corresponding AUC in training-data set patients. 
Time point (h) ra Number of patients 
0.50 0.25 13 
1.50 0.14 13 
1.67 0.14 13 
1.83 0.08 12 
2.00 0.22 13 
2.50 0.35 13 
3.00 0.22 12 
3.50 0.09 10 
5.50 0.25 13 
6.50 0.15 12 
10.0 0.24 13 
25.5 0.48 13 
33.5 0.49 11 
49.5 0.68 11 
57.5 0.82 7 
191.5 0.54 13 
361.5 0.54 10 
501.5 0.34 10 
a r: Pearson's correlation coefficient 
Multiple-regression analysis, based on one or two additional time points led to 
significantly improved correlation coefficients. Based on a variety of considerations, 
including, low values for RMSE and MPE with high correlation coefficients, the optimal 
LSM was a bivariate model containing concentration data at 2 time points: 
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AUCsN-38 (ng.h/ml) = (6.588 X c2.Sh) + (146.4 X c49.Sh) + 15.53 
where C,sh and c.95h represent plasma concentrations of SN-38 (in ng/ml) at 2.5 
hours after the start of infusion (1 hour post-infusion) and 49.5 hours (48 hours post-
infusion), respectively. In both the training set and validation sets, this model showed 
little bias (MPE, 0.33% and 0.76%) and excellent precision (RMSE, 4.9% and 9.1%), 
with correlation coefficients of 0.99 and 0.96, respectively (Figure 6). 
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Figure 6. Correlation between the observed AUC from a linear three~compartment model and 
the predicted AUG from the LSM lor SN-38 total. Closed symbols represent training 
set data; open symbols represent validation set data. The solid line represents the 
line of identity (y=x). 
Trivariate models were also evaluated using the clinically most optimal sample-
time points (i.e 1, 190 and 360 hours post-infusion). Unfortunately, the predictive 
performance of this model appeared to be worse (validation set MPE = 1.6%; RMSE = 
18%; r2 = 0.83), despite acceptable training set statistics (MPE = 0.62%; RMSE = 
9.5%; r2= 0.95). 
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DISCUSSION 
This study shows that the prolonged exposure at low circulating concentrations of 
the pharmacologically active CPT-11 metabolite, SN-38, in plasma of cancer patients 
after a single dose has important cytotoxic potential in vitro and therewith may have 
clinical relevance toward SN-38-induced toxicity and antitumor activity. In our in vitro 
experiments we exposed several cancer cell lines to SN-38 concentrations, which were 
known to be circulating in plasma for up to 3 weeks after a 90-minute i.v. infusion of 
CPT-11 at a dose of 350 mg/m2• After a 3-week incubation period in the presence of 
SN-38 at concentrations of 100 pM, 1.00 nM and 10.0 nM, significantly reduced tumour 
growth was observed as compared to untreated cells, suggesting significant cytotoxic 
activity, even at these low drug levels. Using pharmacokinetic data from 26 patients 
treated with CPT-11, with sampling up to 500 hours after drug administration, PK/PD 
relationships were evaluated between systemic exposure (AUC) to SN-38 and the 
percent decrease in ANC at nadir or by taking the entire time course of ANC into 
account (AOC), using a modified Hill function (sigmoidal Emax model). Taking into 
consideration the entire time course of SN-38 concentrations {AUCsooh), the most 
optimal relationships were observed for the AOCs. These data not only emphasise the 
need to apply appropriate PKIPD models with sufficient sampling-time points for the 
accurate estimation of complete concentration-time profiles, but also has direct clinical 
relevance in view of the fact that relationships between drug exposure and effect (i.e., 
toxicity and efficacy) were poorly defined previously (2). 
We have shown earlier that the use of an extended sample-collection period of 
500 hours led to terminal disposition half-life and AUC estimates for SN-38 after 
CPT-11 administration of 47 ± 7.9 hours and 2.0 ± 0.79 J.iM.h, respectively {13), both 
representing a 2-fold increase as compared to earlier reported estimates. As an 
explanation for this phenomenon, we previously observed a substantial formation of 
SN-38 from CPT-11 and the cytochrome P-450 3A4-mediated metabolite, NPC, by 
plasma carboxylesterases. In addition, transport studies in Caco-2 cell monolayers 
indicated that SN-38 could cross the membrane from the apical to the basolateral 
side, indicating the potential for re-circulation processes that can prolong circulation 
limes {13). More recently, we also noted extensive partitioning of CPT-11 in 
erythrocytes resulting in prolonged association of the parent drug in the central blood 
compartment (25). Regardless of the exact underlying causes for the prolonged SN-
38 circulation, the fact that low circulating levels of SN-38 demonstrate profound 
cytotoxic potential indicates the need to not take an oversimplified view when 
modelling drug-induced hematological toxicity. 
Pharmacokinetic information on the concentration-time profiles has previously 
been combined with efficacy-toxicity data to form PKIPD models for drugs in a wide 
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variety of therapeutic areas. The most common type of this kind of PK!PO model is 
one in which a summary measure of exposure, such as AUG, is related to the principal 
side effect of the treatment, in this case hematological toxicity, for which singly 
measured nadir counts are usually employed. However, experimental evidence 
suggests that information on an entire time course of changes in blood cell counts is 
more important than the nadir count. For example, it has been demonstrated that 
patients with prolonged neutropenia have a greater risk of infection than patients who 
have the same nadir count with rapid recovery. Therefore, we hypothesised that using 
data from the entire time course of neutropenia after CPT-11 treatment would provide 
useful information. Thus, we analysed our data using two different types of analysis 
(percent decrease in toxicity at nadir and a measure of time course (AOC)) using two 
different variables based on AUG calculated using 56-hour or 500-hour sampling 
periods, with those based on AOC showing superiority for prediction of hematological 
toxicity. For both PO parameters, the quantity of available data is positively correlated 
with the quality (accuracy) of the determined outcome variables. Thus, at least several 
data points are required for an accurate estimate of the nadir count. In our current 
study, a rich data set was available with hematological toxicity data, which might 
explain the moderate predictive performance of the PK!PO relationship using 
(assumed) nadir counts. Clinically even more important PO parameters than the just 
mentioned parameters may be (l) the time period during which the neutrophil count 
remains below a certain level (for instance 4x1 09 cells/L) or (ii) the area between the 
curve of time versus leukocyte count and the line representing a cell count of 4x1 09 
cells/L (26). Also in our current study, this area was shown to be demonstrated the 
best correlation of all tested PK!PO combinations. In order to further optimise PKIPO 
relationships, a population model for CPT-11-induced neutropenia by modelling the full 
time course of hematological toxicity is currently being developed, as done previously 
for paclitaxel and etoposide (26-28). 
Some clinical implications from the data presented in this study, particularly with 
respect to considerations of treatment schedule, are easily envisaged. Regarding 
administration regimens of CPT -11 used in cancer patients, it is particularly noteworthy 
that different schedules are being used in Europe (350 mg/m2 once every 3 weeks), 
the USA (125 mg/m2 weekly for 4 or 6 weeks) and Japan (1 00 mg/m2 every week). 
Furthermore, there is a current trend for the use of protracted intravenous or oral 
dosing regimens of CPT-11 using daily drug administration (29), based on earlier 
clinical experience with camptothecin analogues with relatively short terminal 
disposition half-lives, such as topotecan. However, the unique pharmacokinetic 
behavior of SN-38, coupled to our current pharmacodynamic observations, suggests 
117 
Chapter 6 
that a single administration of CPT-11 repeated every third week is the preferred 
regimen, and that increased frequency of administration may result in drug 
accumulation. 
Obviously, the clinical applicability of SN-38 AUG as a PK parameter predicting 
toxicity would increase by the availability of accurate and predictive limited sampling 
models (LSM). Earlier developed models for the determination of SN-38 total AUG 
were only useful for the estimation of AUG models up to 24 or 56 hours (21 ). 
Therefore, a new LSM was developed for determination of SN-38 AUCsooh using only 2 
timed samples: AUCsooh (ng.h/ml) = (6.S88xC2.s h) + (146.4xC49.5 h) + 15.53, where C,_5 
h and C49.5 h are plasma concentrations at 2.5 and 49.5 hours after start of CPT-11 
infusion, respectively. The model was shown to be precise (RMSE = 4.9%) with no 
demonstration of any bias (MPE = 0.33%). This model enables us to perform PK 
studies in a very efficient manner, and it is less expensive and might therefore be 
applicable to large-scale investigations. For example, PK sampling might be performed 
easily in an outpatient setting. In addition, the use of this LSM may open up historic 
databases for a re-evaluation, or at least provide prospective studies to obtain 
information about SN-38-mediated (hematological) toxicity in cancer patients treated 
with CPT-11. For the determination of SN-38 AUG, this model is currently being 
implemented in a multi-institutional clinical trial with CPT-11 administered at a dose 
level of 350 mg/m2 in the presence or absence of the aminoglycoside antibiotic, 
neomycin. 
In conclusion, we have shown that the prolonged circulation of SN-38 at low 
concentrations following CPT-11 administration has clinical implications, and resulted 
in altered exposure-toxicity relationships. This information, coupled to the prospective 
implementation of the newly developed LSM, may be of importance for future 
individualization of drug therapy in order to avoid excessive toxicity. 
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ABSTRACT 
Puroose: To evaluate relationships between various body-size measures and 
irinotecan (CPT-11) clearance and metabolism in cancer patients, and to provide 
future dosing recommendations for this agent. 
Patients and Methods: Pharmacokinetic data were obtained from 82 adult patients 
(50 men, 32 women; median age, 54 years) receiving CPT-11 as a 90-minute 
intravenous infusion (dose range, 175 to 350 mg!m2 ). In each patient, plasma 
samples were collected at timed intervals in the first administration of a 3-week 
schedule, and CPT-11 and its metabolite, SN-38, were measured by a liquid 
chromatographic assay. 
Results: The mean (±SD) CPT-11 clearance was 33.6 ± 10.8 Uh, with an 
interindividual variability (I IV) of 32.1 %. When clearance was adjusted for body-
surface area (BSA), the IIV was similar (34.0%). In addition, in a multiple linear-
regression analysis, none of the studied measures (BSA, lean-body mass, [adjusted] 
ideal body weight, and body-mass index) was a significant covariate (P > .13; f2 < 
.014) in our population. Similarly, BSA did not significantly contribute to variability in 
the relative ex1ent of conversion to SN-38 (P= .26). 
Conclusion: BSA is not a predictor of CPT-11 clearance or SN-38 pharmacokinetics 
and does not contribute to reducing kinetic variability. These findings provide a 
rationale for the conduct of a comparative phase Ill study between BSA-based 
dosing and flat or fixed dosing of CPT-11. 
INTRODUCTION 
I rinotecan (7-ethyl-1 0-[4-(1-piperidino )-1-piperidino ]carbonyloxycamptothecin; 
CPT-11) belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug 
of SN-38, which is approximately 1 00- to 1 ,000-fold more cytotoxic than the parent 
drug (1). CPT-11 has shown a broad spectrum of antitumor activity in preclinical 
models as well as clinically, with responses observed in various disease types, 
including colorectal, lung, cervical and ovarian cancer (2). The pharmacokinetics and 
metabolism of CPT-11 are ex1remely complex and have been the subject of intensive 
investigation in recent years. Both CPT-11 and SN-38 are known in an active lactone 
form and an inactive carboxylate form, between which equilibrium exists that 
depends on the pH and the presence of binding proteins. In addition, CPT-11 is 
subject to ex1ensive metabolic conversion by both phase I and phase II enzyme 
systems, including carboxylesterases to form SN-38 (3), uridine 
diphosphoglucuronate glucuronosyltransferases (UGT1A 1) mediating 
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glucuronidation of SN-38 (4), as well as cytochrome P-450 isoforms (mainly 
CYP3A4) which form several pharmacologically inactive oxidation products (5, 6). 
Elimination routes of CPT-11 also depend on the presence of drug-transporting 
proteins, notably P-glycoprotein (7) and a canalicular multispecific organic anion 
transporter (cMOAT; ref. 8), present on the bile canalicular membrane. 
The various processes that mediate drug elimination, either through metabolic 
breakdown or excretion, likely have a substantial impact on interindividual variability 
in drug handling. Strategies are now underway to individualize CPT-11 administration 
schedules based on patient differences in enzyme or protein expression or by 
coadministration of specific agents modulating side effects (9). These strategies may 
ultimately lead to more selective chemotherapeutic use of this agent. In contrast, the 
prescribed dose of CPT-11 is currently calculated using body-surface area (BSA) as 
the only independent variable, and it has been shown that this approach still results 
in large interindividual variability in exposure. Although this has been widely 
recognized for some agents, until recently its significance has not been fully 
appreciated and remains unstudied for most anticancer drugs used in today's clinical 
practice. The purpose of this report was to assess CPT-11 clearance and 
metabolism as a function of commonly used body-size measures in adult cancer 
patients to provide a pharmacokinetic rationale for the appropriate dosing of CPT-11. 
PATIENTS AND METHODS 
Patients population 
Records collected as part of clinical CPT-11 monitoring at the Erasmus MC 
were examined retrospectively; the full clinical profiles have been documented 
elsewhere (1 0-13). All patients had a malignant solid tumor that stipulated a CPT-11-
based regimen and had adequate hematopoietic (absolute neutrophil count <:1.5 
x1 09/L; platelet count <:1 00 x1 09/L), hepatic, and renal function at the time of study 
entry. Inclusion also required an Eastern Cooperative Oncology Group performance 
status of 2 or less and age between 18 and 75 years. All patients with complete 
information (consisting of age, disease, height, weight, and first-dose 
pharmacokinetic data) were included in the current analysis. No other agents known 
to interfere with CPT-11 disposition were administered immediately before or 
concomitantly with CPT-11. All patients provided informed consent for the 
pharmacologic analysis. 
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Drug administration 
CPT-11 was provided as the hydrochloride trihydrate salt by Aventis Pharma 
(Antony Cedex, France) in 40- or 100-ml vials containing 20 mg CPT-11/ml in d-
sorbitol and a lactic acid-sodium hydroxide buffer system (pH 3.5 to 4.5). Before 
dosing, the pharmaceutical preparation was diluted in 250 ml of sterile, isotonic 
sodium chloride. The drug was administered every 3 weeks as a 90-minute continuous 
intravenous infusion at a dose level between 175 and 350 mg/m2, and each patient 
received an intravenous premedication schedule that included ondansetron (8 mg) and 
dexamethasone (1 0 mg). The pharmacokinetic behavior of CPT-11 at these dose 
levels is linear and dose-independent (14). 
Pharmacokinetic analysis 
Heparinized blood samples for pharmacokinetic analysis were drawn from an 
indwelling cannula. These samples were collected before infusion, at 0.5 and 1.5 h 
during infusion, and 10, 20, and 30 minutes and 1, 2, 3, 3.5, 4, 5, 6.5, 1 0.5, 24, 30.5, 
48, and 54.5 hours after the end of infusion. Plasma fractions were obtained 
immediately after collection by centrifugation (3000 x g for 1 0 minutes). Concentrations 
of CPT-11 and SN-38 were determined by a validated reversed-phase high-
performance liquid chromatography system with fluorescence detection (15). A 
preliminary analysis of the initial raw data indicated that CPT-11 and SN-38 total drug 
levels (i.e., the total of lactone and carboxylate forms) provided a consistent and 
accurate reflection of the lactone concentration with little variability (not shown). This is 
in agreement with previous findings (16) and suggests that total drug monitoring serves 
as an appropriate surrogate of the lactone forms. Therefore, we decided, for practical 
purposes, to use only total drug forms in further analysis. 
Concentration-time data of CPT-11 and SN-38 were fitted to a tri-exponential 
equation, using the software package Siphar, version 4.0 (lnnaPhase, Philadelphia, 
PA), on the basis of a previously described model discrimination (17). Inverse square 
weighting of the measured concentrations was used for all compartmental analyses. 
The absolute clearance of CPT-11 (in Llh) was calculated by dividing the dose 
administered (in mg) by the observed AUC values. The apparent clearance (in Llh!m2) 
was also calculated by dividing the absolute clearance of irinotecan by a patient's 
individual BSA value. For SN-38, the apparent metabolic clearance and the relative 
extent of conversion, defined as the area under the curve (AUC; in Mxh) ratio of SN-38 
and CPT-11, were calculated. 
The various body size measures, including BSA (in m2; ref. 18), lean body mass 
(LBM; in kg; ref. 19), ideal body weight (IBW; in kg; ref. 20), adjusted ideal body weight 
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(AIBW; in kg; ref. 20), and body mass index (BMI; ref. 20), were calculated using the 
following equations, with length expressed in meters and weight in kg: 
BSA = --1 ((lenght x weight) I 36) or 0.007184 x weight 0·425 x length 0·725 
LBM (men) = 1.1 0 x weight- 120 x (weight/ (length x 1 00))2 
LBM (women)= 1.07 x weight- 148 x (weight/ (length x 1 00))2 
IBW (men)= 50+ 0.91 x ((length x1 00) -152) 
IBW (women)= 45 + 0.91 x ((length x 100) -152) 
AIBW = IBW + 0.25 x (weight -IBW) 
BMI =weight I (lengthf 
(eq. 1) 
(eq. 2) 
(eq. 3) 
(eq. 4) 
(eq. 5) 
(eq. 6) 
(eq. 7) 
After studying the whole included population, patients were divided in several 
groups. First, sex was studied separately. Second, patients were classified into three 
BSA-groups: BSA less than 1.7 m2, BSA between 1.7 and 2.0 m2, and BSA more than 
2.0 m2, respectively. 
Statistical analysis 
All phannacokinetic parameters are reported as mean values±SD. lnterindividual 
variability in parameters was evaluated by the coefficient of variation, defined as the 
ratio of SO and the observed mean. Univariate and multivariate linear-regression 
analysis were performed to evaluate potential relationships between CPT-11 clearance 
or relative extent of conversion to SN-38 and each of the studied body-size measures, 
sex, tumor type, and age. After tests for normality in parameter variability, absolute 
clearance (dependent variable) was plotted to BSA, LBM, IBW, AIBW, BMI, weight, 
and length (independent variables). Probability values and adjusted r 2 were calculated 
as measurements for correlation. One-way analysis of variance was used to compare 
difference in body-size nonnalized clearance among different BSA categories with the 
Bonferroni correction for multiple comparisons. All statistical calculations were 
pertonned using the NCSS package version 5.X (J.L. Hintze, East Kaysville, UT). 
Probability values of less than .05 were regarded as statistically significant. 
RESULTS 
Patient population 
The entire population studied consisted of 82 patients, of whom 50 were male 
and 32 were females (Table 1 ). The median age was 54 years (range, 36 to 71 years), 
and the majority of patients suffered from a colorectal carcinoma. Administered CPT-
11 dose levels varied from 175 to 350 mg/m2. 
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Table 1. Demographics. 
Patient characteristic 
Total number of patients 
Age [years (range)] 
Sex (male/ female) 
length [m (range)] 
Weight [kg (range)] 
BSA [m2 (range)] 
LBM [kg (range)] 
IBW [kg (range)] 
AIBW [kg (range)] 
BMI (range) 
Primary tumor site 
Colo rectal 
Gastrointestinal 
Lung 
Head and neck 
Miscellaneous 
Unknown 
lrinotecan dose (mg/m2) 
175 
200 
230 
260 
300 
350 
a Results expressed as mean value. 
CPT-11 clearance 
Number of patients 
82 
54a (36-71) 
50:32 
1.73a (1.51-1.92) 
75a (47-115) 
1.90a (1.47-2.40) 
57" (38-80) 
67a (44-86) 
69a (49-90) 
25a (16-37) 
52 
4 
6 
6 
6 
8 
6 
22 
7 
12 
9 
26 
The mean plasma clearance of CPT-11 was 33.6 ± 10.8 Uh (range, 13.5 to 64.8 
Uh), with an interindividual variability of 32.1% (Table 2). After correction of the 
clearance lor BSA, a mean value of 17.9 ± 6.1 Uh/m2 was found, along with a similar 
degree of variability (i.e., 34.0%). Similarly, after adjustments of CPT-11 clearance for 
LBM, IBW, AIBW, BMI, weight, or length, the interpatient variability was not reduced 
(Table 2). 
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Table 2. Mean CPT-11 clearance as a function of body-size measures. 
Body-size measure CV (%) Clearance (mean± SD) 
None 32.1 33.6 ± 10.8 Uh 
BSA 34.0 17.9±6.1 U hi m2 
LBM 35.3 1.37 ± 0.48 Uhlkg 
IBW 36.7 0.51 ± 0.19 Uhlkg 
AIBW 36.0 0.49±0.18 u hi kg 
BMI 35.3 1.37 ± 0.48 
Weight 38.3 0.46 ± 0.18 Uhlkg 
Length 32.6 19.4±6.3 Uhlm 
Abbreviation: CV, coefficient of variation 
Using linear-regression analysis, we found that CPT-11 was not significantly related 
to any ol the studied body-size estimates (Figs 1 and 2). In a univariate analysis, 
which included weight, length, dose, sex, age, and tumor type as independent 
variables, no significant covariates were identified (P-values between .09 and .58; 
adjusted 1- between < .0001 and .023) (Table 3). Multiple regression analysis also 
did not result in any significant correlation with CPT-11 clearance (P = .21, 1- = .032). 
The interindividual variability in CPT-11 clearance was similar between men (33.4%) 
and women (34.6%), whereas variabilities in absolute clearance were 32.0% and 
32.3 % lor these two groups, respectively. No differences in clearance lor the three 
studied BSA groups (i.e., < 1.7 m2, between 1.7 and 2.0 m2 , and > 2.0 m2) were 
found (P = .06), with mean values of 33.8, 31.0 and 37.4 Uh respectively. Neither 
BSA nor any other body-size estimate could reduce interpatient variability (not 
shown). 
SN-38 pharmacokinetics 
The overall apparent metabolic clearance of SN-38 was 1 ,490 ± 934 Uh, with 
an interindividual variability as high as 63%. Similar to the CPT-11 clearance data, 
this value remained in the same order (approximately 65%) after correction for 
patients' individual BSA values. As expected, the metabolic clearance of SN-38 and 
the relative extent of conversion to SN-38 were not related to BSA using linear-
regression analysis (P = .26, adjusted ! = .0032 and P = .55, adjusted ! < .0001, 
respectively) (Fig. 1 ). 
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Figure 1. Relationship between absolute CPT-11 clearance (A) or metabolic clearance of 
SN-38 (B) and BSA (n=82). 
Table 3. Relationships between CPT-11 clearance and patient characteristics. 
Variable p r' 
BSA .14 .014 
LBM .20 .0081 
IBW .52 <.0001 
AIBW .28 .0026 
BMI .13 .016 
Weight .09 .023 
Length .58 <.0001 
Dose .27 .0030 
Gender .43 <.0001 
Age .15 .013 
Tumortype .52 <.0001 
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Figure2. Relationship between absolute CPT-11 clearance and LBM (A), IBW (B), AIBW (C), 
BMI (D), weight (E), and length (F) (n~82). 
DISCUSSION 
A common practice in clinical oncology is to dose anticancer drugs on the basis 
of a patienfs BSA with the aim of reducing interindividual pharmacokinetic variability. 
Despite the lack of evidence of the clinical relevance for this dose selection in adults, 
the use of BSA for this purpose is widespread (21, 22). The most commonly used 
formula to estimate BSA originates from 1916 (18), and during the last decade, several 
critical notes concerning this BSA-based dosing concept have been published (21-29). 
With the possible exception of docetaxel (30), it has been demonstrated that the 
clearance of most agents, including epirubicin (25-27), topotecan (28), cisplatin (29) 
and busulfan (20), is not related to BSA. Various alternative body-size measures have 
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been proposed in recent years, e.g. IBW, AIBW, BMI, and LBM, that might be better 
predictors of drug clearance, but no clear rationale for their use has yet been found 
(18, 25). 
In the present study, we evaluated the relationship between CPT-11 clearance 
and metabolism with BSA and several other body-size measures in a group of 82 
cancer patients. The interindividual variability in CPT -11 clearance is large and is an 
important determinant of toxicity (14). The coefficients of variation for the absolute 
CPT -11 clearance or that expressed relative to BSA when including all patients in 
this study were 32.1% and 34.0%, respectively. Thus, we found that, similar to the 
case with most other chemotherapeutic agents, dose calculations based on BSA did 
not reduce interpatient variability in CPT-11 clearance. In addition, in a multiple 
regression analysis with body-size measures as the independent variable, no 
significant covariate on clearance could be identified. In contrast, some estimates of 
body size (i.e., LBM, IBW, and AIBW) were shown to be even worse predictors of 
CPT-11 clearance and metabolism than BSA. Interestingly, it was reported by Miya 
eta/ (31) that BMI was an independent predictor of peak plasma concentrations of 
CPT-11 in a group of 36 patients who received the drug as a 90-minute intravenous 
infusion at a dose of 100 mg/m2 (P = .01, f = .40). These authors speculated that 
water-soluble drugs such as CPT-11, with drug doses calculated on the basis of 
BSA, are poorly distributed to adipose tissue and might produce elevated peak 
concentrations in plasma as compared to hydrophobic agents in obese patients (31 ). 
In our current data set, such a correlation between peak levels and BMI could not be 
established. The basis for these discrepant findings is presently unknown, although 
they may relate, for example, to patient-specific (ethnic) differences in the studied 
patient populations. 
Much controversy has also arisen with respect to potential sex-dependent 
differences in the pharmacokinetic behavior of camptothecin anticancer agents. At 
least one recent obseNation indicated that whole blood and plasma concentrations 
of unchanged CPT-11 were generally lower in males as compared to females (32). In 
addition, sex has been identified recently as an important independent variable for 
the occurrence of severe CPT-11-induced leukocytopenia (grade 4) and/or diarrhea 
(grade 3 or worse) (33). However, because of substantial interindividual variability 
and the small sample size, differences in pharmacokinetic parameters or the effects 
of sex on severe toxicity were not statistically significant. In our patient population, 
sex was unrelated to (variability in) CPT-11 clearance, which finding is supported by 
earlier pharmacokinetic data (34). In addition, in a recent population pharmacokinetic 
model developed using NONMEM (S.L. Seal and LB. Sheiner, San Francisco, CA), 
sex was not a significant covariate on CPT -11 clearance and formation ratio of SN-
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38 (35). In contrast, for the related agent topotecan, a sex-dependent difference in 
clinical pharmacokinetics was noticed recently resulting from physiologic differences 
in hematocrit between males and females (36). These differences in kinetic behavior 
as a function of hematocrit between the various camptothecin analogs are not 
completely understood but may involve a variable degree in binding affinity for 
plasma proteins mediating erythrocyte partitioning and sequestration. 
Using univariate and multivariate-regression analyses, we also found that 
various additional demographic variables, including disease type, drug dose, and 
age, were unrelated to CPT-11 clearance. This is in agreement with previous data 
(37, 38), suggesting that reduced starting doses are not required for elderly patients. 
The results of this study also suggest that CPT-11 clearance is similar in lean and 
obese subjects, whereas the metabolic clearance of SN-38 is slightly higher, 
although not significantly different, in obese patients as compared with lean controls. 
These findings with CPT -11 and SN-38 are consistent with data indicating that the 
absolute clearance of xenobiotics eliminated by hepatic P450 oxidase metabolism is 
similar in obese and lean patients, whereas the absolute clearance of drugs 
eliminated primarily by phase II enzymes is higher in the obese (20). 
The only current factor routinely taken into consideration in clinical practice to 
predict toxicity following CPT-11 administration and to optimize or alter the dosage is 
a pathologic condition indicating hepatic dysfunction. It has been demonstrated that 
(elevated) bilirubin and alkaline phosphatase levels in plasma samples taken before 
treatment correlate positively with CPT-11 clearance, which may (partly) be 
explained by cMOAT activity (39). Also, correlations between CPT-11 clearance and 
y-glutamyl transferase (negative), y-glutamyl transpeptidase (negative), aspartate 
aminotransferase (positive) and alanine aminotransferase (positive), respectively, 
were recently observed (40, 41 ). In addition, it has been documented that 
interindividual variability in cMOAT-expression, as for instance in the Oubin..Johnson 
syndrome (42), can result in hyperbilirubinemia, and require dose modifications. 
Importantly, however, it is increasingly recognized that bilirubin level is not an 
appropriate parameter per se to predict severe CPT-11-induced toxicity, and it 
seems clinically negligible as a tool to predict toxicity (33), unless patients abstain 
from drug and alcohol and are strictly fasted. Thus, at present, bilirubin 
measurements have low predictability and are highly impractical. In addition, in view 
of the multiple enzyme systems and drug transporters involved in CPT-11 
elimination, it seems that pharmacogenetic analysis such as that described for 
UGT1A1 (43-47), CYP3A4 (48), and P-glycoprotein (49, 50) polymorphism is unlikely 
to be the sole factor contributing to interindividual variability in CPT-11 clearance. We 
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believe that this inherent uncertainty, as well as a host of logistic problems 
associated with its implementation in routine clinical practice for the near future, 
presents significant limitations of pharmacogenetic analyses to individualization of 
CPT-11 dosage. In contrast, the concept of fixed rather than BSA-normalized dosing 
should be an area for fruitful clinical pharmacologic studies with CPT-11. We intend 
to conduct a study to prospectively evaluate the feasibility of delivering a fixed dose 
of CPT-11 as a 90-minute intravenous infusion every 3 weeks, based on the known 
flat dose (mg)-area under the plasma concentration-versus-time curve and systemic 
exposure-toxicity relationships of the compound (14), rather than following the 
standard practice of administering the drug on a mg/m2 basis. Clearly, 
implementation of such concepts would have significant economic implications. The 
ability to manufacture a unit dose has obvious benefits for the pharmaceutical 
company involved. Similarly, reconstituting a fixed dose without subsequent 
individualization for different patients is more efficient and cost-effective than 
preparing individualized doses, and it would eliminate a significant source of error in 
attempting to obtain precise dosing (51). 
In conclusion, we have shown that BSA as well as all other tested body-size 
measures are unrelated to CPT-11 clearance and metabolism. In view of the 
significant degree of interindividual variability in systemic exposure to CPT-11 and 
SN-38 and the small range in observed BSA within the studied population, CPT-11 
can be added to the list of anticancer agents where BSA-based dosing does not 
seem to be more accurate and might suggest a (harmful) false sense of accuracy. 
Better individual predictors of CPT-11 elimination and pharmacodynamics might be 
available in the future. However, further research into the exact relationships 
between these key factors and pharmacologic endpoints is clearly required before 
they can be implemented in routine clinical practice. Therefore, the findings of this 
study provide a rationale for the conduct of a comparative phase Ill study between 
BSA-based dosing and fixed dosing of CPT-11. In case of fixed dosing, variability in 
drug clearance will still be approximately five-fold, and many patients will still be over-
or underdosed. Since CPT-11 clearance and SN-38 pharmacokinetics correlate with 
toxicity, adjusting the dose for subsequent cycles based on toxicity induced by the 
drug is clearly recommended. The economic advantage may not be lost, since a 
range of fixed doses could be made available. As better methods of dose calculation 
become available in the future, these same doses could still be used as starting 
doses. 
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ABSTRACT 
Purpose: lrinotecan (CPT-11) is a prod rug of SN-38 and has been registered for the 
treatment of advanced colorectal cancer. It is converted by the cytochrome P450 
3A4 isozyme (CYP3A4) into several inactive metabolites, including APC. To 
investigate the role of CYP3A4 in irinotecan pharmacology, we evaluated the 
consequences of simultaneous treatment of irinotecan with a potent enzyme 
inhibitor, ketoconazole, in a group of cancer patients. 
Patients and Methods: A total of 7 evaluable patients was treated in a randomized 
cross-over design with irinotecan (350 mg/m2 i.v. over 90 min) given alone and 
followed 3 weeks later by irinotecan (1 00 mg/m2) in combination with ketoconazole 
(200 mg orally for 2 days), or vice versa. Serial plasma, urine and feces samples 
were obtained up to 500 hours after dosing and analyzed for irinotecan, metabolites 
(SN-38, SN-38 glucuronide [SN-38G], APC), and ketoconazole by high performance 
liquid chromatography. 
Results: With ketoconazole co-administration, the relative formation of APC was 
reduced by 87% (P = .002), whereas the relative exposure to the carboxylesterase-
mediated SN-38 as expected on the basis of dose (area under the plasma-
concentration-time curve normalized to dose) was increased by 109% (P = .004). 
These metabolic alterations occurred without substantial changes in irinotecan 
clearance (P = .90) and formation of SN-38G (P = .93). 
Conclusion: Inhibition of CYP3A4 in cancer patients treated with CPT-11 leads to 
significantly increased formation of SN-38. Simultaneous administration of various 
commonly prescribed inhibitors of CYP3A4 can potentially result in fatal outcomes, 
and up to four-fold reductions in CPT-11 dose are indicated. 
INTRODUCTION 
There is considerable motivation for understanding adverse drug interactions 
with anticancer agents because of their narrow therapeutic index and the numerous 
concomitant medications that are administered routinely or intermittently (1 ). Indeed, 
drug interactions, including those with anticancer agents are a major cause of 
morbidity and mortality in modern medical practice (2), causing more than 100,000 
deaths per year in the United States, and making it between the fourth and sixth 
leading cause of death in 1994 (1 ). Usually such interactions arise as a result of 
altered pharmacodynamics or pharmacokinetics of the drugs involved (3). In the 
latter case, this is usually due to changes in metabolic routes, and several 
mechanisms contributing to clinically important interactions have been identified, 
including expression of cytochrome P450 (GYP) isozymes. This class of enzymes, 
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particularly the CYP3A4 isozyme, is responsible for the oxidation of more than 50% 
of all drugs currently administered to humans (4), resulting in more polar and usually 
pharmacologically inactive metabolites, which can be excreted efficiently by the 
kidneys and the liver. It is evident that anticancer substrate drugs given in 
combination with drugs that are efficiently metabolized by CYP3A4 are likely to result 
in serious toxicity. However, most of the data currently available to evaluate possible 
drug interactions with anticancer agents have been addressed by animal 
experiments or the use of test systems in vitro (4). 
In this study, we investigated the effect of CYP3A4 inhibition, using the model 
inhibitor ketoconazole (5), on the pharmacokinetics and toxicity profile of irinotecan 
(CPT-11 ), which is an important drug used in the treatment of colo rectal cancer (6), 
and a partial substrate of the CYP3A4 isozyme (7). 
MATERIALS AND METHODS 
Patients and Treatment 
Patients were eligible if they had a histologically confinmed diagnosis of 
metastatic colorectal cancer and proven progressive disease after first line 
chemotherapy (with fluorouracil) or a malignancy for which there was no effective 
standard regimen. Additional eligibility criteria were identical as documented 
elsewhere (8, 9). The original primary end point of the study was a measurable effect 
of ketoconazole on SN-38 and APC pharmacokinetics. Based on the standard 
deviation (SO) of the changes expected in irinotecan disposition (sct), a power (1-~) of 
0.8 (80%), a clinically relevant difference (S; standardized difference, 2Sisct) of 30%, 
and a two-sided significance level (a) of 0.01 (1 %), a patient sample size of seven 
was required in a paired, two-sided analysis. The Sct was estimated from an 
unpublished data set of 26 patients treated with irinotecan at 350 mg/m2 and the 
assumption of no variance increase as a result of ketoconazole coadministration. 
The Ethics Board of the Erasmus MC approved the protocol, and all patients signed 
informed consent before study entry. 
Patients screened and meeting study entry criteria were randomly assigned to 
receive either irinotecan alone (as a SO-minute intravenous infusion) at a dose of 350 
mg/m2 and followed 3 weeks later by irinotecan at a dose of 100 mg/m2 given in 
combination with ketoconazole (200 mg) orally 1 hour before and 23 hours after the 
infusion of irinotecan, or both treatment cycles were given vice versa. A restricted 
randomization was performed to avoid bias in cycle sequence and to keep the 
number of patients close for both arms. This was achieved by choosing a 
randomized block at random using a table of random numbers to create the 
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allocation sequence. Before drug administration, the clinical irinotecan formulation 
(Aventis Pharma, Hoevelaken, the Netherlands) was diluted in 250 mL of isotonic 
sodium chloride. 
Patients received a standard regimen of ondansetron and dexamethasone 
therapy, both given 30 minutes prior to chemotherapy. Atropine (0.25 mg) was 
administered subcutaneously as a prophylaxis for irinotecan-induced acute 
cholinergic syndrome in case the patient experienced this side effect in the previous 
cycle. Physical examination and toxicity assessment was performed on a weekly 
basis, as were clinical chemistry tests, for both treatment cycles. 
Pharmacologic Analysis 
lrinotecan, SN-38, SN-38-glucuronide (SN-38G), and APC pharmacokinetics 
were performed during both cycles. Blood samples (approximately 5 mL) were 
collected immediately before irinotecan infusion, at 30 minutes after the start of the 
infusion, at 5 minutes before the end of infusion, at 10, 20 and 30 minutes, and at 1, 
1.5, 2, 4, 5, 8.5, 24, 32, 48, 56, 196 {day 8), 360 {day 15), and 500 (day 21) hours 
after the end of infusion. Complete urine and stool was collected in 24-hour intervals 
for 3 days after the start of treatment in both cycles. All biologic matrices were 
handled as outlined {1 0), and irinotecan and metabolite (SN-38, SN-38G, and APC) 
concentrations were determined by validated assays based on reversed-phase high-
performance liquid chromatography (HPLC) with fluorescence detection, as 
described (11, 12). 
Pertinent pharmacokinetic parameters, including peak concentration, area 
under the plasma concentration-time curve {AUC), total plasma clearance {defined 
as the ratio of dose administered in mg/m2 and AUC), the rate constant of the 
terminal disposition phase, and the half-life of the terminal disposition phase were 
calculated using a linear three-compartment model running on Siphar version 4.0 
{lnnaPhase, Philadelphia, PA) (13). Metabolic ratios were calculated from plasma 
AUCs as well as urinary and fecal excretion data, as described previously (14). 
Previously, it has been shown that the AUC of irinotecan is dose-proportional over a 
large dose range {1 00 to 750 mg/m2) in the tested 3-week regimen with the drug 
administered as a 90-minute intravenous infusion, indicating a linear 
pharmacokinetic behavior (7). Similarly, irinotecan metabolite concentrations 
increase linearly with the dose, and metabolic ratios are dose-independent in this 
dose range (7). Therefore, values for total plasma clearance of irinotecan and the 
various metabolic ratios between the treatment courses with and without 
ketoconazole co-administration were compared directly without any correction. 
Plasma concentrations of ketoconazole were measured by reversed-phase HPLC 
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with UV detection (15). 
Pharmacodynamic evaluation involved analysis of pretherapy and nadir values 
of white blood cell counts and absolute neutrophil counts as a function of treatment 
course, expressed in absolute values (in 109/L) and in percent decrease relative to 
pretherapy values (eg, [(pretherapy value- nadir value) I pretherapy value] x 100%). 
Enzyme Activity in Plasma 
Total esterase activity in plasma samples was determined by a 
spectrophotometric assay using o-nitrophenyl acetate as a substrate (16), using 
purified esterase from porcine liver (EC3.1.1.1; Sigma, St Louis, MO) as a reference. 
Briefly, extracts prepared by sonication in 50 mM HEPES buffer (pH value of 7.4) 
were incubated in 3 mM of o-nitrophenyl acetate, and the absorbance at 420 nm was 
measured at 1-minute intervals for 1 0 minutes. Protein concentrations in extracts 
were determined using a Coomassie brilliant blue G250 dye-binding assay (17), 
using bovine serum albumin as a reference standard. Esterase activity is reported as 
micromoles of o-nitrophenyl acetate converted per minute per milligram of protein 
(~mol/min/mg). 
Hepatic Metabolism In Vitro 
Pooled human liver microsomes (Gentes! Corp., Woburn, MA) containing 1 mg 
of protein per ml were incubated with irinotecan or SN-38 (both at a final 
concentration of 1 ~M) in the presence and absence of ketoconazole (1 ~M) as 
described (18). Reactions were incubated for 60 min at 37°C in the presence or 
absence of an NADPH-regenerating system. The decrease in substrate 
concentration as well as the formation of potential metabolites was measured at 
serial time points by HPLC as described (19). 
Drug Transport Assays 
Caco-2 cells were cultured and treated as described earlier (20). Transport 
studies of CPT-11 and SN-38 across complete monolayers in 12-well Transwell 
clusters (Costar, Cambridge, MA) with 1-cm2 polycarbonate membrane filters (0.4-
~m pore size) were conducted in a controlled environment at a temperature of 3JOC. 
The integrity of the cell monolayers was evaluated by measuring transepithelial 
transport of [' 4C]mannitol as described elsewhere (21 ). The experiments were 
initiated with the addition of the lactone forms of irinotecan and SN-38 at an initial 
concentration of 1 0 f!M, both diluted from metanolic stock solutions diluted in 
Dulbecco's minimum-essential medium to avoid precipitation due to the limited 
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solubility in physiological buffers. This drug concentration was used to allow 
sufficiently accurate determination of transport rates of both irinotecan and SN-38 
across the Caco-2 cell monolayers given the sensitivity limit of the available 
analytical method {11 ). Transport inhibition experiments were also performed under 
identical conditions in the presence of ketoconazole or the P-glycoproteinlbreast 
cancer-resistance protein {BCRP) inhibitor GF120918 {Giaxo Wellcome, Research 
Triangle Park, NC) added to the apical or basolateral side of the monolayer {22). At 
various continuous exposure durations of 1, 1.5, 2, 2.5, and 3 hours, aliquots of the 
apical and basolateral solutions were collected, centrifuged for 5 min at 24,000 x g 
{4°C), and immediately stored at -80°C until analysis lor total drug concentrations 
{lactone plus carboxylate forms) by a liquid chromatographic assay {11 ). For each 
experiment, performed in triplicate on three separate occasions, the mean transport 
rate was calculated from the linear part of the plot of the total amount of drug 
transported versus time. The apparent permeability coefficient {P app), expressed in 
centimeters per second was calculated as Ll.Q/Ll.t x 1/60 x 1/A x 1/Co, where Ll.Q/Ll.t is 
the permeability rate {in ~g/min), A is the surface area of the membrane (in cm2), and 
Co is the initial concentration in the donor chamber {in ~g/ml) {21 ). 
Statistical Considerations 
All data are presented as mean values ± SD, unless stated otherwise. The 
statistical significance of differences in data between treatments was evaluated using 
two-tailed, paired t tests after testing for approximate normality or a modification for 
the case with unequal variances detected using a variance-ratio test, assuming weak 
period and/or sequence effects {7). The significance level was set at P < .05. 
Statistical calculations were performed on NCSS version 5.X {J.L. Hintze, East 
Kaysville, UT; 1992) or SISA binomial {D.G. Uitenbroek, Hilversum, the Netherlands; 
2001; http://home.clara.net/sisa/binomial.htm). 
RESULTS 
Patients and Toxicity Profiles 
To determine the influence of CYP3A4 inhibition by ketoconazole on CPT-11 
pharmacokinetics and toxicity, a total of nine patients was accrued to the study. In 
two of nine patients, ketoconazole was only administered on day 1 in the combined 
schedule, and these patients were considered not evaluable. Of the seven remaining 
patients, three were male and four were female with a median age of 54 years 
{range, 42 to 71 years) and a median performance score of 1 {range, 0 to 2). All 
patients completed the study within the scheduled time without delay. The 
predominant disease type was colorectal cancer {n = 5), and the principal toxicity 
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consisted of neutropenia. Paired analysis of hematological pharmacodynamic 
parameters indicated that the degree of myelosuppression, including the percent 
decrease in absolute neutrophil count, was similar between the courses, in spite of a 
3.5-fold reduced irinotecan dose when given in combination with ketoconazole 
(Table 1 ). Non-hematological toxicities (nausea, vomiting and diarrhea) were 
observed on both arms, but were also not substantially different in severity or 
incidence. 
Table 1. Summary of Hematological Pharmacodynamics• 
Parameter 
Leukocytes 
%decrease WBC 
Nadir (x1 09/L) 
Neutrophils 
%decrease ANC 
Nadir (x1 09/L) 
CPT-11 CPT-11/ketoconazole 
67.1 ±27.2 (29.9-98.0) 55.4±29.8 (17.0-91.7) 
2.33 ± 1.70 (0.55- 4.70) 3.29 ± 1.61 (0.97- 4.90) 
74.5 ± 22.5 (42.4- 99.6) 56.9 ± 23.3 (46.0- 96.5) 
1.11 ± 0.87 (0.1 0 - 2.30) 1.93 ± 1.19 (0.34- 3.40) 
Abbreviations: WBC, white blood cell count; ANC, absolute neutrophil count. 
*Data are expressed as mean values± SO, with range in parenthesis. 
lrinotecan Disposition and Effects of Ketoconazole 
Since ketoconazole is a known potent inhibitor of CYP3A4, and given the 
prominent role of this enzyme in irinotecan metabolism, we assessed the influence of 
ketoconazole on disposition profiles (Table 2). The peak concentration of 
ketoconazole was 4.72 ± 2.53 ~g/ml, and the AUG amounted to 15.4 ± 9.80 
~g.h/mL, which is similar to previous findings (5). In the presence of ketoconazole, 
the relative exposure to the CYP3A4-mediated metabolite APC was reduced by 87% 
(P = .002), while the relative exposure to the pharmacologically active metabolite SN-
38 increased by 109% (P = .004). The opposing effects of these metabolic routes on 
drug elimination left the systemic clearance of irinotecan almost unaffected (P = .90). 
Similarly, ketoconazole had no effect on circulating levels of SN-38G (P = .93), 
suggesting no effect on J3-glucuronidation pathways. The cumulative exposure to the 
total of all metabolites, on a molar basis and normalized to a 350 mg/m2 dose, was 
also not dependent on the presence of ketoconazole (13.7 ± 5.00 vs 11.5 ± 4.50 
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~M.h; P = .65). In addition, the cumulative fecal excretion of CPT-11, expressed as 
the percentage of the absolute dose excreted in feces within the first 56 hours after 
drug administration, was not different in the presence or absence of ketoconazole 
(13.8% ± 15.9% vs 19.5% ± 13.9%; P = .48). However, the fecal recovery of SN-38 
was increased by 207% and that of APC was reduced by 78.0%. The similarity of the 
terminal disposition phases in plasma of these metabolites (Fig. 1) between 
treatment courses indicate that the altered fecal excretion in the presence of 
ketoconazole is related to altered formation rather than diminished biliary secretion. 
Table 2. Summary of Pharmacokinetic Parameter Estimates"" 
Parameter CPT-11 CPT-11/keto Difference (%) 
CPT-11 dose (mg)t 650 (600- 875) 180 (175 - 230) 
Infusion time (h)t 1.50 (1.45- 1.60) 1.50 (1.30- 1.50) 
lrinotecan 
Cmax (~M) 7.65 ± 1.53 2.13± 1.02 
AUC (~M.h) 46.9 ± 16.0 12.1 ±2.73 
CL (Uh) 30.6 ± 12.3 29.8 ± 8.90 -0.13 ± 15.1 (P= .90) 
SN-38 
Cmax (~M) 0.164 ± 0.063 0.088 ± 0.043 
AUC (~M.h) 1.11 ±0.476 0.597 ± 0.245 
REC 0.023 ± 0.005 0.049 ± 0.013 109 ± 36.6 (P= .004) 
SN-38G 
Cmax (~M) 0.312 ± 0.083 0.138 ± 0.012 
AUC (~M.h) 4.53 ± 1.64 2.45 ± 1.04 
REG 4.18 ± 0.372 4.14±1.17 -1.56±22.6 (P = .93) 
APC 
Cmax (~M) 0.627 ± 0.283 0.040 ± 0.014 
AUC (~M.h) 8.03 ± 3.80 0.241 ±0.125 
REM 0.177 ± 0.092 0.020 ± 0.012 -86.9±7.14 (P= .002) 
Abbreviations: Cmax. peak plasma concentration; AUC, area under the plasma concentration 
versus time curve; Cl, apparent plasma clearance; REC, relative extent of conversion (AUC 
ratio of SN-38 to CPT-11); REG, relative extent of glucuronidation (AUC ratio of SN-38G to 
SN-38); REM, relative extent of metabolism (AUC ratio of APC to CPT-11 ). 
*Data are expressed as mean values± SO. 
tMedian with range. 
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Figure 1. Plasma concentration-time curves of irinotecan (A), SN-38 (B) and APC (C) in the 
presence (irinotecan 100 mg/m2 , solid line, closed symbols) and absence 
(irinotecan 350 mg/m2, dashed line, open symbols) of ketoconazole. 
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Ex Vivo Analysis of Esterase Activity in Patient Plasma 
To gain insight into the observed altered pharrr,acokinetic behavior of irinotecan 
in the presence of ketoconazole, various in vitro experiments were performed. The 
esterase activity in patient plasma, measured for 50 hours after irinotecan 
administration using the artificial substrate o-nitrophenyl acetate, was relatively 
consistent and independent of sampling time points, with mean values of 20.7 ± 1.58 
and 20.9 ± 2.40 ~mol/min/mg in the absence and presence of ketoconazole, 
respectively (P = .89). 
Effect of Ketoconazole on SN-38 Metabolism by Human Liver Microsomes 
To assess a possible effect of ketoconazole on metabolism of SN-38 by human 
liver microsomes, we incubated microsomal preparations with irinotecan and SN-38 
for 60 min at 37°C. In line with previous findings, we found that irinotecan was 
extensively metabolized to various polar compounds, including APC, but not in the 
presence of ketoconazole (99-100% inhibition) (18). In contrast to previous data 
published in abstract form (23), no metabolic degradation by liver microsomes to a 
very polar, CYP3A-mediated peak was observed for SN-38, and no additional effects 
of ketoconazole were noted (data not shown). 
Polarized Transport of SN-38 in Human Intestinal Cells 
We next studied the transepithelial flux of irinotecan and SN-38 in Caco-2 cell 
monolayers, a well-established model of human intestinal absorption (24), to further 
define the potential role of active transport mechanisms in SN-38 pharmacokinetics 
and the influence on these processes by ketoconazole. Previously, we showed that 
Caco-2 cells demonstrate significant expression of P-glycoprotein, multidrug-
resistance associated protein (MRP-1), and the canalicular multispecific organic 
anion transporter (cMOAT or MRP-2) (20). We also recently observed pronounced 
staining using immunoprecipitation at the apical side of Caco-2 cells with an antibody 
to BCRP (Sparreboom et al, unpublished data), a recently identified member of the 
ATP-binding cassette transporter family, for which SN-38 is one of the best known 
substrates (25). 
The flux of irinotecan and SN-38 across Caco-2 cell monolayers, when drug 
was loaded on the apical side of the cells was essentially linear for up to 3 hours 
(Fig. 2). In the presence of the P-glycoprotein/BCRP inhibitor GF120918, the Papp for 
the apical tO basolateral transport increased from 3.6 X 1 0"6 tO 7.0 X 1 0"6 em/SeC and 
from 3.6 x 1 o·6 to 9.7 x 1 o·6 em/sec for irinotecan and SN-38, respectively, consistent 
with the known prominent role of P-glycoprotein and BCRP activity in SN-38 
transport (26). With ketoconazole, the flux of irinotecan and SN-38 was increased by 
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47.2% (Papp = 5.3 x 1 o·6 em/sec) and 55.6% (Papp = 5.6 x 10·6 em/sec), respectively, 
whereas addition of ketoconazole to GF120918 had essentially no additional effect 
as compared to GF120918 alone (CPT-11, Papp= 6.2 x 10·6 em/sec; SN-38, Papp= 
8.0 x 10'6 em/sec). Since Caco-2 cells fail to express significant CYP3A4 activity 
under the culture conditions employed (24), the most likely explanation for the 
observed effect on drug transport is inhibition of P-glycoprotein activity, a known 
property of ketoconazole (27). 
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Figure 2. Transepithelial (apical to basolateral direction) transport of irinotecan (A) and SN-
38 (B) across Caco-2 cells in the absence (circles) and presence of ketoconazole 
(lozenges), the P-glycoprotein!BCRP inhibitor GF120918 (pyramides), or 
ketoconazole plus GF120918 (triangles). Results are presented as mean values 
(symbol)± SO (error bar). 
DISCUSSION 
This study shows that inhibition of CYP3A4 by the potent enzyme inhibitor, 
ketoconazole, results in a substantial pharmacokinetic interaction with CPT-11. The 
overall results indicate a significantly reduced exposure to the principal oxidative 
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metabolite APC by 87%, as well as highly increased (approximately 1 09%) 
circulating concentrations of the pharmacologically active metabolite SN-38. These 
data not only emphasize the need to consider the plausibility of kinetic interactions in 
the development of anticancer drugs, but also have a direct significant clinical 
relevance for chemotherapeutic treatment with irinotecan. 
Clinically, one of the most important pathways of irinotecan elimination consists 
of an esterase-mediated hydrolysis of the bipiperidine moiety, leading to SN-38 
(considered essential for antitumor activity) (7). Subsequently, UDP 
glucuronosyltransferase (UGT) 1A1 mediates a ~-glucuronic-acid conjugation, 
forming SN-38G (7), a metabolite that may play a role as a precursor for hydrolysis 
by intraluminal glucuronidases to form SN-38 in the occurrence of irinotecan-induced 
diarrhea (28). The previous recognition that irinotecan is a substrate of CYP3A4 is a 
salient finding, since it makes the agent potentially subject to a host of enzyme-
mediated drug interactions, even with commonly prescribed medication (18). For 
example, the prototypical CYP3A4 inhibitor troleandromycine inhibits the conversion 
of irinotecan into APC in vitro almost completely (18), which is consistent with our 
current in vivo findings (see http://www.drug-interactions.com/ for an updated CYP 
drug interaction table). In addition, both loperamide and racecadotril inhibit APC 
formation by more than 50%, whereas ondansetron causes inhibition by >25% (18), 
suggesting that some degree of interaction is to be expected with simultaneous 
administration of these agents with irinotecan. 
The potential clinical implications of CYP3A4-mediated metabolism of 
irinotecan have until now received little more than cursory interest .from both 
pharmacologists and oncologists, most likely because the contribution of this 
pathway to the overall elimination of irinotecan is rather low (1 0), and in view of the 
fact that oxidative metabolism of irinotecan is generally considered an efficient 
detoxification route (18). Previously, it was demonstrated that co-administration of 
irinotecan with another substrate of CYP3A4, cyclosporine, results in significantly 
reduced irinotecan clearance in both rodents and humans (29, 30). There was no 
change in the volume of distribution at steady-state (indicative for unchanged protein 
and tissue binding) and in the metabolic conversion of irinotecan to SN-38 due to the 
cyclosporine pretreatment,'implicating reduced biliary secretion of the parent drug as 
the potential cause for this interaction (29). 
The current observation that inhibition of CYP3A4-mediated metabolism of 
irinotecan by ketoconazole leads to an induced esterase-mediated hydrolysis to form 
SN-38 was thus rather unexpected, and in order to discriminate between increased 
formation and reduced elimination of SN-38 as the principal mechanism underlying 
this phenomenon, several additional in vitro experiments were performed. By 
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measuring the total esterase activity in plasma of patients, ketoconazole was found 
to have no inducing effect on circulating enzyme levels that might explain the 
increase in relative exposure to SN-38. However, these data need to be interpreted 
with caution, as it has not yet been conclusively demonstrated that the plasma 
hydrolysis of the artificial substrate used (o-nitrophenyl acetate) is an accurate 
marker of irinotecan activation. Moreover, it is not known whether o-nitrophenyl 
acetate is a substrate for either of the two currently identified human 
carboxylesterases isoforms (hCE1 and hCE2) (31 ), or whether plasma enzyme 
activity correlates with hepatic activity, which may be more relevant to the plasma 
pharmacokinetics. 
We found that ketoconazole had no effect on SN-38 biotransformation in 
human liver microsomes, in contrast to a previous observation suggesting prominent 
CYP3A4-mediated oxidation of SN-38 to a polar, currently unidentified compound 
(23). Our in vitro data obtained in the Caco-2 cell monolayers suggest that 
ketoconazole might interfere with active drug transport mediated by P-glycoprotein, 
which is consistent with previous observations that ketoconazole is a (poor) inhibitor 
of P-glycoprotein (27). In our patients, we observed that co-administration with 
ketoconazole had a marked effect on the fecal elimination of both APC and SN-38. 
However, the similarity of the terminal disposition phases in plasma of both 
metabolites between treatment courses indicates that the increased fecal excretion 
of SN-38 in the combination courses is unlikely related to diminished (P-glycoprotein-
mediated) biliary secretion. Collectively, these findings suggest that the 
pharmacokinetic interference described here appears to be the result of inhibition of 
one of two competing enzymes involved in (hepatic) irinotecan metabolism, which 
results in shunting of parent drug to SN-38. 
As mentioned previously, various classes of enzymes are involved in irinotecan 
metabolism, and variability in the expression of each of these will contribute to 
variability in drug handling between patients. In addition, this variability is further 
influenced by the recognition that polymorphic drug-metabolizing enzymes (e.g., 
UGT1A1) exist that can alter drug disposition (32). Recent studies have shown that 
determination of UGT1A1-gene promotor polymorphism (UGT1A1'28) may identify 
patients with altered SN-38 glucuronidation rates and greater susceptibility to 
irinotecan induced toxic effects (33, 34). In view of our current observation that 
CYP3A4-mediated metabolism of irinotecan might be more important than held 
previously, we have recently initiated a prospective trial to corroborate the usefulness 
of gene diagnosis of UGT1 A 1 in combination with CYP3A4 polymorphism prior to 
irinotecan chemotherapy. In addition, because CYP3A5 represents at least 50% of 
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the total hepatic CYP3A content in people polymorphically expressing CYP3A5, this 
isozyme may be the most important genetic contributor to interindividual and 
interracial differences in CYP3A-dependent drug clearance and in responses to 
many agents (35). In this context, it is of particular importance, however, that recent 
data indicate that the in vitro metabolism of irinotecan by Ad 293 cells or human liver 
microsomes expressing CYP3A5 was markedly different because, in contrast to 
kinetic studies performed in cells expressing CYP3A4, instead of APC a new 
metabolite was formed by de-ethylation of the camptothecin moiety (36). The 
production of this metabolite was totally absent from incubations with microsomes 
devoid of CYP3A5, and was almost completely prevented in vitro by the addition of 
ketoconazole, confirming the involvement of CYP3A isozymes. Importantly, the 
catalytic activity and the relative affinity of irinotecan for CYP3A5 were substantially 
weaker than those of CYP3A4 (36). This finding, as well as the polymorphic 
expression of CYP3A5 suggest that the de-ethylated metabolite plays a minor role in 
irinotecan disposition, and that effects of ketoconazole on CYP3A5 have no 
important clinical ramifications in this particular case. 
Clinically we found that hematologic toxicity and non-hematologic toxicity 
between the treatment courses were very similar, in spite of the reduced irinotecan 
dose in the presence of ketoconazole, which might be explained by the increased 
exposure to SN-38. Previously, the idea of intentionally adding ketoconazole to 
systemic treatment with CYP3A4 substrate drugs (e.g. cyclosporine) for the purpose 
of decreasing toxicity and costs through a reduction in dosage regimens has been 
advanced (37). However, before taking advantage of the metabolic interaction 
between ketoconazole and irinotecan described here to supply the two drugs as a 
unique preparation for clinical use, a number of important questions needs to be 
solved. Most importantly, it is not yet known whether systemic circulating 
concentrations of SN-38 have any predictive ability toward antitumor activity. In fact, 
recent data from a study of irinotecan administered in combination with cyclosporin A 
(a competitive inhibitor of CYP3A4) and phenobarbital (an inducer of UGT1A1) 
suggest responses to treatment in patients with metastatic colorectal and 
esophageal cancer without any significant diarrhea, despite a very low exposure to 
SN-38 (38). This finding supports the hypothesis that intratumoral hydrolysis of 
irinotecan by esterases may be more important than plasma concentrations of SN-38 
(39, 40). This suggests that the concept of using intentional CYP3A4-mediated 
interactions with irinotecan therapy may increase toxicity but not the overall antitumor 
activity. 
In conclusion, ketoconazole considerably increased the plasma concentrations 
of the pharmacologically active irinotecan metabolite SN-38 relative to those 
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expected on the basis of dose, as a result of inhibition of CYP3A4-mediated 
biotransformation. With concomitant use of irinotecan and ketoconazole (or other 
potent substrates or inhibitors of CYP3A4), potentially fatal interactions are likely and 
extreme caution and substantial dose reductions should be employed if both drugs 
have to be administered together. 
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SUMMARY 
StJohn's Wort (SJW), a widely used herbal product, has been implicated in drug 
interactions resulting from the induced expression of the cytochrome P450 CYP3A4 
isoform. In this study, we determined the effect of SJW on the metabolism of 
irinotecan, a pro-drug of SN-38 and a known substrate for CYP3A4. Five cancer 
patients were treated with irinotecan (350 mg/m2, intravenously) in the presence and 
absence of SJW (900 mg daily, orally for 18 days) in an unblinded, randomized 
crossover study design. The plasma levels of the active metabolite SN-38 decreased 
by 42% (95% confidence inteNal [CI] = 14% to 70%) following SJW cotreatment with 
1.0 IJ.Mxh (95% Cl = 0.34 ~Mxh to 1.7 ~Mxh) versus 1.7 ~Mxh (95% Cl = 0.83 ~Mxh to 
2.6 ~Mxh), P = .033, two-sided paired Student's t-test. Consequently, the degree of 
myelosuppression was substantially worse in the absence of SJW. These findings 
indicate that patients on irinotecan treatment should refrain from taking SJW because 
plasma levels of SN-38 were dramatically reduced, which may have a deleterious 
impact on treatment outcome. 
INTRODUCTION 
St John's Wort (SJW) has become one of the world's most popular herbal 
preparations, particularly among cancer patients (1) because of its alleged activity in 
mild to moderate forms of depression (2-4). Previous case reports and clinical 
investigations suggest that SJW induces the expression of the cytochrome P-450 
enzyme system and drug-transporting proteins (5-8). Specifically, SJW was shown to 
directly induce the expression of the cytochrome P-450 CYP3A4 isoform in intestinal 
and hepatic cells and to induce the expression of MDR1 P-glycoprotein in intestinal 
cells (9-11 ). These obseNations might have profound clinical implications for patients 
with colorectal cancer receiving the chemotherapy agent irinotecan because the drug 
is, in part, eliminated via CYP3A4- and P-glycoprotein-mediated routes (12). Moreover, 
irinotecan, a topoisomerase I inhibitor, has a narrow therapeutic range, and the 
induction of CYP3A4 and P-glycoprotein by SJW might theoretically result in 
decreased systemic levels of the pharmacologically active metabolite SN-38, the 
consequence of which might be a loss of antitumor activity. 
MATERIALS AND METHODS 
We evaluated the potential of SJW to affect plasma concentrations of SN-38 in a 
group of cancer patients treated with irinotecan in an unblinded, randomized crossover 
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study design, wtth and wrthout SJW coadministration. The clinical protocol was 
approved by the Erasmus MC Ethics Board, and all patients signed informed consent 
forms before study entry. lrinotecan was administered once every 3 weeks as a 90-
minute continuous intravenous infusion at a dose of 350 mg/m2• Fourteen days before 
the start of the first or second irinotecan administration, patients received one SJW 
tablet (300 mg; Bio Nutrition Health Products, Den Bosch, The Netherlands) three 
times a day (i.e., one tablet with each meal). The patients continued this co-medication 
while receiving the irinotecan therapy and stopped 4 days after irinotecan dosing. 
Patients were asked to abstain from alcohol, caffeine, grapefruit juice, other herbal 
dietary supplements and/or substances known to influence the expression of CYP3A4 
for a period of 2 weeks before the first irinotecan administration up to 3 weeks after the 
second irinotecan administration. Blood sampling, drug analyses, and pharmacokinetic 
parameter calculations were performed as described (13, 14). Data are presented as 
mean value with 95% confidence intervals (Cis), and statistical calculations were 
performed on the Number Cruncher Statistical System version 5.X (J. L. Hintze, East 
Kaysville, UT). 
RESUlTS AND DISCUSSION 
There were five evaluable patients: two men and three women, with a median 
age of 58 years (range, 54 to 66 years) and a median World Health Organization 
(WHO) performance score of 1 (range, 0 to 1) (http://www.who.int/home-page/). All 
five completed the study within the scheduled time without delay. Two patients had 
colorectal cancer, two had lung cancer, and one had sarcoma. Clinically, irinotecan-
induced neutropenia, as measured by a decrease in the number of circulating 
neutrophils, was the most prominent side effect, and that the spectrum of side 
effects was unchanged by SJW. The degree of myelosuppression differed 
substantially between the treatment course with irinotecan alone and the 
combination course with irinotecan and SJW. At nadir, leukocyte and neutrophil 
counts decreased 56% (95% Cl = 32% to 80%) and 63% (95% Cl = 48% to 78%), 
respectively, during the course with irinotecan alone but decreased only 8.6% (95% 
Cl = 0% to 29%) and 4.3% (95% Cl = 0% to 20%), respectively, during the 
combination course with irinotecan and SJW. 
We next measured the levels of the active irinotecan metabolite SN-38 and its 
CYP3A4-mediated detoxified metabolite 7 -ethyl-1 0-[4-N-(5-aminopentanoic acid)-1-
piperidino]-carbonyl-oxycamptothecin (APC). Compared with courses of irinotecan 
alone, the area under the curve (AUG) of SN-38 decreased by 42% (95% Cl = 14% 
157 
Chapter9 
to 70%) in the combination course with irinotecan and SJW from 1.7 ~Mxh (95% Cl = 
0.83 ~Mxh to 2.6 ~Mxh) to 1.0 ~Mxh (95% Cl = 0.34 ~Mxh to 1.7 ~Mxh), P = .033, 
two-sided Student's 1-test; Fig. 1 and Table 1. 
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Figure 1. Effect of St. John's wort (SJW) on the plasma concentration of the active 
irinotecan metabolite SN-38 over time. The plasma concentration of SN-38 was 
measured over time as described (13, 14). Each data points represents an 
individual data time point of the plasma concentration of SN-38 measured in the 
absence (closed symbols; solid line) and presence (open symbols; dotted line) of 
SJW. The lines represent computer fits of the SN-38 concentration-time curves ·In 
the absence and presence of SJW, respectively. 
Surprisingly, the AUC ratio of APC to irinotecan was also reduced by 28% (95% 
Cl = 0% to 80%) in the combination course with irinotecan and SJW, although this 
reduction was not statistically significant. This result suggests that the induction of 
CYP3A4 expression results in the formation of presently unknown metabolites other 
than APC (15), as has been described previously (16) in pediatric high-grade glioma 
patients treated with irinotecan and CYP3A4-inducing anticonvulsants. Alternatively, 
the lack of effect on APC might be attributed to the fact that during both treatment 
158 
CPT-11 and St. John's Wort 
courses, patients were receiving dexamethasone. Dexamethasone is another known 
inducer of GYP3A4 expression and might already stimulate APG formation during the 
course without SJW co-treatment (17). In the liver, SN-38 can be metabolized to a 
glucuronic acid conjugate (SN-38G), a process which is catalyzed by uridine 
diphosphate glucuronosyltransferases (UGT). The rate of SN-38 glucuronidation 
(i.e., the AUG ratio of SN-38G to SN-38) was not influenced by SJW (Table 1 ), 
suggesting that increased glucuronidation through the induction of UGT was not 
contributing to the reduced SN-38 levels. 
Table 1. Effect of St. John's wort (SJW) on irinotecan metabolism. 
Parameter lrinotecan [95% Gl] lrinotecan/SJW [95% Gl] pt 
lrinotecan 
AUG (~Mxh) 
GL (Uh) 
Gmax (~M) 
SN-38' 
AUG (~Mxh) 
Gmax (~M) 
ty,(z) (h) 
AUG ratios' 
SN-38/irinotecan 
SN-388/SN-38 
APG/irinotecan 
33 [5.0 to 60] 29 [6.6 to 52] 
36 [8.7 to 64] 40 [9.3 to 71] 
6.2 [4.8 to 7.5] 4.9 [1.3 to 8.5] 
1.7 [.83 to 2.6] 1.0 [0.34 to 1.7] 
0.19 [0.12 to 0.28] 0.11 [0.044 to 0.17] 
26 [0 to 72] 20 [6.1 to 34] 
0.054 [.036 to .073] 0.036 [.0054 to .067] 
3.2 [2.6 to 3.8] 3.4 [2.6 to 4.3] 
0.33 [0 to 0.97] 0.23 [0 to 0.55] 
.14 
.11 
.35 
.033 
.016 
.52 
.054 
.33 
.31 
Abbreviations: AUC :;; area under the plasma concentration versus time curve; APC ::;; 7-
ethyl- 1 0- [4-N-(5-amino-pentanoic acid) -1-piperidino]-carbonyloxycamptothecin; Gl = 
confidence interval; CL = apparent clearance; Cmax = peak plasma concentration; t;s,(zJ = 
apparant half-life of the terminal disposition phase. 
t Two-sided Student's I-test for matched pairs. 
'SN-38 is the active metabolite of irinotecan, also known as CPT-11; SN-38G is a detoxified 
metabolite of SN-38 that involves uridine diphosphate glucuronosyltransferase (UGT); APC 
is a detoxified metabolite of irinotecan that involves the CYP3A4 isoform of cytochrome 
P450. 
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Similar changes in SN-38 levels (peak plasma concentrations and AUCs) were 
noted among all patients, regardless of when they received SJW. The changes were, 
however, more pronounced for the three patients who received SJW during the 
second course of irinotecan than for those who received SJW during the first course. 
Previous work (18) has shown that the ability of SJW to induce CYP3A4 expression 
is dependent on the length of therapy, with no observable effects when given for 8 
days or less. It has been hypothesized that this may be the result of the formation of 
an intermediate or slowly accumulating metabolite of the components of SJW [i.e., 
(pseudo)hypericin and hyperforin] with CYP3A4-inducing effects (19). Thus, one 
potential explanation for the schedule-dependent effects of SJW on irinotecan 
metabolism may be a prolonged effect of SJW on CYP3A4 expression with long-
term administration regimens. 
It has also been proposed that induction of MDR1 P-glycoprotein expression 
may be a component of the mechanism for interactions between several other drugs 
and SJW (11 ). Preclinical studies have shown that biliary transport of SN-38 is 
unchanged in mice lacking mdr1-type P-glycoprotein, which suggests no major role 
of MDR 1 P-glycoprotein in the elimination of SN-38 in patients (20). These 
observations, together with our current observation that the half-lives of SN-38 are 
unchanged in the presence and absence of SJW coadministration (Table 1 ), makes 
it unlikely that MDR1 P-glycoprotein is involved in the observed interaction. This is 
because a prominent role of MDR1 P-glycoprotein in the interaction would be 
associated with increased biliary transport of SN-38, resulting in a decreased half-life 
of SN-38 in plasma. 
Overall, our findings suggest that irinotecan metabolism and toxicity are altered 
by SJW and that the two agents cannot be given safely in combination without 
compromising overall antitumor activity. We expect that the results presented here 
for irinotecan are representative of other anticancer drugs that are at least partial 
substrates for CYP3A4. This hypothesis is supported by recent observations that the 
pharmacokinetics of several commonly used agents, including taxanes [e.g., 
paclitaxel (21)] and camptothecines [e.g., irinotecan (22) and topotecan (23)], are 
altered in patients on anticonvulsants as a result of CYP3A4 induction, which leads 
to increased dose requirements to achieve similar pharmacologic effects. Until 
specific dosing guidelines are available, it is strongly recommended that patients 
receiving chemotherapeutic treatments with such agents refrain from taking SJW. 
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ABSTRACT 
Purpose: The objective of this study was to explore the relationships between 
irinotecan disposition and allelic variants of genes coding for ATP binding-cassette 
transporters and enzymes of putative relevance for irinotecan. 
Patients and Methods: lrinotecan was administered to 65 cancer patients (32 males, 
33 females; 63 European Caucasian, 2 Asian) as a 90-minute infusion (dose, 200-
350 mg/m2), and pharmacokinetic data were obtained during the first cycle. All 
patients were genotyped for variants in genes encoding MDR1 P-glycoprotein 
(ABCB1), multidrug resistance-associated proteins MRP-1 (ABCC1) and MRP-2 
(cMOAT; ABCC2), breast cancer-resistance protein (ABCG2), carboxylesterases 
(CES1, CES2), cytochrome P450 isozymes (CYP3A4, CYP3A5), uridine diphosphate 
glucuronosyltransferase (UGT1A1), and a DNA-repair enzyme (XRCC1), which was 
included as a non-mechanistic control. 
Results: Twenty genetic variants were found in 9 genes of putative importance for 
irinotecan disposition. The homozygous T allele of the ABCB1 1236 C> T 
polymorphism was associated with significantly increased exposure to irinotecan (P = 
.038) and its active metabolite SN-38 (P = .031 ). Pharmacokinetic parameters were 
not related to any of the other multiple-variant genotypes, although irinotecan 
clearance was slower in the two CYP3A4*3 carriers (P = .059). The extent of SN-38 
glucuronidation was slightly impaired in homozygous variants of UGT1 A 1 *28, 
although differences were not statistically significant (P = .22). 
Conclusion: It is concluded that genotyping for ABCB1 1236 C> T may assist with dose 
optimization of irinotecan chemotherapy in cancer patients. Further investigation is 
required to confirm these findings in a larger population, and to assess relationships 
between irinotecan disposition and the rare variant genotypes, especially in other 
ethnic groups. 
INTRODUCTION 
The topoisomerase I inhibitor irinotecan (CPT-11) has a major role in the 
management of metastatic colo rectal cancer (1 ), and has been approved either in 
combination with 5-fluorouracil and folinic acid in the first line treatment setting (2) or as 
monotherapy in the second line setting (3). In clinical use, irinotecan is subject to very 
substantial interindividual variability in pharmacokinetic behavior (4), treatment efficacy 
(5), and the occurrence of unpredictable, sometimes severe toxic side effects that 
might be life-threatening in some patients. Potential causes for such variability in drug 
effects include the pathogenesis and severity of the disease being treated, the 
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occurrence of unintended drug interactions [eg, with ketoconazole (6) and St John's 
wort (7)], and impairment of hepatic (8, 9) and renal function (10), or both (11). Despite 
the potential importance of these clinical variables in determining drug effects, it is now 
recognized that inherited differences in the metabolism and excretion into the feces 
and urine can have an even greater impact on the efficacy and toxicity of drugs (12-
15). 
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Figure 1. Pathway of genes with a putative role in regulating irinotecan disposition. 
The metabolism of irinotecan is very complex, and involves several phase I and II 
metabolizing enzymes (Ref. 4; Fig. 1 ). In humans, the ester bond of irinotecan is 
cleaved by carboxylesterases to form the primary pharmacologically active metabolite 
7-ethyl-1 0-hydroxycamptothecin (SN-38) (16), which is further conjugated by uridine 
diphosphate glucuronosyltransferases (UGT) to form an inactive ~-glucuronic acid 
conjugate (SN-38G) (17). Another prominent pathway of irinotecan metabolism 
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consists of a cytochrome P450 (CYP) 3A4 and 3A5-mediated oxidation of the 
bipiperidine side-chain attached to the core structure (18), which results in the 
formation of a major metabolite identified as 7-ethyl-10-[4-N-(5-aminopentanoic acid)-
1-piperidino]-carbonyloxy-camptothecin (APC) (19). The pharmacologic behavior of 
irinotecan is further complicated by the fact that its elimination pathways are partially 
mediated by membrane-localized, energy-dependent outward drug pumps that 
facilitate cellular efflux mechanisms (Ref. 20; Fig. 1). These proteins belong to the 
superfamily of ATP-binding cassette (ABC) transporters and include MDR1 P-
glycoprotein (ABCB1; Ref. 21 ), multidrug resistance-associated protein (MRP1, 
ABCC1; Ref. 22) and its homologue MRP2 (also referred to as cMOAT or ABCC2; 
Ref. 23), and the breast cancer-resistance protein BCRP (also referred to MXR or 
ABCG2; Ref. 24). The aim of this study was to link genetic polymorphisms in enzymes 
and transporters involved in irinotecan elimination to interindividual differences in 
measures of drug exposure, in order to provide a stronger scientific basis for optimizing 
irinotecan therapy on the basis of each patienfs genetic constitution. 
PATIENTS AND METHODS 
Patients and Treatment 
Patients with a histologically-confirmed diagnosis of a malignant solid tumor for 
which there was no effective standard regimen and irinotecan was a reasonable 
treatment option were treated with a 90-minute intravenous infusion of irinotecan. 
The drug was given once every 3 weeks until progression of disease or dose-limiting 
toxicities appeared at a dose of 200-350 mg/m2 • All patients were treated between 
January 1997 and June 2001 at the Erasmus MC (Rotterdam, the Netherlands). 
Eligibility and exclusion criteria, premedication regimens, and protocols for treatment 
of drug-induced side effects (eg, diarrhea) were identical to those documented 
elsewhere (25). None of the patients received other drugs, dietary supplements or 
herbal preparations known to interfere with irinotecan pharmacokinetics. The clinical 
protocols, including blood sampling for the purpose of pharmacokinetic and 
pharmacogenetic analyses, were approved by the Erasmus MC Ethics Board, and all 
patients provided written informed consent prior to study entry. 
Pharmacokinetic Data Analysis 
Blood samples of approximately 5 ml were collected during the first cycle of 
treatment at the following time points: immediately prior to infusion; at 30 minutes 
after the start of the infusion; 5 minutes before the end of infusion; and at 10, 20 and 
30 minutes, and 1, 1.5, 2, 4, 5, 8.5, 24, 32, and 48 hours after the end of infusion. In 
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37 of 65 patients, additional blood samples were taken at 56 hours, 196 hours (day 
8), 360 hours (day 15) and 500 hours (day 21) after the end of infusion. Blood 
samples were handled as outlined (26), and concentrations of irinotecan and SN-38 
were determined in all patients by reversed-phase high-performance liquid 
chromatography with fluorescence detection as described in detail elsewhere (27, 
28). Concentrations of SN-38G and APC in plasma were measured in only 53 and 12 
patients, respectively, because of limited sample supply that precluded an additional 
analysis on the same material. 
Previously developed population pharmacokinetic models were used to predict 
the pharmacokinetic parameters of the lactone and carboxylate forms of the analytes 
(29). The considered parameters included clearance (CL), volume of distribution in 
the central compartment (V1), and the accumulated area under the plasma 
concentration-time curve (AUC). The latter parameter was simulated for irinotecan 
and its metabolites in all patients from time zero to 100 hours after start of infusion 
(AUCo-1ooh) for a 90-minute intravenous infusion and a standard dose of 350 mg/m2 
This data analysis was performed using NONMEM version VI (S.L. Beal and L.B. 
Sheiner, San Francisco, CA). Metabolic ratios were calculated as described 
previously (30), and included the relative extent of conversion (REC; the AUC ratio of 
SN-38 to irinotecan), the relative extent of glucuronidation (REG; the AUC ratio of 
SN-38G to SN-38), and relative extent of metabolism (REM; the AUC ratio of APC to 
irinotecan). The REG in each individual patient was also calculated on the basis of 
the linear trapezoidal-rule AUC values from time zero to 24 hours alter start of 
infusion, without extrapolation to infinity, with uniform weighting using non-
compartmental analysis in WinNonlin version 3.0 (Pharsight Corp., Mountain View, 
CA), to allow for a comparative analysis with literature data. 
Pharmacogenetic Data Analysis 
Genomic DNA was extracted from 1 ml whole blood or plasma using the Gentra 
PureGene Blood Kit (Gentra, Minneapolis, MN) and the QIAamp DNA Blood midi kit 
(Qiagen Inc, Valencia, CA), respectively, following the manufacturers instructions, and 
was reconstituted in a buffer containing 10 mM Tris (pH 7.6) and 1 mM EDT A. 
Single nucleotide polymorphisms and other genetic variations were identified from 
the literature or were mined using the publicly available SNP databases (31 ). 
Variations in the ABCB1 (1236 C> T, 2677 G>AIT, and 3435 C> T), ABCC1 
(23210 C>T and 34215 C>G), ABCC2 (156231 A>G), ABCG2 (828 T>C), CES1 
(1509 A> T and 1592 A>C), CES2 (1703 C> T), CYP3A4 (*1 B, *2 and *3), CYP3A5 
(*3 and *6), UGT1A1 (*7 and *28), and XRCC1 (26304 C>T, 27466 G>A and 28152 
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G>A) genes were analyzed by polymerase chain reaction (PCR)-restriction fragment 
length polymorphism (RFLP) or by Pyrosequencing. XRCC1 variations were included 
as negative control genes. PCR lor ABCB1 3435 C> T and UGT1 A 1 *28 was carried 
out as previously described (32, 33). All other PCR primers were designed using 
Primer Express version 1.5 (ABI, Foster City, CA), and the Pyrosequencing primers 
were designed using the Pyrosequencing SNP Primer Design Version 1.01 software 
(http://www.pyrosequencing.com). RFLP sites were determined using Rebase 
(http://rebase.neb.com). The PCR primers, conditions, and restriction enzymes 
(NEB, Beverly, MA) used in the current study are listed in Table 1. PCR was carried 
out using Amplitaq Gold PCR master mix (ABI, Foster City, CA), 5 pmole of each 
primer, and 1 0-50 ng DNA isolated from whole blood or DNA from 1 ~ undiluted 
plasma. Pyrosequencing was carried out as previously described (34) using the 
Pyrosequencing AB PSQ96 instrument and software (Uppsala, Sweden). RFLP 
results were analyzed by electrophoresis using 4% agarose (Promega Corporation, 
Madison, WI). The genotype was called variant il it differed from the Refseq 
consensus sequence for the single-nucleotide polymorphism (SNP) position 
(http://www.ncbi.nlm.nih.gov/Locuslink/refseq.html). Genotype-frequency analysis ol 
Hardy-Weinberg equilibrium was carried out using Clump version 1.9 
(http://www.mds.qmw.ac.uk/statgen/dcurtis/software.html: Ref. 35). Linkage was 
determined as a percentage of identical genotypes (wild type, heterozygous or 
variant) between SNPs in the same gene. 
Statistical Considerations 
All pharmacokinetic data are presented as mean values ± SD, unless stated 
otherwise. To relate pharmacokinetic parameters with each polymorphism, a non-
parametrical Kruskai-Wallis test was used following a logarithmic transformation of 
the data because of skewed distribution. These statistical calculations were 
performed using SPSS version 9.0 (Paris, France) with an a priori cutoff of P < .05. 
To relate REG with the UGT1A1*28 polymorphism, a nonparametric-trend analysis 
was conducted using Stata version 7.0 (Stata Corp., College Station, TX), as 
described previously (39). 
RESULTS 
Patients and Pharmacokinetics 
A total of 65 adult cancer patients (32 males and 33 females) with a median age 
of 53 years was enrolled onto this study (Table 2). The majority of patients was 
European Caucasian, the most prominent disease type was a gastrointestinal 
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Table 1. PCR primers, conditions, Pyrosequencing primers and restriction enzymes. 
Polymorphism 
ABCB11236 C>T 
ABCB1 2677 G>AIT 
ABCB1 3435 C> T 
ABCC1 14008 G>A 
ABCC1 23210 C> T 
ABCC1 34215 C>G 
ABCC2 156231 A>G 
ABCG2 828 T>C 
CE$1 1509 A> T 
CE$1 1592 A>C 
CE$21703 C>T 
CYP3A4 -392 A>G 
CVP3A4 15713 T>C 
CYP3A4 23172 T>C 
CVP3AS 22893 G>A 
CYP3A5 30597 G>A 
UGT1A1 (TA)o 
UGT1A11456 T>G 
XRCC1 26304 C> T 
XRCC1 27466 G>A 
XRCC1 28152 G>A 
Polymorphism 
ABCB1 1236 C> T 
ABCB1 2677 G>AfT 
ABCB1 3435 C> T 
ABCC1 14008 G>A 
ABCC1 23210 C> T 
ABCC1 34215 C>G 
ABCC2156231 A>G 
ABCG2 828 T>C 
CES1 1509 A> T 
CES1 1592 A>C 
CE$21703 C>T 
CYP3A4 -392 A>G 
CYP3A4 15713 T>C 
CYP3A4 23172 T>C 
CYP3AS 22893 G>A 
CYP3AS 30597 G>A 
UGT1A1 (TA)n 
UGT1A11456 T>G 
XRCC1 26304 C> T 
XRCC1 27466 G>A 
XRCC1 28152 G>A 
•biotinylated. 
Forward primer 5' -3' Reverse primer 5'-3' 
'TGTGTCTGTGAATTGCCTTGAAG CCTCTGCATCAGCTGGACTGT 
•ATGGTTGGCAACTAACACTGTTA AGCAGTAGGGAGTAACAAAATAACA 
GAGCCCATCCTGTTTGACTG •GCATGTATGTTGGCCTCCTT 
•GAGGGCACTTTGGGGCA TCTTGAAGCGGAGGTCGTG 
GGTAAATTGAGGCTCGGTGG •ccCCTCCACTTTGTCCATCTC 
GGGTGCATGTCCCACCTT •cGTCTCGAGCCAGCAGCT 
GCAAGATCCAGGGGACTTGTC CATCGTACAGTACACGAAGGTGAAA 
CAGTTTATCCGTGGTGTGTCTGG AAAGGACAGCATTTGCTGTGCT 
TGGACTTAATGGGGGACGTA GCCATATGGAATCAGCCTTT 
CCCAAGACGGTGATAGGAGA CCAGGAGAGGACAAAATTGC 
TGAATGAATGGCGAAGTGAA GCCCAGAGTGACCCTCATAC 
AGGACAGCCCATAGAGACAAGG •ATCAATGTTACTGGGGAGTCC 
AACAATCCACAAGACCCCTT •ATCTTCAAATGTACTACAAATCACTGA 
CCCACGTATGTACCACCCAGC ATTAGGGTGTGACACAGCAAGA 
~cCCACGTATGTACCACCCAGC ATTAGGGTGTGACACAGCAAGA 
•TCTTTGGGGCCTACAGCATG AAAGAAATAATAGCCCACATACTTATTGAGAG 
•GTCACGTGACACAGTCAAAC TTTGTTCCTGCCAGAGGTT 
TCTCCAGCCTTCACAAGGAC ATTTCCCACCCACTTCTCAA 
CTTCTCCCTGCCTCTCCAC CTACCCTCCTCCCTCAGAACC 
CCTGGATTGCTGGGTCTG AGCCACTCAGCACCACTACC 
GCCCCTCAGATCACACCTAA TCCCGCTCCTCTCAGTAGTC 
Annealing Product Pyrosequencing Restriction 
Temp (0 C) size (bp) primer 5' -3' enzyme 
65 148 GCACCTTCAGGTTCAG 
50 207 TCATCTATTTAGTTTGACTC 
ACCTTC 
60 250 GGTGGTGTCACAGGAAGA 
62 214 ATAAGCCCAGGGTCA 
64 197 CACCTTCTCCATCCC 
64 257 GTCTCACACATGTGCACT 
55 100 Hhal 
55 136 Mboll 
55 200 Haelll 
55 180 Msel 
60 354 Xhol 
55 116 CCATAGAGACAAGGGCA 
55 212 TTTGGATCCATTCTTTC 
60 160 Niall I 
65 176 CCAAACAGGGAAGAGA 
62 153 AGAAACCAAATTTTAGGAA 
50 100 AGGTTGGCCCTCTCCTA 
60 291 Bsrl 
66 485 Pvull 
60 640 Pvul 
60 593 Neil 
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Table 2. Patient demographics. 
Characteristic No. of patients 
Number of patients 65 
Males 32 
Females 33 
Age (years) 
Body-surface area (m2) 
Performance score 
Ethnicity 
European Caucasian 63 
Asian 2 
Tumor types 
Gastrointestinal 49 
(A)CUP 7 
Miscellaneous 9* 
lrinotecan dose 
200 - 230 mg/m2 6 
250 - 300 mg/m2 8 
350 mg/m2 51 
Concomitant medication 
Cisplatin 3 
None 62 
Abbreviation: (A)CUP, (adeno-) carcinoma of unknown primary. 
*pancreas (live), lung (two), cervix (two). 
Median (range) 
53 (34·75) 
1.86 (1.29·2.36) 
1 (0·1) 
malignancy, and 62 of 65 individuals received single agent irinotecan (51 at a dose 
level of 350 mg/m2). The observed plasma concentration-time profiles of irinotecan and 
its metabolites SN-38, SN-38G and APC were well predicted by our previously defined 
NONMEM models (29), as indicated by goodness-cHit plots (data not shown). The 
individual and mean pharmacokinetic parameters of irinotecan and its metabolites are 
consistent with previous findings from patients on a similar regimen (reviewed in Ref. 
4), showing extensive glucuronidation of SN-38 with wide interindividual variability 
(Table 3). All AUC ratios found in this group of patients were highly variable, with up to 
6-fold, 22-fold and 15-fold difference between the lowest and highest values for REC, 
REG and REM, respectively (Table 3). 
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Table 3. Summary of pharmacokinetic parameters (n = 65). 
Parameter 
lrinotecan 
GL lactone {Uh) 
AUG lactone (~g·h/mL) 
AUG total (~g•h/mL) 
SN-38 
GL(m) lactone (Uh) 
AUG total (ng•h!mL) 
SN-38G 
AUG total (~g·h/mL)* 
APC 
AUG total (~g•h/mL)** 
AUG ratios 
SN-38/GPT -11 
SN-38G/SN-38* 
APG/GPT-11** 
Mean ±SD 
73.0 ± 19.9 
5.73 ± 0.856 
20.5 ±7.07 
1 ,264 ± 690.0 
637 ± 336 
4,455 ± 4,666 
4,569 ± 4,015 
0.032 ± 0.015 
7.60 ±5.88 
0.21 ±0.15 
Range 
31.1 -109 
4.05-8.04 
10.4- 46.1 
299.8- 3,334 
216-1,746 
962-29,961 
1,118-13,935 
0.014- 0.088 
1.70- 37.45 
0.35-0.53 
Abbreviations: n, number of patients studied; CL, clearance; AUC, area under the plasma-
concentration time curve; CL (m), metabolic clearance. 
·n=53, --n=12. 
Genotyping 
Twenty SNPs and 1 dinucleotide repeat were analyzed in 9 genes of putative 
relevance for irinotecan disposition (Fig. 1 ), and 1 gene likely to act downstream of 
topoisomerase I inhibition (ie, XRGG1; Ref. 36). XRGG1 was included as a control 
gene of unlikely significance to irinotecan disposition. All the SNPs in ABGG1, ABGG2, 
ABGG2, GES1 and GES2 represent novel data. These SNPs were described in 
databases but had not been previously validated. In 7 of the tested SNPs (ie, ABGG1 
34215 G>G, ABGG2 156231 A>G, ABGG2 828 T>G, GES1 1703 G>T, GYP3A4*2, 
GYP3A5*6 and UGT1A1*7), no variants were obseNed. In the other polymorphisms 
studied, frequencies of the rarest alleles ranged from 0.01 to 0.47 (Table 4). The 
ABGB1 2677 G>AIT contains a tri-allelic SNP, with G at nucleotide 2677 found in the 
wild-type sequence, and with A or T at that position being the two possible variants. All 
genotype frequencies were found to be in Hardy-Weinberg equilibrium. 
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Table 4. Genotype and allele frequencies for the studied genes. 
Polymorphism 
ABCB1 1236 C> T* 
ABC81 3435 C> T 
ABCB1 2Sn G>AIT 
ABCC1 14008 G>A 
ABCC1 23210 C> T 
ABCC1 34215 C>G 
ABCC2156231 A>G 
ABCG2 828 T>C 
CES1 1509 A> T 
CES1 1592 A>C 
CE$2 1703 C> T 
CYP3A4 -392 A>G 
CYP3A415713 T>C 
CYP3A4 23172 T>C 
CYP3A5 22893 G>A 
CYPSAS 30597 G>A 
UGT1A1 (TA)o ... 
UGT1A11456 T>G 
XRCC1 26304 C> T 
XRCC1 27466 G>A 
XRCC1 28152 G>A 
Polymorphism 
ABCB11236 C>T* 
ABCB1 3435 C> T 
ABCB1 26n G>Aff 
ABCC1 14008 G>A 
ABCC1 23210 C>T 
ABCC1 34215 C>G 
ABCC2 156231 A>G 
ABCG2 828 T>C 
CES11509A>T 
CES1 1592 A>C 
CES2 1703 C> T 
CYP3A4 -392 A>G 
CYP3A415713 T>C 
CYP3A4 23172 T>C 
CYP3A5 22893 G>A 
CYP3AS 30597 G>A 
UGT1A1 (TA)o ... 
UGT1A1 1456 T>G 
XRCC1 26304 C> T 
XRCC1 27466 G>A 
XRCC1 28152 G>A 
Nomen- Description 
clature 
n/a G411G .... 
n/a E1143E 
n/a A893T or S 
n/a intron 27 
n/a P154P 
n/a intron 18 
n/a intron 3 
n/a F208S 
n!a L480F 
n!a N509H 
n!a L549L 
CYP3A4*1B Promoter 
CYP3A4*2 S222P 
CYP3A4*3 M445T 
CYP3A5"3C Splice variant 
CYP3As·a Splice variant 
UGT1A1*28 Promoter 
UGT1A1/ Y486D 
n/a R194W 
n/a R280H 
n/a R399Q 
Allele frequencies (95% Cl) 
p q 
0.66 (0.52·0.78) 
0.57 (0.44·0.69) 
0.48 (0.35-0.61) 
0.71 (0.59·0.81) 
1.00 
0.17 (0.1·0.28) 
1.00 
1.00 
1.00 
0.99 (0.92·1) 
0.99 (0.92·1) 
0.97 (0.88·0.99) 
1.00 
0.98 (0.91·1) 
0.94 (0.85·0.98) 
1.00 
0.78 (0.66-0.87) 
1.00 
0.91 (0.79·0.96) 
0.98 (0.91·1) 
0.68 (0.55·0.79) 
0.34 (0.22·0.48) 
0.43 (0.31·0.56) 
0.47 (0.34-0.60) 
0.29 (0.19-0.41) 
0.00 
0.83 (0.72·0.90) 
0.00 
0.00 
0.00 
0.01 (0·0.08) 
0.01 (0·0.08) 
0.03 (0.01·0.12) 
0.00 
0.02 (0·0.09) 
0.06 (0.02·0.15) 
0.00 
0.22 (0.13-0.34) 
0.00 
0.09 (0.04-0.21) 
0.02 (0·0.09) 
0.32 (0.21-0.45) 
n 
46 
59 
53 
64 
45 
60 
65 
63 
64 
61 
57 
49 
39 
64 
64 
63 
58 
62 
43 
62 
57 
Genotype frequencies 
wt het var 
23 15 8 
16 35 8 
12 23/4 13/1 
32 27 5 
45 0 0 
0 20 40 
65 0 0 
63 0 0 
64 0 0 
60 0 
56 1 0 
46 3 0 
39 0 0 
62 2 0 
56 8 0 
63 0 0 
34 22 2 
62 0 0 
35 8 0 
60 2 0 
25 27 5 
0.05 (0.02·0.14) 
Abbreviations: n, number of samples; Wt, Wild-type; Het, Heterozygous; Var, variation; n/a, 
information not available; VI, confidence intervals. 
* number represents position in nucleotide sequence; ** number represents amino acid codon; 
••• p = 6 dinucleotide repeats, q = 7 dinucleotide repeats. 
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Complete genetic linkage was not seen between polymorphisms from within the 
same gene. SNPs in the ABCB1 gene (1236 C> T, 2677 G>AIT, and 3435 C> T) have 
been previously described to be in linkage with each other (37). In this study, ABCB1 
3435 C> T shared 52% linkage with ABCB1 1236 C> T and 49% linkage with ABCB1 
2677 G>AIT. ABCB1 1236 C>T shared 51% linkage with ABCB1 2677 G>A!T. 
Overall, 35% linkage was observed between the 3 ABCB1 SNPs. The 26% allele 
frequency for UGT1 A 1 *28, a seven copy dinucleotide repeat polymorphism in the 
promotor region, was somewhat lower than the 38-40% reported in some previous 
studies (38, 39). 
Table 5. Summary of genotype-phenotype associations. 
Polymorphism 
ABCB11236C>T 
ABCB1 3435 C> T 
ABCB1 2677 G>AIT 
ABCC114008 G>A 
ABCC1 34215 C>G 
CYP3A4*1B 
CYP3A4*3 
CYP3A5*3C 
UGT1A1*28 
Phenotypic consequence* 
lrinotecan total AUC increased 
SN-38 total AUC increased 
SN-38 lactone CL reduced 
lrinotecan lactone AUC 
I rinotecan lactone CL 
SN-38 lactone CL 
APCAUC 
SN-38 lactone CL 
lrinotecan lactone CL 
lrinotecan carboxylate CL 
SN-38G/SN-38 AUC ratio 
P- value** 
.038 
.031 
.015 
.100 
.083 
.127 
.345 
.213 
.059 
.174 
.211 
* Represents the best association (lowest P-value) between a given polymorphism (wild type 
versus heterozygous variant versus homozygous variant type patients) and a change in a 
pharmacokinetic parameter. * ... Kruskal-Wallis test following logarithmic transformation for 
data with a skewed distribution; except for ABCB1 1236 C> T, no statistically significant 
associations were found. 
Genotype-Phenotype Associations 
For the 9 polymorphisms in 5 genes in which variant alleles were observed, only 
one of the ABCB1 SNPs was associated with differences in irinotecan and SN-38 
levels (Table 5). The systemic exposure to both irinotecan and SN-38, based on total 
drug concentrations, was significantly higher for patients with two variant alleles in 
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ABCB1 1236 C> T (ie, the TT allele) when compared to the patients with only one or 
no variant alleles. The mean AUC values for irinotecan and SN-38 were 25.5 ± 8.21 
j.tg.h/ml versus 19.8 ± 6.81 J.tg.h!ml (P = .038) and 889 ± 445 ng.h/ml versus 604 ± 
293 ng.h/ml (P = .031 ), respectively. Likewise, the metabolic clearance of the lactone 
form of SN-38 was significantly different between homozygous variants of this SNP 
and wild-type or heterozygous carriers (P = .015) (Table 5; Fig. 2). No statistically 
significant association was observed between the other variants in ABC-transporters 
and any of the studied pharmacokinetic parameters (Table 5). 
Comparison of pharmacokinetic data in patients wild-type versus heterozygous 
for CYP3A4*3 (no homozygous patients for this allele were observed in the data set) 
suggested that the clearance of irinotecan lactone might be reduced and that the 
AUC might be increased in the heterozygotes, although these differences were not 
statistically significant (P = .059 and P = .070, respectively) (Fig. 3). Statistically 
significant differences were also not observed in pharmacokinetic parameters 
between variants in UGT1 A 1 *28 (wild type > heterozygous variant > homozygous 
variant, P > .22) (Table 6). 
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Figure 2. Single-nucleotide polymorphism ABCB1 1236 C> T in relation to the metabolic 
clearance of SN-38 lactone. Boxplots show the median, interquartile range and 
outliers of individual variables. Abbreviations: Wt, Wild type patient; Het, 
Heterozygous variant type patient; Var, Homozygous variant type patient 
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Figure 3. Single-nucleotide polymorphism GYP3A4•3 in relation to the clearance of 
irinotecan lactone. Abbreviations: Wt, Wild type patient; He!, Heterozygous 
variant type patient. 
Table 5. Effect of UGT1 A 1·2s on the extent of SN-38 glucuronidation. 
Genotype Reference n AUC0.1 (24h) ratio• AUCo.iot (1 OOh) ratio .. 
SN-38G/SN-38 SN-38G/SN-38 
mean± SD (median) mean± SD (median) 
Wt this study 32 7.6 ± 4.1 (6.6) 6.9 ± 3.5 (6.4) 
39 9 9.3 ± 11 n!a 
Het this study 19 7.1 ± 3.6 (6.6) 6.7 ± 3.2 (6.1) 
39 7 4.0± 1.7 n/a 
Var this study 2 2.2, 5.2 (3.7) 2.5, 4.6 (3.6) 
39 4 2.4±1.1 n/a 
Abbreviations: n, number of patients studied; AUC, area under the plasma concentration-
time curve; Wt, Wild type patient; Het, Heterozygous variant type patient; Var, Homozygous 
variant type patient; n/a, information not available. ·sN-38G/SN-38 AUG ratio based on 
nonparametric analysis of samples taken upto 24 h after irinotecan administration [trend 
analysis (Wt>Het>Var), P = .272]; --sN-38G/SN-38 AUG ratio based on NONMEM model 
[trend analysis (Wt>Het>Var), P = .300]; lyer et at. (39) [trend analysis (Wt>Het>Var), P = 
.001]. 
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DISCUSSION 
The desire for better tools to individualize chemotherapy has led to new ways of 
evaluating patients. The observation that most chemotherapy agents have a high 
degree of variability in drug disposition has prompted the use of genetics to try and 
identify the meachanistic basis for this variation. Previous investigations have shown 
that pharmacogenetic testing may contribute to the individualization of drug 
treatment, and hence may have an increasing impact on enhanced drug safety and 
efficacy (12, 14, 15). In the present study, we assessed the relationships between 
disposition characteristics of the topoisomerase I inhibitor irinotecan and 21 allelic 
variants of 10 genes coding for various ABC transporters and drug-metabolizing 
enzymes in a group of 65 cancer patients. 
The most relevant finding of this study was a significant association between 
the presence of the homozygous T allele of ABCB1 1236 C> T (located at exon 12) 
and increased exposure to both irinotecan and SN-38. This appears to be the first 
observation that this allelic variant is functionally polymorphic, in that it alters the 
activity of the encoded protein in relation to the wild-type and heterozygous 
sequences. ABCB1 1236 C> Tis a synonymous cSNP located in codon 411 of the P-
glycoprotein. It is unlikely that this variation directly affects P-glycoprotein expression, 
however, it may have an indirect effect such as altering RNA stability. 
Comprehensive analysis of all DNA variations in this gene is warranted to uncover 
the basis of the association between P-glycoprotein and irinotecan and SN-38 
exposure. 
Previously, Hoffmeyer eta/. found an association between ABCB1 gene 3435 
C> T (located at exon 26) and increased exposure to the P-glycoprotein substrate 
drug digoxin following oral administration (40). Although this SNP is also a silent 
polymorphism (ie, present in the amino acid coding region but not coding for an 
amino acid substitution), intestinal P-glycoprotein expression was significantly 
decreased, leading to increased absorption of the drug. More recently, a study was 
published that confirmed the functional importance of the ABCB1 3435 C> T 
polymorphism, although in this case the variant allele was associated with lower 
plasma concentrations of the anti-retroviral drugs nelfinavir and efavirenz (41). To 
explain this paradox, it was hypothesized that low levels of P-glycoprotein expression 
might be compensated for by overexpression of other ABC transporter proteins with 
affinity for these anti-retroviral drugs, and/or the induction of CYP3A isoforms (41 ). In 
our study, neither the ABCB1 3435 C> T nor the ABCB1 2677 G>A!T SNP was 
associated with altered plasma concentrations of irinotecan and/or its metabolites. 
The latter mutation leads to the replacement of Ala to Ser or Thr, but does not 
appear to result directly in an altered expression of P-glycoprotein (42, 43). 
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Recent investigations indicated that the metabolism of irinotecan is substantially 
influenced by a nucleotide polymorphism in the TATA-box sequences of UGT1A1. 
This gene encodes the enzyme UGT1A1 that is responsible for the glucuronidation 
of several compounds, including SN-38 (17). An extra (7th) TA-repeat [A(TA)7TAA] in 
one allele results in approximately 70% reduction in transcriptional activity compared 
with wild type UGT1 A 1 [A(TA)6 T AA]. Inheritance of the promotor containing 
[A(TA)7TAA] is one of the m9st common genotypes leading to Gilbert's syndrome 
(44), which is characterized by mild nonhemolytic, unconjugated bilirubinemia. 
Genetic abnormalities in UGT1 A 1 are also associated with the Crigler-Najjar hepatic 
syndromes with absent (type-1) or reduced (type-11) UGT1A1 activity (45, 46). As 
such patients cannot metabolize SN-38 adequately, they might be at increased risk 
for severe drug-related toxicities. Indeed, it has been suggested that screening for 
UGT1A1*28 prior to treatment might identify patients with lower SN-38 
glucuronidation rates and greater susceptibility to irinotecan-induced hematological 
and non-hematological toxicities (39, 47, 48). Unfortunately, these results could not 
be confirmed in our study, although the study-settings were comparable. One reason 
for this discrepancy may be found in the allele-frequency of the variant allele in our 
population that was clea~y lower than mentioned in literature for a normal Caucasian 
population (38). However, although differences in our study among genotypes were 
not statistically significant, an overall trend in reduced SN-38 glucuronidation rate (ie, 
REG) in homozygous variants of UGT1A1*28 could be observed (Table 6), 
particularly in the median values, both with pharmacokinetic data based on 
noncompartmental analysis or those based on the NONMEM population model. 
Furthermore, it is particularly noteworthy that one of the two patients with the variant 
allele in our study with data for REG was the only individual that experienced grade 4 
diarrhea in the entire cohort. Clearly, further investigation is required to 
unambiguously define the association between genetic variation in UGT1 A 1 and 
irinotecan pharmacokinetics and pharmacodynamics. 
Novel SNPs in ABCC1, ABCG2, CES1 and CES2 were identified and evaluated 
in this patient set. Due to the rapid expansion of SNP discovery and the present lack 
of overlap amongst the various SNP databases, it is possible that further functional 
polymorph isms in these genes are still to be described (31 ). Recent data also 
suggest that molecular determinants of SN-38 glucuronidation and irinotecan 
response might include common allelic variants of the hepatic UGT1A9 isozyme (49, 
50). Consideration of these polymorphisms may eventually provide further 
refinement of the predictive strategies for irinotecan. 
One might seriously question if our current findings already provide meaningful 
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tools for medical decision making in clinical practice. It is probably too simplistic to 
think that the complex metabolism of irinotecan can be predicted by screening for 
one or even a small number of genetic variants. Because every individual represents 
a combination of drug-metabolizer and transporter phenotypes, and given the large 
number of enzymes involved in irinotecan metabolism, it is apparent that some 
individuals are destined to have unusual reactions to this agent due to the 
coincidental occurrence of multiple genetic defects. Furthermore, it has been shown 
before that various physiologic and environmental factors are also involved in the 
way patients react to the irinotecan therapy (4). Besides the condition of the patient 
and measures of hepatic dysfunction, the role of co-medication and dietary 
supplements should not be underestimated. For example, sedatives, antiepileptic 
drugs and some corticosteroids, which are very commonly used among patients on 
chemotherapy treatment, can induce UGT1A 1 (51, 52) and CYP3A4 activity (53, 54). 
In addition, co-administration of a wide variety of agents (eg, ketoconazole) can 
result in competitive inhibition of CYP3A4 activity (6), while recommended levels of 
the natural product St. John's wort significantly induce the activity of this enzyme 
(55), resulting in altered SN-38 concentrations in plasma (7). Therefore, the next step 
in predicting the pharmacokinetic and pharmacodynamic outcome of therapy would 
be by focusing on phenotyping strategies, as these combine both physiologic, 
environmental and genetic factors. Hopefully, these procedures will eventually lead 
toward individualized dosing of this drug. Trials implementing a strategy to phenotype 
total CYP3A4 expression by using the erythromycin-breath test and/or midazolam 
clearance as surrogate markers of hepatic activity prior to treatment with irinotecan 
are currently ongoing at our institute. 
In conclusion, individuals homozygous for the T allele of ABCB1 1236 C> T 
appear to have altered irinotecan plasma concentrations in comparison with 
heterozygous and wild-type patients. Although this polymorphism does not 
completely explain the differences in irinotecan pharmacokinetics between patients, 
it may be of relevance in our aim to achieve individualized treatment strategies with 
this agent. Further investigation is required to confirm these findings in a larger 
population, and to assess relationships between irinotecan disposition and the rare 
variant genotypes, especially in other ethnic groups. 
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Although irinotecan has recently been registered for the first-line 
chemotherapeutic treatment of colorectal cancer, the unpredictability of serious side 
effects (neutropenia and diarrhea) remains a concern for many oncologists. In this 
thesis, we further elucidated the complex pharmacokinetic profile of the drug, which 
should lead to an improvement of the predictability of irinotecan tolerability. 
In chapter 2, we review the (pre-) clinical research that has been done into the 
pharmacokinetics and metabolism of irinotecan, up to the year 2001. The drug's two 
most important routes of elimination have been described; i.e. the carboxylesterase-
mediated pathway and the cytochrome P450-mediated route. This includes the 
involvement of many phase I and II enzymes and drug transporting proteins {like P-
glycoprotein and the canalicular multispecific organic anion transporter; cMOA T). 
Common pharmacokinetic parameters such as the plasma disposition, protein 
binding, and excretion have been discussed for irinotecan and its metabolites, along 
with several schedules and routes of administration of irinotecan. It was difficult to 
provide unequivocal pharmacokinetic-pharmacodynamic relationships, as the 
findings of such studies varied highly. 
The last decade, irinotecan has been combined with several other anticancer 
drugs, in view of additive or synergistic antitumor effects in preclinical models. Here, 
we also reviewed combinations with platinum-analogs, taxanes and other agents. 
One of the best pharmacokinetic parameters to decribe the exposure to a drug is 
the "area under the plasma concentration-time curve" (AUG). Unfortunately, up to now, 
17 to 20 plasma samples were required to adequately calculate this parameter. In 
chapter 3, we developed limited sampling models, to predict the AUG out of only 3 
samples (taken at 30m in, 1 h40min and 5h30min after the start of infusion). Univariate 
and multivariate regression analyses were employed to generate these models, using 
data from 24 patients. In another 24 patients, these models for both irinotecan and SN-
38, and each total and lactone form, were validated. It was demonstrated that all the 
AUCs could be predicted sufficiently unbiased and precise. The implication of these 
models in clinical practice may enable PK sampling in an outpatient setting or in multi-
institutional trials. Also, this procedure is more cost-effective for the hospital and 
convenient for patient, nurse and technician. 
In chapter 4, irinotecan and SN-38 (both total and lactone forms), SN-38 
glucuronide, APC, and NPC data of 70 patients were used to perform a population-
analysis lor this drug. The built mathematical models adequately describe the 
disposition characteristics of the drug. Generally, the compartmental models 
confirmed the pathways suggested from a traditional pharmacologic scope. 
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Meanwhile, these data refine our understanding of the clinical phannacokinetics of 
the drug, like an assumed preferential formation of SN-38 and NPC out of the lactone 
form of irinotecan. 
These models may be used to predict the most important phannacokinetic 
parameters (like AUC, clearance, and volume of distribution) from measured plasma 
concentrations for irinotecan and its metabolites after various administration 
regimens of irinotecan. 
Population phannacokinetic models, built by the principles described in chapter 
4, were used to predict irinotecan phannacokinetics in 1 09 patients, which were 
sampled for irinotecan kinetics during one or two courses. In chapter 5, these 
pharmacokinetic outcomes were correlated with irinotecan's main toxicity, diarrhea. 
For the first time, a significant relationship between the AUCs of both irinotecan and 
SN-38 glucuronide and the grade of diarrhea could be described. Presumably, local 
re-activation of excreted SN-38 glucuronide into SN-38 by bacterial J3-glucuronidases 
may be an explanation for this finding. 
Recently, tt was observed that SN-38 circulates for a longer period of time in the 
human body then previously thought. Hence, blood sampling based on a short time 
period (56 hours) can underestimate the SN-38 AUC substantially, and sampling up 
to 500 hours (3 weeks) was advised. In chapter 6, we studied the clinical relevance 
of this prolonged exposure. We found that the SN-38 concentrations circulating three 
weeks after an irinotecan infusion, were capable of inhibiting cell growth of several 
human tumor cell-lines in vitro. We also compared the SN-38 phannacokinetics 
(based on a 56 hour and a 500 hour sampling time period) with phannacodynamics. 
We used the percentage decrease in neutrophil count at nadir as a common 
phannacodynamic parameter. Also, we introduced a new pharmacodynamic 
parameter, which described the decrease in blood-cell count during time. We showed 
that the phannacokinetics based on 500 hours of sampling and the new 
phannacodynamic parameter had the best phannacokinetic/pharmacodynamic 
correlation. New limited sampling models were developed to predict the AUC of SN-
38, based on prolonged sampling. This model, in which only 2 timed samples are 
required, enables to open up historic databases to retrospectively obtain information 
about SN-38-induced toxicities in patients treated with irinotecan. Currently, this 
limited sampling model is also applied in a multi-institutional trial. 
For most anti-cancer drugs, including irinotecan, a dose is given to the patient 
which is based on the patient's body-surface area (BSA). Although there is lack of 
evidence of the clinical relevance of this procedure in adults, it was intended to 
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reduce the interindividual variability {I IV) in pharmacokinetics and result in less severe 
toxicities. In chapter 7, we studied the effect of BSA (and other body size measures) 
on the pharmacokinetics of irinotecan and SN-38 in 82 patients. The IIV in the 
clearance of irinotecan did not alter when the drug was dosed on BSA (I IV= 34.0%) 
or not (I IV = 32.1 %). Also for SN-38, any other adjustment for body-size measures, 
did not effect pharmacokinetics in univariate and multiple regression analyses. 
Therefore, there is no rationale to dose irinotecan based on a body-size measure, 
and it is recommended to conduct a phase Ill study to prospectively compare BSA-
based dosing and fixed dosing of this drug. 
Anticancer drugs usually have narrow therapeutic margins. As cytochrome 
P450 (GYP) 3A4 is involved in the metabolism of irinotecan and this enzyme is 
susceptible to modulation by co-medication, we studied the effect of a potent 
CYP3A4 inhibitor on the pharmacokinetics of irinotecan in chapter 8. During a 
randomized, cross-over study, a total of 7 patients received one course of irinotecan 
(1 00 mg/m2) combined with· ketoconazole (200 mg orally for 2 days) and another 
course at the recommended dose of irinotecan (350 mg/m2) without ketoconazole. 
With ketoconazole coadministration, the relative formation of APC was reduced with 
87%, while the relative exposure to SN-38 increased with 109%. As irinotecan and 
SN-38 glucuronide concentrations did not change, we concluded that the inhibition of 
CYP3A4 by ketoconazole leads to a significantly increased formation of SN-38. 
Physisians should be warned that the simultaneous administration of CYP3A4 
inhibitors and irinotecan may potentially result in fatal outcomes. Dosis reductions for 
irinotecan are indicated in case the patient has to use an effective CYP3A4 inhibitor. 
In chapter 9, we studied the effect of a potent CYP3A4 inducer. As inhibition of 
CYP3A4 leads to higher levels of SN-38, we hypothesized that stimulation of this 
enzyme might do the opposite. St. John's wort (SJW), a very popular herbal product 
in the treatment of mild to moderate forms of depression, is known for its induction of 
CYP3A4. In a randomized cross-over setting, 5 patients were treated with irinotecan 
during 2 courses at a dose of 350 mg/m2 intravenously. Prior to, during, and 4 days 
after one of these courses, patients received SJW orally 3 times a day at 300 mg. 
The AUG of SN-38 decreased by more than 40% as a result of SJW co-treatment, 
while the exposure to CPT-11 did not change. In addition, in the course following the 
combination treatment, this effect was still seen in the patients studied. Also, the 
degree of myelosuppression was substantially milder in the presence of SJW. As 
circulating levels of SN-38 are thought to be related with antitumor activity, these 
findings indicate that patients on irinotecan treatment should refrain from taking SJW. 
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In the chapters 7-9 we reported that BSA did not have an effect on irinotecan 
pharmacokinetics, and that co-medication did. The next step was to see if genetic 
differences between patients had an affect. In chapter 10, we studied single-
nucleotide polymorphisms in irinotecan-metabolizing enzymes and ABC transporters 
in 65 patients. Subsequently, we compared these polymorphisms, one by one, with 
the pharmacokinetics of irinotecan and metabolites, using the population 
pharmacokinetic model described in chapter 4. Patients were genotyped for variants 
in P-glycoprotein, cMOAT, BCRP, carboxylesterases, cytochrome P450 isozymes 
and UGT1A1. A significant positive relation was found between the homozygous T-
allele of P-glycoprotein and the exposure to irinotecan. Also, a negative trend was 
seen for the relation between mutants in CYP3A4'3 and irinotecan clearance. In 
addition, we found a lower glucuronidation in patients carrying an extra TA-repeat in 
the promotor area of the UGT1A1 gene in both alleles. Further investigation is 
required to confirm these findings and assess relationships between irinotecan 
disposition and other variant genotypes. The clinical relevance in other ethic groups 
remains uncertain. 
As shown in this thesis, many factors are involved in irinotecan metabolism. 
Dose individualization for this drug should focus on strategies which combine both 
environmental influences and genetic factors. Currently, a phenotyping procedure for 
this drug is ongoing at the Erasmus MC - Daniel den Hoed. In this study, patients 
receive two noninvasive test-compounds; ery1hromycin and midazolam (also called 
"probes"), for the estimation of CYP3A4 activity in that specific individual at a specific 
moment in time. When this activity can be correlated with the pharmacokinetics of 
irinotecan, future patients can undergo these probe-tests to predict to which extent 
irinotecan will be metabolized in that individual, and thus can be dosed individually. 
Finally, all important factors which influence and/or predict the PK of irinotecan 
(like co-medication, organ (dys-) function, patient's condition, clinically relevant 
genetic polymorphisms, and maybe even a body-size measure in extreme cases) 
should be taken into account in a formula with the aim to predict the PK of this drug 
with high reliability. Despite all our efforts, this probably cannot be achieved at this 
moment. But maybe in a near future, when most missing links in this puzzle are 
found, patients can be dosed more optimally, with positive effects for the antitumor 
activity. 
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Appendices 
Het geneesmiddel irinotecan (ook wei GPT-11 genoemd) heeft het laatste 
decennium bewezen bij de meest actieve middelen tegen veel vormen van kanker te 
behoren. Het word! momenteel als eerste keus medicament beschouwd bij de 
behandeling van niet-operabele dikke darm kanker. Helaas is het zeer lastig om de 
werking eNan bij een individuele patient te voorspellen. Sommige mensen reageren 
gunstig op de therapie, terwijl anderen er geen of nauwelijks baat bij hebben. 
Hetzelfde geld! voor de bijwerkingen van deze therapie (zoals diarree en een daling 
van de witte bloedcellen); sommige mensen hebben vrijwel geen klachten, terwijl bij 
anderen de bijwerkingen levensbedreigend kunnen zijn. In dit proefschrift hebben we 
belangrijke factoren, welke betrokken zijn bij de variatie in werking en bijwerkingen 
tussen patienten, bestudeerd. 
Nadat het geneesmiddel door middel van een infuus in de bloedbaan word! 
gebracht, zal het zich door het lichaam verdelen. Zo kan het middel bij de tumor 
komen, maar ook bij gezonde weefsels, waardoor bijwerkingen optreden. Onder 
andere in de lever word! irinotecan met behulp van zogenaamde "enzymen" deels 
omgezet in afbraakprodukten (metabolieten). Deze omzettings-produkten kunnen via 
de darmen en de nieren he! lichaam verlaten. De beschrijving van de processen 
zoals verdeling door het lichaam, omzettingen en uitscheiding noemen we (farmaco-) 
kinetiek. 
Na een inleiding (hoofdstuk 1) alwaar in het kort de historische ontwikkeling en 
het werkingsmechanisme van irinotecan word! beschreven, volgt in hoofdstuk 2 een 
overzicht van de belangrijkste farmacokinetische processen (voor zover nu bekend), 
betrokken bij het irinotecan metabolisme. Niet irinotecan zelf, maar een van de 
afbraakprodukten hieNan (genaamd SN-38) is actief tegen kanker. Aile andere 
gevormde metabolieten zijn niet actief, waardoor onze aandacht zich vooral rich! op 
de kinetiek van SN-38. 
Een van de meest gebruikte en belangrijkste farmacokinetische functies is de 
zogenaamde AUG. Met de AUG geven we de blootstelling (concentratie) van een 
medicijn gedurende de tijd weer. Aangezien de concentraties in het bloed 
voortdurend veranderen als gevolg van verdeling, afbraak en uitscheiding van 
irinotecan, moesten tot op heden vele bloedmonsters worden afgenomen om de 
AUGs van irinotecan en SN-38 goed te kunnen berekenen. In hoofstuk 3 word! 
beschreven hoe he! met behulp van speciaal ontwikkelde wiskundige modellen 
mogelijk word! om met slechts 3 bloedmonsters loch nauwkeurig een AUG te kunnen 
bepalen. Dit schept vele voordelen. Voor de patient word! deelname aan een studie 
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met farmacokinetiek iets minder onplezierig, aangezien minder vaak geprikt hoeft te 
worden. Ook hoeft deze niet meer opgenomen te worden, maar kan poliklinisch 
behandeld worden. Voor verpleegkundige en analist betekent dit aanzienlijk minder 
werk, waardoor ook de werkdruk en de kosten kunnen afnemen. 
De ontwikkeling en het gebruik van modellen hebben we doorgetrokken in 
hoofdstukken 4 en 5. Omdat patienten (zoals eerder beschreven) zeer gevarieerd 
op de therapie met irinotecan reageren en het tot op heden zeer moeizaam lukte een 
verband met werking en bijwerkingen te leggen, bestond de behoefte aan een geheel 
nieuwe aanpak van dit probleem. Aile kinetiek gegevens van 70 patienten, 
behandeld met irinotecan, werden verzameld. In samenwerking met wiskundigen van 
de universiteit van Uppsala (Zweden) werden zogenaamde populatie-modellen voor 
irinotecan en metabolieten ontwikkeld, zoals beschreven in het vierde hoofdstuk. 
Deze modellen geven vanuit een alternatieve benadering (namelijk met behulp van 
wiskundige patronen, in plaats van het medische gedachtengoed) weer hoe het 
metabolisme van dit medicijn plaatsvindt in een grate groep mensen (populatie). In 
het vijfde hoofdstuk worden deze modellen toegepast en word! een sterke relatie 
gelegd tussen een eerder nauwelijks relevant geacht afbraakprodukt van irinotecan, 
genaamd SN-38G, en het voorkomen van diarree bij patienten. 
lnmiddels is bekend geworden dat SN-38 Ianger in de bloedbaan van de patient 
verblijft dan eerder werd aangenomen. Wat de klinische relevantie hiervan is word! 
weergegeven in hoofdstuk 6. Verschillende cellijnen (dit zijn gekweekte 
kankercellen) werden in het laboratorium blootgesteld aan SN-38 gedurende een 
periode van 3 weken. Zelfs bij een continue blootstelling aan zeer lage concentraties 
SN-38 (welke in de bloedbaan van een gemiddelde patient circuleren na 3 weken), 
blijken kankercellen nog steeds gevoelig te zijn voor deze metaboliet. Oftewel, indien 
deze experimenten met gekweekte cellen representatief zijn voor een gezwel bij de 
patient, werkt SN-38 maar liefst 3 weken lang! Mogelijk is dit een verklaring waarom 
irinotecan zo effectief is in tegenstelling tot veel andere anti-kanker middelen welke 
veel kortdurender, of aileen bij hogere concentraties, werkzaam zijn. 
Van oudsher bestaat de gedachte dat grotere mensen een hogere dosis 
chemotherapie kunnen verdragen dan kleinere mensen. Dit zou dan kunnen komen 
omdat grotere mensen sneller het medicijn kunnen afbreken en uitscheiden dan 
kleinere mensen. In medische termen noemen we dit het "klaren" van het 
medicament. Door te doseren op het lichaamsoppervlakte van de patient (welke 
wordt berekenend uit diens lengte en gewicht) zou een ieder een gepaste en veilige 
dosis toegediend krijgen. De aanbevolen dosis van irinotecan wordt tot op heden ook 
op deze wijze weergegeven; deze is namelijk gesteld op 350 mg/m2 per 3 weken. 
Een goed onderbouwd onderzoek naar deze gedachte is echter nooit gedaan! In 
hoofdstuk 7 hebben we bestudeerd of het doseren per lichaamsoppervlak bijdraagt 
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aan het verkleinen van de verschillen in klaring tussen de patienten. Het bleek dat 
sommige kleine mensen (dus met een klein lichaamsoppervlak) in staat waren tot 
een snelle klaring van irinotecan, terwijl anderen dat niet waren. Hetzelfde gold voor 
grote mensen. De oude gedachte is dus onjuist gebleken en het doseren op 
lichaamsoppervlak is daarom niet zinvol. Zolang geen betere doseringsstrategieen 
worden uitgevonden, raden wij een vaste dosering van 600 mg per 3 weken voor 
iedere patient (klein of groot, dik of dun) aan. 
Als het lichaamsoppervlak geen rol speelt bij de wijze waarop patienten op hun 
irinotecan-chemotherapie reageren, wat zijn dan wei belangrijke factoren? Zoals 
eerder genoemd wordt irinotecan via enzymen omgezet in metabolieten. De vorming 
van SN-38 (de actieve metaboliet) is ook afhankelijk van enzymen en deze spelen 
dus mogelijk een belangrijke rol. Een van de betrokken enzymen word! CYP3A4 
genoemd. Dit enzym blijkt minder goed of juist beter te gaan werken onder invloed 
van andere medicijnen. In hoofdstuk 8 hebben we onderzocht wat er gebeurt 
wanneer irinotecan gecombineerd wordt met ketoconazol. Ketoconazol is een anti-
schimmel medicament waarvan bekend is dat het de werking van CYP3A4 kan 
remmen. Het bleek dat deze combinatie leidde tot een enorme stijging van de actieve 
metaboliet SN-38. Hiermee is een belangrijk bewijs geleverd dat de activiteit van 
CYP3A4 een cruciale rol speelt bij het metabolisme van irinotecan. Bovendien 
dienen we te waarschuwen voor het gedachtenloos combineren van irinotecan met 
ketoconazol (of andere CYP3A4 remmers), aangezien ernstige bijwerkingen kunnen 
ontstaan als gevolg van de stijging van SN-38 concentraties. 
In hoofdstuk 9 onderzochten we de combinatie van irinotecan met een zeer vee! 
gebruikt "alternatief' geneesmiddel tegen depressies, genaamd St. Jan's kruid. Uit 
eerdere studies met St. Jan's kruid, waarin het werd gecombineerd met andere 
geneesmiddelen werd gevonden dat ook St. Jan's kruid de werking van CYP3A4 kan 
be'invloeden. Juist vanwege he! grote gebruik van St. Jan's kruid onder kanker-
patienten zagen we het hierdoor als een noodzaak om de combinatie van het kruid 
met irinotecan te onderzoeken. Uit onze resultaten bleek dat de concentraties van 
SN-38 in het bloed met meer dan 42% daalden, wanneer deze twee middelen 
gecombineerd werden. Bovendien houdt het effect een behoorlijke tijd aan; zelfs 3 
weken na he! stoppen van St. Jan's kruid. Mensen dienen dus gewaarschuwd te 
worden voor de combinatie van dit "natuurlijke" (en zonder recept verkrijgbare) 
middel en dit anti-kanker middel, want de therapie wordt mogelijk ge·inactiveerd door 
het gebruik van St. Jan's kruid. 
De werking van enzymen word! niet aileen bepaald door co-medicatie, maar kan 
ook het gevolg zijn van genetische aanleg. Bij een grote groep patienten namen we 
genetisch materiaal (DNA) af om relevante genetische afwijkingen (variaties of 
polymorfismen genoemd) aan te tonen en deze te relateren aan hun irinotecan-
191 
Appendices 
kinetiek (hoofdstuk 1 0). Er bleken enkele goede relaties te zijn tussen bepaalde 
genetische variaties en het irinotecan-metabolisme. Een voorbeeld hiervan is het 
enzym UGT1 A 1, wat betrokken is bij de afbraak van SN-38. Wanneer een afwijking 
in het genetisch materiaal behorende bij dit enzym bestaat, werkt het enzym minder 
goed. Hierdoor word! SN-38 slechter afgebroken, waardoor hogere concentraties 
SN-38 in het bloed komen. Nog dramatischer zou het zijn wanneer dit enzym totaal 
niet meer werkt, waardoor SN-38 haas! niet meer omgezet zou kunnen worden en dtt 
tot zeer emstige bijwerkingen kan lei den. 
Uit de laatste 3 hoofdstukken leerden we dat CYP3A4-be'invloedende co-medicatie 
en genetische aanleg een belangrijkere invloed kunnen hebben op de irinotecan-
kinetiek. Momenteel voeren we een studie in he! Erasmus MC uit, waarbij we al voor 
he! toedienen van de chemotherapie de werking van CYP3A4 in een individuele 
patient te weten proberen te komen. Daarbij dienen we de patient een onschuldig 
middel toe dat, net als irinotecan, via CYP3A4 word! omgezet. Wanneer er een goed 
verband blijkt te bestaan tussen de kinetiek van dit onschuldige middel en de kinetiek 
van irinotecan, kunnen we in de toekomst het onschuldige middel als een soort 'tesf' 
geven om te zien hoe de patient op de irinotecan-chemotherapie zal gaan reageren. 
Op deze wijze houden we rekening met zowel de co-medicatie als de genetische 
aanleg van die individuele patient en word! de kinetiek, en daarmee de mogelijkheid 
van ongewenste neveneffecten, beter voorspelbaar. 
Met hoofdstuk 1 0 zijn we aanbeland in een nieuw tijdvak, waarbij het be lang van de 
genetische achtergrond van een individu steeds centraler word!. Ook de titel van dit 
proefschrift, "Van klinische farmacokinetiek naar farmacogenetica", refereert hier aan. 
Waarschijnlijk zullen in de toekomst steeds meer rechtstreekse verbanden tussen 
genetische variaties en kinetiek worden gevonden en mogelijk kan ook een direct 
verband met anti-kanker werking worden aangetoond. Door rekening te houden met 
de genetische basis van een patient en belangrijke co-factoren kan gezocht worden 
naar een individuele en optimale doserings-strategie van he! meest ideale 
medicament. Een optimist ziet de voordelen voor de toekomstige patient. 
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Dankwoord 
• In de eerste plaats wil ik mijn moeder danken. Met ongelooflijk veel moed en 
kracht heb je je ziekte gedragen. Je strijd heeft als een rode draad door de 
afgelopen twee jaar gelopen en het zal me er elke dag weer aan doen herinneren 
waarom ik dit werk doe. 
• Prof. dr Jaap Verweij en dr Alex Sparreboom; wat heb ik ontzettend veel aan jullie 
te danken. Misschien een open deur, maar ik respecteer jullie beiden zeer; zowel 
persoonlijk als wetenschappelijk. Natuurlijk was jullie prettige wijze van werken 
niet geheel onbekend voor me, maar tach heeft het me nog aangenaam verrast. 
Jullie hebben werkelijk wetenschappelijk vuur en ik denk dat er een vonk is 
overgeslagen. Ondanks de soms massale hoeveelheid werk heb ik zeer genoten 
van mijn promotie-onderzoek. (lk weet dat dit eigenlijk niet zo hoort te zijn, maar 
daarvoor houd ik jullie mede verantwoordelijk!) Alex, wat vind ik het jammer dat je 
naar de States bent gegaan. lk hoop desondanks dat we de komende jaren nog 
veel samen kunnen blijven werken; misschien kan ik dan nog eens iets terug 
doen wat enigszins in verhouding staat tot hetgeen jij voor mij gedaan hebt. 
• Prof. dr Gerrit Stater en Prof. dr Huib Pols. Zander jullie was deze opleidings-
constructie nooit tot stand gekomen. lk hoop dat ik de komende jaren met net 
zoveel plezier mijn opleiding tot internist kan voltooien, orn daarna in het oude 
vertrouwde nest tot oncoloog te kunnen worden opgeleid. 
• Dr Kees Nooter; bedankt voor al je adviezen bij elke lab-bespreking. En met 
name bij de GLP-operatie zullen we je hulp nog hard nodig hebben! 
• Prof. dr Mats Karlsson, dr Rujia Xie, dr Howard Mcleod, dr Sharon Marsh, and dr 
Sharyn Baker; I am really thankful that I got the chance to work with you. I have 
learned a lot from you, and hope that our recent collaborations form the basis for 
new projects. 
• Prof. dr Emst de Bruijn; je zult bij het lezen van dit proefschrift wei een specifiek 
onderwerp missen. Geen probleem; ik ben het niet vergeten. Er word! aan 
gewerkt! 
• lng. Peter de Bruijn; mijn irino-maatje. Het spijt me dat ik je de afgelopen jaren 
met zoveel meetwerk heb opgezadeld. En dan geduldig op de uitslag wachten; 
nee, ho maar! Zander jou had mijn promotie nooit in dit tempo kunnen verlopen. 
• Dr Walter Laos. Dankzij jou zal ik secuur op het juiste aantal significante getallen 
in een label blijven !etten! Je morele ondersteuning voor de persconferentie en 
presentatie in San Francisco heeft me ook goed gedaan. 
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• lng. Desiree van Boven-van Zomeren; de vrolijke noot van het lab. Het zal 
duidelijk zijn dat me dat wei aanstaat. Dr Alessandra Felici. mi displace per il 
brutto tempo che hai trovato in Olanda, rna spero che tu sia stata bene qui! 
Marine Goffinet, je voudrais te remercier pour le travail enorrne de saisie 
informatique que je t'aie demande de realiser. 
• Dr Maja de Jonge, dank voor aile hulp bij onder andere de protocollen. Voor je 
adviezen met betrekking tot de ziekte van mijn moeder blijf ik je eeuwig dankbaar. 
Het betekent meer voor me dan je misschien beseft. 
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sowieso voor de gezellige tijd. Dr Diederik Kehrer en dr Hans Gelderblom; dankzij 
jullie krijgen congressen altijd weer een speciaal cachet. 
• Carla Hartman, drs. Agnes Klaren, Leny van Doorn, Miranda Frijters, Hans van 
der Meulen en Tatjana Prank. lk wil jullie danken voor he! instrueren van de 
patienten en het uitvoeren van al mijn gedachtenkronkels. Met narne het 
organiseren van de fenotyperings-studie moe! een ware crime zijn! 
• Simla Sital, je zal heel wat kilometers afgelopen hebben in het kader van de 
kinetiek. (Dank mij maar, want ik zorg er indirect voor dat je in conditie blijft). 
• Afdeling 81 en behandelcentrum: verpleging, secretaressen en patienten; zonder 
jullie inzet is het goed uitvoeren van een kinetiek-studie onmogelijk. 
• Dr Sjaak Burgers, dr Wirn van den Berg, Jan Francke, Trinet Rietveld, drs. 
Frederike Engels en Dirk Buijs. Oak jullie zijn (zonder het te beseffen) onmisbare 
schakels geweest in mijn onderzoeken. 
• Marijke Westerhout-Kersten en Kerstin van der Veen, hoeveel dagen zullen jullie 
niet hebben gevuld rnet het opzoeken en aanvragen van artikelen voor mij? 
• Datamanagers; dankzij jullie ordening was het mogelijk om eens wat jaartjes 
terug in de tijd te gaan voor oude gegevens. Anders zou al deze mooie informatie 
definitief verloren zijn gegaan. 
• Overige commissieleden; ik wil u hartelijk danken voor het plaatsnemen in mijn 
prornotie-commissie. 
• Vrienden. Robbert van Alphen; vijf jaar geleden wilde jij naar de Daniel. Pieter ter 
Borg, je was de eerste uit onze groep die met promotie-onderzoek startle na het 
arts-examen. Normaal ben ik niet zo volgzaam zoals jullie weten, maar ik ben blij 
dat ik jullie in deze wei gevolgd ben. Niet meer dan logisch dus, dat ik jullie 
gevraagd heb paranimf te willen zijn. Ook Iris Waanders, Laura de Jong, 
Annemarie de Nijs en Bhartie ter Borg-Sewradj; jullie hebben het afgelopen jaar 
maar weer eens bewezen echte vrienden te zijn. 
• Papa, Claudia, Alvarez en familie; zonder een hechte band zou deze tijd 
ondraaglijk zijn geweest. Sam en helpen we elkaar er wei doorheen. 
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